Any feedback?
Information on EC 1.14.14.55 - quinine 3-monooxygenase and Organism(s) Homo sapiens and UniProt Accession P08684
for references in articles please use BRENDA:EC1.14.14.55Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
1.14.14.55 quinine 3-monooxygenaseIUBMB Comments
A cytochrome P-450 (heme-thiolate) protein.
Specify your search results
Word Map
- 1.14.14.55
- cyp2d6
- cyp1a2
-
drug-drug
- hepatocytes
- midazolam
- ketoconazole
- p-glycoprotein
-
dosing
- xenobiotics
-
drug-metabolizing
-
concentration-time
- clopidogrel
- testosterone
-
disposition
-
interindividual
-
pharmacodynamics
-
pharmacogenetic
-
pregnane
- omeprazole
-
coadministration
- rifampicin
-
antiplatelet
- erythromycin
-
open-label
- dextromethorphan
- phenobarbital
- tacrolimus
- ritonavir
-
coadministered
-
n-demethylation
- itraconazole
- grapefruit
- tolbutamide
- quinidine
-
first-pass
- warfarin
- carbamazepine
-
androstane
- phenytoin
- clarithromycin
- voriconazole
-
pharmacogenomics
- methadone
-
p450-mediated
-
infinity
- ugt2b7
- efavirenz
- ugt1a1
- vkorc1
- saquinavir
- medicine
The taxonomic range for the selected organisms is: Homo sapiens
The enzyme appears in selected viruses and cellular organisms
The enzyme appears in selected viruses and cellular organisms
Reaction Schemes
Synonyms
cyp3a4, cyp2c19, cyp3a, cytochrome p450 isoform, nifedipine oxidase, nf-25, quinine 3-hydroxylase, cypiiia4, 
more
topPlease wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYNONYM 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
CYP2C19
-
-
-
-
CYP3A4
CYPIIIA4
-
-
-
-
cytochrome P450 isoform
-
-
-
-
NF-25
-
-
-
-
Nifedipine oxidase
-
-
-
-
P450-PCN1
-
-
-
-
quinine 3-hydroxylase
-
-
-
-
Quinine 3-monooxygenase
-
-
-
-
CYP3A4
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
redox reaction
-
-
-
-
oxidation
-
-
-
-
reduction
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYSTEMATIC NAME
IUBMB Comments
quinine,[reduced NADPH-hemoprotein reductase]:oxygen oxidoreductase
A cytochrome P-450 (heme-thiolate) protein.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CAS REGISTRY NUMBER
COMMENTARY
205394-96-3
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBSTRATE
PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
quinine + [reduced NADPH-hemoprotein reductase] + O2
3-hydroxyquinine + [oxidized NADPH-hemoprotein reductase] + H2O
quinine + [reduced NADPH-hemoprotein reductase] + O2
3-hydroxyquinine + [oxidized NADPH-hemoprotein reductase] + H2O
-
-
-
-
?
teniposide + [reduced NADPH-hemoprotein reductase] + O2
teniposide catechol + [oxidized NADPH-hemoprotein reductase] + ?
-
-
-
?
quinine + [reduced NADPH-hemoprotein reductase] + O2
3-hydroxyquinine + [oxidized NADPH-hemoprotein reductase] + H2O
-
-
-
?
quinine + [reduced NADPH-hemoprotein reductase] + O2
3-hydroxyquinine + [oxidized NADPH-hemoprotein reductase] + H2O
-
-
-
-
?
quinine + NADPH + O2
3-hydroxyquinine + NADP+ + H2O
-
quinine is used for treatment of severe forms of Plasmodium falciparum malaria, phenotyping of two different populations, overview
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
quinine + NADPH + O2
3-hydroxyquinine + NADP+ + H2O
-
quinine is used for treatment of severe forms of Plasmodium falciparum malaria, phenotyping of two different populations, overview
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
COFACTOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
grape seed extract
inhibition ranges from 6.4% to 26.8% dependent on the product
-
green tea extract
most pronounced inhibition of CYP3A4, which ranges from 5.6% to 89.9% dependent on the product
-
2-naphthoflavone
-
0.05 mM 2-naphthoflavone is inhibitory (about 60%) in the presence of low substrate concentrations (0.1 mM)
ketoconazole
-
i.e. KTZ, is a antifungal drug, known as an inhibitor of, especially, the CYP3A subfamily, KTZ racemate and four separate enantiomers are evaluated for their selectivity in inhibiting quinine metabolism
additional information
ginseng products have little to no effect on the activity of CYP3A4
-
additional information
-
ginseng products have little to no effect on the activity of CYP3A4
-
additional information
-
enzyme activity is not significantly altered following low or high dose of Nigeria honey
-
additional information
-
not inhibited by lignocaine, pyrimethamine, dapsone, chloroquine, diazepam, norfloxacin, proguanil, cycloguanil, and 4-chlorophenylbiguanide
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
2-naphthoflavone
-
0.05 mM 2-naphthoflavone activates the enzyme (about 40%) in the presence of high substrate concentrations (0.5 mM)
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
abc-type xenobiotic transporter deficiency
Effect of ABCC2 (MRP2) Transport Function on Erythromycin Metabolism.
abc-type xenobiotic transporter deficiency
P-glycoprotein deficiency enhances metabolic activation of and platelet response to clopidogrel through marked up-regulation of Cyp3a11 in mice: Direct evidence for the interplay between P-glycoprotein and Cyp3a.
Abscess
Erratum: A probable drug-to-drug interaction between voriconazole and haloperidol in a slow metabolizer of CYP2C19 patient.
Achlorhydria
CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms.
Acne Vulgaris
Gefitinib: new preparation. Non small-cell lung cancer: stricter assessment needed.
Acquired Immunodeficiency Syndrome
Differential roles of P-glycoprotein, multidrug resistance-associated protein 2, and CYP3A on saquinavir oral absorption in Sprague-Dawley rats.
Acquired Immunodeficiency Syndrome
Discordant Associations Between SLCO1B1 521T?C and Plasma Levels of Ritonavir-boosted Protease Inhibitors in AIDS Clinical Trials Group Study A5146.
Acute Coronary Syndrome
A pharmacodynamic analysis for the co-administration of inducers of CYP3A with ticagrelor: A cautionary tale in managing patients with acute coronary syndromes.
Acute Coronary Syndrome
A Pharmacogenetic Study of CYP2C19 in Acute Coronary Syndrome Patients of Colombian Origin Reveals New Polymorphisms Potentially Related to Clopidogrel Therapy.
Acute Coronary Syndrome
A risk-benefit assessment of prasugrel, clopidogrel, and genotype-guided therapy in patients undergoing percutaneous coronary intervention.
Acute Coronary Syndrome
A synergic effect between CYP2C19*2, CYP2C19*3 loss-of-function and CYP2C19*17 gain-of-function alleles is associated with Clopidogrel resistance among Moroccan Acute Coronary Syndromes patients.
Acute Coronary Syndrome
Association of CYP2C19 Polymorphism with Clopidogrel Resistance in Patients with Acute Coronary Syndrome in China.
Acute Coronary Syndrome
Both CYP2C19 and PON1 Q192R Genotypes Influence Platelet Response to Clopidogrel by Thrombelastography in Patients with Acute Coronary Syndrome.
Acute Coronary Syndrome
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update.
Acute Coronary Syndrome
Clinical Utility of CYP2C19 Genotyping to Guide Antiplatelet Therapy in Patients With an Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention.
Acute Coronary Syndrome
Clopidogrel in noncarriers of CYP2C19 loss-of-function alleles versus ticagrelor in elderly patients with acute coronary syndrome: A pre-specified sub analysis from the POPular Genetics and POPular Age trials CYP2C19 alleles in elderly patients.
Acute Coronary Syndrome
Clustering of ABCB1 and CYP2C19 Genetic Variants Predicts Risk of Major Bleeding and Thrombotic Events in Elderly Patients with Acute Coronary Syndrome Receiving Dual Antiplatelet Therapy with Aspirin and Clopidogrel.
Acute Coronary Syndrome
Combination of the CYP2C19 metabolizer and the GRACE risk score better predicts the long-term major adverse cardiac events in acute coronary syndrome undergoing percutaneous coronary intervention.
Acute Coronary Syndrome
Comparison of the effect of CYP2C19 polymorphism on clinical outcome between acute coronary syndrome and stable angina.
Acute Coronary Syndrome
Cost-effectiveness of CYP2C19 LOF-guided antiplatelet therapy in Chinese patients with acute coronary syndrome.
Acute Coronary Syndrome
Cost-effectiveness of using CYP2C19 genotype to guide selection of clopidogrel or ticagrelor in Australia.
Acute Coronary Syndrome
Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary intervention.
Acute Coronary Syndrome
CYP2C19 activity and cardiovascular risk factors in patients with an acute coronary syndrome.
Acute Coronary Syndrome
CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: a decision analysis.
Acute Coronary Syndrome
CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis.
Acute Coronary Syndrome
CYP2C19 phenotype in South-East Asian Acute Coronary Syndrome patients and impact on major adverse cardiovascular events.
Acute Coronary Syndrome
CYP2C19 polymorphism frequency in Russian patients in Central Russia and Siberia with acute coronary syndrome.
Acute Coronary Syndrome
CYP2C19 polymorphisms in acute coronary syndrome patients undergoing clopidogrel therapy in Zhengzhou population.
Acute Coronary Syndrome
CYP2C19*17 May Increase the Risk of Death Among Patients with an Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Who Receive Clopidogrel and Rivaroxaban.
Acute Coronary Syndrome
CYP2C19*2 and Other Allelic Variants Affecting Platelet Response to Clopidogrel Tested by Thrombelastography in Patients with Acute Coronary Syndrome.
Acute Coronary Syndrome
Distribution of polymorphisms in the CYP2C19 and ABCB1 genes among patients with acute coronary syndrome in Lower Silesian population.
Acute Coronary Syndrome
Dual Antiplatelet Therapy Guided by CYP2C19 Polymorphisms after Implantation of Second-Generation Drug-Eluting Stents for Management of Acute Coronary Syndrome.
Acute Coronary Syndrome
Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review.
Acute Coronary Syndrome
Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
Acute Coronary Syndrome
Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome.
Acute Coronary Syndrome
Effects of coexisting polymorphisms of CYP2C19 and P2Y12 on clopidogrel responsiveness and clinical outcome in patients with acute coronary syndromes undergoing stent-based coronary intervention.
Acute Coronary Syndrome
Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study.
Acute Coronary Syndrome
Financial Analysis of CYP2C19 Genotyping in Patients Receiving Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention.
Acute Coronary Syndrome
Frequency of CYP3A4, CYP3A5, CYP2C9, and CYP2C19 variant alleles in patients receiving clopidogrel that experience repeat acute coronary syndrome.
Acute Coronary Syndrome
Genetic and Nongenetic Factors Affecting Clopidogrel Response in the Egyptian Population.
Acute Coronary Syndrome
Genetic and nongenetic factors influencing the response to clopidogrel.
Acute Coronary Syndrome
Genetic Determinants of P2Y12 Inhibitors and Clinical Implications.
Acute Coronary Syndrome
Genetic Polymorphism of CYP2C19 and Inhibitory Effects of Ticagrelor and Clopidogrel Towards Post-Percutaneous Coronary Intervention (PCI) Platelet Aggregation in Patients with Acute Coronary Syndromes.
Acute Coronary Syndrome
Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis.
Acute Coronary Syndrome
Genetic variability in response to clopidogrel therapy and its clinical implications.
Acute Coronary Syndrome
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.
Acute Coronary Syndrome
Genotype-Phenotype Association and Impact on Outcomes following Guided De-Escalation of Anti-Platelet Treatment in Acute Coronary Syndrome Patients: The TROPICAL-ACS Genotyping Substudy.
Acute Coronary Syndrome
Genotyping and phenotyping CYP3A4\CYP3A5: no association with antiplatelet effect of clopidogrel.
Acute Coronary Syndrome
High-dose clopidogrel versus ticagrelor for treatment of acute coronary syndromes after percutaneous coronary intervention in CYP2C19 intermediate or poor metabolizers: a prospective, randomized, open-label, single-centre trial.
Acute Coronary Syndrome
Impact of CYP2C19 genetic testing on provider prescribing patterns for antiplatelet therapy after acute coronary syndromes and percutaneous coronary intervention.
Acute Coronary Syndrome
Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel.
Acute Coronary Syndrome
Impact of Implementing CYP2C19 Genotype-Guided Antiplatelet Therapy on P2Y12 Inhibitor Selection and Clinical Outcomes in Acute Coronary Syndrome Patients After Percutaneous Coronary Intervention: A Real-World Study in China.
Acute Coronary Syndrome
Impact of point-of-care testing for CYP2C19 on platelet inhibition in patients with acute coronary syndrome and early dual antiplatelet therapy in the emergency setting.
Acute Coronary Syndrome
Implementation of Cell Samples as Controls in National Proficiency Testing for Clopidogrel Therapy-Related CYP2C19 Genotyping in China: A Novel Approach.
Acute Coronary Syndrome
Implementing a pharmacogenetic-driven algorithm to guide dual antiplatelet therapy (DAPT) in Caribbean Hispanics: protocol for a non-randomised clinical trial.
Acute Coronary Syndrome
Influence of CYP2C19 Polymorphisms in Platelet Reactivity and Prognosis in an Unselected Population of Non ST Elevation Acute Coronary Syndrome.
Acute Coronary Syndrome
Influence of CYP450 Enzymes, CES1, PON1, ABCB1, and P2RY12 Polymorphisms on Clopidogrel Response in Patients Subjected to a Percutaneous Neurointervention.
Acute Coronary Syndrome
Interaction of CYP2C19 G681A polymorphism and omeprazole on clopidogrel responsiveness and impact in patients with acute coronary syndrome.
Acute Coronary Syndrome
Is there a benefit for CYP2C19 genotype-guided antiplatelet treatment in elderly acute coronary syndrome patients?
Acute Coronary Syndrome
Lack of clopidogrel-CYP3A4 statin interaction in patients with acute coronary syndrome.
Acute Coronary Syndrome
Measuring preferences for CYP2C19 genotyping in patients with acute coronary syndrome - a discrete choice experiment.
Acute Coronary Syndrome
P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes.
Acute Coronary Syndrome
Personalized Antiplatelet Therapy Based on CYP2C19 Genotypes in Chinese ACS Patients Undergoing PCI: A Randomized Controlled Trial.
Acute Coronary Syndrome
Perspective on CYP2C19 genotyping test among patients with acute coronary syndrome - a qualitative study.
Acute Coronary Syndrome
Pharmacodynamic study of prasugrel or clopidogrel in non-ST-elevation acute coronary syndrome with CYP2C19 genetic variants undergoing percutaneous coronary intervention (PRAISE-GENE trial).
Acute Coronary Syndrome
Pharmacogenetic testing by polymorphic markers 681G>A and 636G>A CYP2C19 gene in patients with acute coronary syndrome and gastric ulcer in the Republic of Sakha (Yakutia).
Acute Coronary Syndrome
Pharmacokinetics and Pharmacodynamics Following Maintenance Doses of Prasugrel and Clopidogrel in Chinese Carriers of CYP2C19 Variants.
Acute Coronary Syndrome
Polymorphisms of genes related to phase-I metabolic enzymes affecting the clinical efficacy and safety of clopidogrel treatment.
Acute Coronary Syndrome
Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention.
Acute Coronary Syndrome
Risk of major adverse cardiovascular events of CYP2C19 loss-of-function genotype guided prasugrel/ticagrelor vs clopidogrel therapy for acute coronary syndrome patients undergoing percutaneous coronary intervention: a meta-analysis.
Acute Coronary Syndrome
Stated Preferences for Attributes of a CYP2C19 Pharmacogenetic Test Among the General Population Presented with a Hypothetical Acute Coronary Syndrome Scenario.
Acute Coronary Syndrome
Switching between ticagrelor and clopidogrel in patients who underwent percutaneous coronary intervention: insight into contemporary practice in Chinese patients.
Acute Coronary Syndrome
The ABCB1, CYP2C19, CYP3A5 and CYP4F2 genetic polymorphisms and platelet reactivity in the early phases of acute coronary syndromes.
Acute Coronary Syndrome
The Cost Effectiveness of Genetic Testing for CYP2C19 Variants to Guide Thienopyridine Treatment in Patients with Acute Coronary Syndromes: A New Zealand Evaluation.
Acute Coronary Syndrome
The Diagnostic Utility of the Point-of-Care CYP2C19 Genotyping Assay in Patients with Acute Coronary Syndrome Dosing Clopidogrel: Comparison with Platelet Function Test and SNP Genotyping.
Acute Coronary Syndrome
The efficacy and safety of CYP2C19 genotype-guided antiplatelet therapy compared with conventional antiplatelet therapy in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials.
Acute Coronary Syndrome
The Frequency of the Minor Polymorphisms in the CYP2C19, VEGFR-2 Genes, and Clinical Outcomes in Russian and Buryat Patients with Acute Coronary Syndrome.
Acute Coronary Syndrome
Usefulness of High Clopidogrel Maintenance Dose According to CYP2C19 Genotypes in Clopidogrel Low Responders Undergoing Coronary Stenting for Non ST Elevation Acute Coronary Syndrome.
Acute Coronary Syndrome
[Correlation between CYP2C19 Gene Polymorphism with Clopidogrel Resistance and Distribution of Chinese Medicine Syndrome in 229 Acute Coronary Syndrome Patients].
Acute Coronary Syndrome
[Effects of clopidogrel resistence and CYP2C19 genotype on the clinical prognosis of patients with acute coronary syndrome undergoing percutaneous coronary intervention].
Acute Coronary Syndrome
[Relationship between ATP-binding cassette subfamily B member 1 and cytochrome P450 2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with acute coronary syndrome].
Acute Coronary Syndrome
[THE FIRST RESULTS OF THE PREVALENCE OF CYP2C19 GENEPOLYMORPHISM IN PATIENTS WITH ACUTE CORONARY SYNDROME IN THE AKTYUBINSK POPULATION].
Acute Kidney Injury
Acute Kidney Injury from Excessive Potentiation of Calcium-channel Blocker via Synergistic CYP3A4 Inhibition by Clarithromycin Plus Voriconazole.
Acute Kidney Injury
Comparative study on altered hepatic metabolism of CYP3A substrates in rats with glycerol-induced acute renal failure.
Acute Kidney Injury
Risks of Adverse Events Following Coprescription of Statins and Calcium Channel Blockers: A Nationwide Population-Based Study.
Addison Disease
Oxcarbazepine accelerates cortisol elimination via cytochrome P450 3A4 induction.
Adenocarcinoma
Collecting data through high throughput in vitro early toxicity and off-target liability assays to rapidly identify limitations of novel thyromimetics.
Adenocarcinoma
Differential activation of human pregnane X receptor PXR by isomeric mono-methylated indoles in intestinal and hepatic in vitro models.
Adenocarcinoma
Induction of cytochrome P450 3A4 and P-glycoprotein by the isoxazolyl-penicillin antibiotic flucloxacillin.
Adenocarcinoma
Liganded VDR induces CYP3A4 in small intestinal and colon cancer cells via DR3 and ER6 vitamin D responsive elements.
Adenocarcinoma
Photosensitive Ru(II) Complexes as Inhibitors of the Major Human Drug Metabolizing Enzyme CYP3A4.
Adenocarcinoma
Real-time quantitative polymerase chain reaction for MDR1, MRP1, MRP2, and CYP3A-mRNA levels in Caco-2 cell lines, human duodenal enterocytes, normal colorectal tissues, and colorectal adenocarcinomas.
Adenocarcinoma
[Regulatory mechanisms of gut microbiota on intestinal CYP3A and P-glycoprotein in rats with dextran sulfate sodium-induced colitis].
Adenocarcinoma of Lung
Regulation of CYP3A5 by glucocorticoids and cigarette smoke in human lung-derived cells.
Adenocarcinoma of Lung
The expression levels of CYP3A4 and CYP3A5 serve as potential prognostic biomarkers in lung adenocarcinoma.
Adenoma
Association of CYP1B1 germ line mutations with hepatocyte nuclear factor 1alpha-mutated hepatocellular adenoma.
Adenoma
Decreased expression of cytochrome P450 protein in non-malignant colonic tissue of patients with colonic adenoma.
Adrenal Cortex Neoplasms
Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5?-reductase, explaining the need for personalized glucocorticoid and androgen replacement.
Adrenal Hyperplasia, Congenital
Clinical Role of CYP2C19 Polymorphisms in Patients with Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency.
Adrenal Hyperplasia, Congenital
Extraadrenal 21-hydroxylation by CYP2C19 and CYP3A4: effect on 21-hydroxylase deficiency.
Adrenal Insufficiency
IATROGENIC CUSHING SYNDROME IN AN HIV-INFECTED PATIENT SECONDARY TO CONCOMITANT THERAPY WITH GENVOYA AND EPIDURAL TRIAMCINOLONE.
Adrenal Insufficiency
Iatrogenic Cushing's syndrome due to drug interaction between glucocorticoids and the ritonavir or cobicistat containing HIV therapies.
Adrenal Insufficiency
Rapid Onset of Iatrogenic Adrenal Insufficiency in a Patient with Cystic Fibrosis-Related Liver Disease Treated with Inhaled Corticosteroids and a Moderate CYP3A4 Inhibitor.
Adrenal Insufficiency
Triamcinolone acetonide induced secondary adrenal insufficiency related to impaired CYP3A4 metabolism by coadministration of nefazodone.
Adrenocortical Carcinoma
Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma.
Alopecia
Association Study Among Candidate Genetic Polymorphisms and Chemotherapy-Related Severe Toxicity in Testicular Cancer Patients.
Alopecia
Finasteride 1 mg has no inhibitory effect on omeprazole metabolism in extensive and poor metabolizers for CYP2C19 in Japanese.
Altitude Sickness
[Effect of high altitude hypoxia on the activity and protein expression of CYP2C9 and CYP2C19].
Alzheimer Disease
Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment?
Alzheimer Disease
Donepezil plasma concentrations, CYP2D6 and CYP3A4 phenotypes, and cognitive outcome in Alzheimer's disease.
Alzheimer Disease
Effect of CYP2D6 and CYP3A4 Genotypes on the Efficacy of Cholinesterase Inhibitors in Southern Chinese Patients With Alzheimer's Disease.
Alzheimer Disease
Enhancement of oral bioavailability of rivastigmine with quercetin nanoparticles by inhibiting CYP3A4 and esterases.
Alzheimer Disease
Impact of CYP2D6 and CYP3A4 genetic polymorphism on combined cholinesterase inhibitors and memantine treatment in mild to moderate Alzheimer's disease.
Alzheimer Disease
The Effects on Metabolic Clearance when Administering a Potent CYP3A Autoinducer with the Prototypic CYP3A Inhibitor, Ketoconazole.
Alzheimer Disease
Transport and uptake of clausenamide enantiomers in CYP3A4-transfected Caco-2 cells: An insight into the efflux-metabolism alliance.
Alzheimer Disease
[The role of CYP2C19 polymorphism in the development of adverse effects to drugs and the risk for diseases]
Amyotrophic Lateral Sclerosis
[The role of CYP2C19 polymorphism in the development of adverse effects to drugs and the risk for diseases]
Anemia, Aplastic
Genetic polymorphisms of CYP3A4, GSTT1, GSTM1, GSTP1 and NQO1 and the risk of acquired idiopathic aplastic anemia in Caucasian patients.
Anemia, Hemolytic
Pharmacogenetic testing in the Veterans Health Administration (VHA): policy recommendations from the VHA Clinical Pharmacogenetics Subcommittee.
Anemia, Sickle Cell
(281) Genetic variability of UGT2B7, CYP3A4, CYP3A5 and CYP2B6 DMETs in a sickle cell disease patient cohort.
Anemia, Sickle Cell
Progressing Preemptive Genotyping of CYP2C19 Allelic Variants for Sickle Cell Disease Patients.
Angina, Stable
Comparison of the effect of CYP2C19 polymorphism on clinical outcome between acute coronary syndrome and stable angina.
Angina, Stable
CYP2C19 Poor Metabolizer Is Associated with Clinical Outcome of Clopidogrel Therapy in Acute Myocardial Infarction but Not Stable Angina.
Angina, Stable
[The value of cytochrome P4502C19 gene assay for anti-platelet therapy after PCI in stable angina patients with left main coronary artery lesions].
Angina, Unstable
A pharmacoepidemiology study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention.
Angina, Unstable
Clopidogrel versus Ticagrelor in CYP2C19 Loss-of-Function Allele Noncarriers: A Real-World Study in China.
Angina, Unstable
Co-administration of cyclosporine and ticagrelor may lead to a higher exposure to cyclosporine: a case report of a 49-year old man.
Angina, Unstable
Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data.
Anosmia
Efficacy of local budesonide therapy in the management of persistent hyposmia in COVID-19 patients without signs of severity: A structured summary of a study protocol for a randomised controlled trial.
Apnea
Induction of cytochrome P450 1A by cow milk-based formula: a comparative study between human milk and formula.
Argininosuccinic Aciduria
Regulation of CYP1A and CYP3A mRNAs by ascorbic acid in guinea pigs.
Arrhythmias, Cardiac
Assessment of the potential for a pharmacokinetic interaction between fluoxetine and terfenadine.
Arrhythmias, Cardiac
Bortezomib: new indication. Second-line treatment of myeloma: limited efficacy, major risks.
Arrhythmias, Cardiac
Integrated Isogenic Human Induced Pluripotent Stem Cell-Based Liver and Heart Microphysiological Systems Predict Unsafe Drug-Drug Interaction.
Arrhythmias, Cardiac
Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.
Arthritis
Changes in expression of hepatic cytochrome P450 subfamily enzymes during development of adjuvant-induced arthritis in rats.
Arthritis, Experimental
Decreased intestinal CYP3A and P-glycoprotein activities in rats with adjuvant arthritis.
Arthritis, Psoriatic
Allelic variants of drug metabolizing enzymes as risk factors in psoriasis.
Arthritis, Rheumatoid
4?-Hydroxycholesterol Level in Patients With Rheumatoid Arthritis Before vs. After Initiation of bDMARDs and Correlation With Inflammatory State.
Arthritis, Rheumatoid
Associations between Cytokine Levels and CYP3A4 Phenotype in Patients with Rheumatoid Arthritis.
Arthritis, Rheumatoid
Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine.
Arthritis, Rheumatoid
CYP2D6 and CYP3A4 variants influence the risk and outcome of COVID-19 infection among rheumatoid arthritis patients maintained on hydroxychloroquine.
Arthritis, Rheumatoid
Discovery of novel PI3-kinase ? specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition.
Arthritis, Rheumatoid
Effects of Upadacitinib Coadministration on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates: A Study With the Modified Cooperstown 5+1 Cocktail.
Arthritis, Rheumatoid
Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Pharmacokinetic Drug Interaction between Tofacitinib and Voriconazole in Rats.
Arthritis, Rheumatoid
Semiphysiologically Based Pharmacokinetic Model of Leflunomide Disposition in Rheumatoid Arthritis Patients.
Aspergillosis
A pharmacokinetic/pharmacodynamic analysis of a standard voriconazole regimen in different CYP2C19 genotypes by Monte Carlo simulation.
Aspergillosis
A prospective observational study of CYP2C19 polymorphisms and voriconazole plasma level in adult Thai patients with invasive aspergillosis.
Aspergillosis
Invasive aspergillosis in a paediatric allogeneic stem cell transplantation recipient owing to a susceptible Aspergillus fumigatus: Treatment failure with high doses of voriconazole and influence of CYP2C19 polymorphisms.
Aspergillosis
Invasive Aspergillus infection requiring lobectomy in a CYP2C19 rapid metabolizer with subtherapeutic voriconazole concentrations.
Aspergillosis
Optimization of Voriconazole Therapy for the Treatment of Invasive Fungal Infections in Adults.
Aspergillosis
Randomised multicentre clinical trial to evaluate voriconazole pre-emptive genotyping strategy in patients with risk of aspergillosis: vorigenipharm study protocol.
Aspergillosis
Successful and safe long-term treatment of cerebral aspergillosis with high-dose voriconazole guided by therapeutic drug monitoring.
Aspergillosis
Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed.
Asthma
Association of matrix metalloproteinase 8 genetic polymorphisms with bronchial asthma in a Japanese population.
Asthma
Bioactivation of a novel 2-methylindole-containing dual chemoattractant receptor-homologous molecule expressed on T-helper type-2 cells/D-prostanoid receptor antagonist leads to mechanism-based CYP3A inactivation: glutathione adduct characterization and prediction of in vivo drug-drug interaction.
Asthma
Discovery of potential asthma targets based on the clinical efficacy of Traditional Chinese Medicine formulas.
Asthma
Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir.
Asthma
Fluticasone Propionate Pharmacogenetics: CYP3A4*22 Polymorphism and Pediatric Asthma Control.
Asthma
Genotype tailored treatment of mild symptomatic acid reflux in children with uncontrolled asthma (GenARA): Rationale and methods.
Asthma
Lack of a pharmacokinetic interaction between steady-state roflumilast and single-dose midazolam in healthy subjects.
Asthma
Lansoprazole Is Associated with Worsening Asthma Control in Children with the CYP2C19 Poor Metabolizer Phenotype.
Asthma
Pharmacogenetic Factors Affecting Asthma Treatment Response. Potential Implications for Drug Therapy.
Asthma
Regulation of CYP3A5 by glucocorticoids and cigarette smoke in human lung-derived cells.
Ataxia
Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.
Atherosclerosis
Age-dependent association of CYP2C19 polymorphisms with clinical outcome of clopidogrel therapy in minor stroke patients with large-artery atherosclerosis.
Atherosclerosis
Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial.
Atrial Fibrillation
CYP2C19 Loss-of-Function is Associated with Increased Risk of Ischemic Stroke after Transient Ischemic Attack in Intracranial Atherosclerotic Disease.
Atrial Fibrillation
CYP2C19*17 May Increase the Risk of Death Among Patients with an Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Who Receive Clopidogrel and Rivaroxaban.
Atrial Fibrillation
Drug-drug interaction of rivaroxaban and calcium channel blockers in patients aged 80 years and older with nonvalvular atrial fibrillation.
Atrial Fibrillation
Effects of different CYP2C19 genotypes on prognosis of patients complicated with atrial fibrillation taking clopidogrel after PCI.
Atrial Fibrillation
Heart rate modulation in stable coronary artery disease without clinical heart failure: What we have already learned from SIGNIFY?
Atrial Fibrillation
Impact of CYP2C19 gene polymorphism on warfarin maintenance doses in patients with non-valvular atrial fibrillation.
Atrial Fibrillation
Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection.
Atrial Fibrillation
Non-vitamin K Oral Anticoagulants and Anti-seizure Medications: A Retrospective Cohort Study.
Atrial Fibrillation
Quantifying the Effect of Covariates on Concentrations and Effects of Steady-State Phenprocoumon Using a Population Pharmacokinetic/Pharmacodynamic Model.
Atrial Fibrillation
[Heart rate modulation in stable ischemic heart disease: what we have learned from the SIGNIFY study?].
Azoospermia
Pharmacogenetic polymorphisms of the AR and metabolism and susceptibility to hormone-induced azoospermia.
Barrett Esophagus
Cytochromes P450 are expressed in proliferating cells in Barrett's metaplasia.
beta-Thalassemia
Modification of CYP2E1 and CYP3A4 activities in haemoglobin E-beta thalassemia patients.
Bile Reflux
Rapid progressive long esophageal stricture caused by gastroesophageal reflux disease after pylorus-preserving pancreatoduodenectomy.
Bile Reflux
[Pathogenesis and treatment of refractory gastroesophageal reflux disease in Japanese patients]
Biliary Tract Neoplasms
A genetic polymorphism of CYP2C19 is associated with susceptibility to biliary tract cancer.
Blister
Hepatotoxicity of the herbal medicine germander: metabolic activation of its furano diterpenoids by cytochrome P450 3A Depletes cytoskeleton-associated protein thiols and forms plasma membrane blebs in rat hepatocytes.
Brain Death
Nonalcoholic Fatty Liver Disease and Diabetes Are Associated with Decreased CYP3A4 Protein Expression and Activity in Human Liver.
Brain Diseases
Possible role of CYP2B6 genetic polymorphisms in ifosfamide-induced encephalopathy: report of three cases.
Breast Neoplasms
A Novel Multiplex PCR-RFLP Method for Simultaneous Genotyping of CYP3A4*4 A>G, CYP3A4*18B G>A and CYP3A4*22 C>T.
Breast Neoplasms
A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis.
Breast Neoplasms
ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy.
Breast Neoplasms
Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma.
Breast Neoplasms
African American-preponderant single nucleotide polymorphisms (SNPs) and risk of breast cancer.
Breast Neoplasms
Analysis of drug metabolism activities in a miniaturized liver cell bioreactor for use in pharmacological studies.
Breast Neoplasms
Association of CYP2C19 polymorphisms with survival of breast cancer patients using tamoxifen: results of a meta- analysis.
Breast Neoplasms
Association of CYP2C19*2 and ALDH1A1*1/*2 variants with disease outcome in breast cancer patients: results of a global screening array.
Breast Neoplasms
Association of CYP2C19*2 and Associated Haplotypes with Lower Norendoxifen Levels in Tamoxifen-treated Asian Breast Cancer Patients.
Breast Neoplasms
Association of CYP2C19*3 gene polymorphism with breast cancer in Chinese women.
Breast Neoplasms
Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen.
Breast Neoplasms
Association of cytochrome P450 genetic polymorphisms with neoadjuvant chemotherapy efficacy in breast cancer patients.
Breast Neoplasms
Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer.
Breast Neoplasms
Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.
Breast Neoplasms
Clinical Drug-Drug Interaction Potential of BFE1224, Prodrug of Antifungal Ravuconazole, Using Two Types of Cocktails in Healthy Subjects.
Breast Neoplasms
Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers.
Breast Neoplasms
Correlations between CYP3A4 polymorphism and susceptibility to breast cancer in Chinese Han population.
Breast Neoplasms
Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients.
Breast Neoplasms
CYP2C19 2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment.
Breast Neoplasms
CYP2C19*2 and CYP2C19*17 variants and effect of tamoxifen on breast cancer recurrence: Analysis of the International Tamoxifen Pharmacogenomics Consortium dataset.
Breast Neoplasms
CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen.
Breast Neoplasms
CYP3A4 expression in breast cancer and its association with risk factors in Mexican women.
Breast Neoplasms
CYP3A4 expression to predict treatment response to docetaxel for metastasis and recurrence of primary breast cancer.
Breast Neoplasms
CYP3A4 mediates growth of ER+ breast cancer cells, in part, by nuclear translocation of phospho-Stat3 through biosynthesis of ({+/-})-14,15-EET.
Breast Neoplasms
CYP3A4 polymorphisms--potential risk factors for breast and prostate cancer: a HuGE review.
Breast Neoplasms
CYP3A4, CYP2C9 and CYP2B6 expression and ifosfamide turnover in breast cancer tissue microsomes.
Breast Neoplasms
Cytochrome P450 Genetic Variation Associated with Tamoxifen Biotransformation in American Indian and Alaska Native People.
Breast Neoplasms
Development, Verification, and Prediction of Osimertinib Drug-Drug Interactions Using PBPK Modeling Approach to Inform Drug Label.
Breast Neoplasms
Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment.
Breast Neoplasms
Do single nucleotide polymorphisms in xenobiotic metabolizing genes determine breast cancer susceptibility and treatment outcomes?
Breast Neoplasms
Drug metabolising enzyme polymorphisms and chemotherapy-related ovarian failure in young breast cancer survivors.
Breast Neoplasms
Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort.
Breast Neoplasms
Effect of CYP2C19 and CYP2D6 genotype on tamoxifen treatment outcome indicates endogenous and exogenous interplay.
Breast Neoplasms
Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse.
Breast Neoplasms
Effects of morin on the pharmacokinetics of etoposide in 7,12-dimethylbenz[a]anthracene-induced mammary tumors in female Sprague-Dawley rats.
Breast Neoplasms
Epidemiological study of urinary 6beta-hydroxycortisol to cortisol ratios and breast cancer risk.
Breast Neoplasms
Frequency and prognostic significant of CYP3A4-A-290G polymorphism in acute myeloid leukemia.
Breast Neoplasms
Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen.
Breast Neoplasms
Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.
Breast Neoplasms
Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women.
Breast Neoplasms
Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study.
Breast Neoplasms
Genetic Variation in the Progesterone Receptor and Metabolism Pathways and Hormone Therapy in Relation to Breast Cancer Risk.
Breast Neoplasms
Heme Binding Biguanides Target Cytochrome P450-Dependent Cancer Cell Mitochondria.
Breast Neoplasms
Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients.
Breast Neoplasms
Immunohistochemical evaluation of cytochrome P450 (CYP) and p53 in breast cancer.
Breast Neoplasms
Immunolocalisation of cytochrome P-450 3A enzymes in human breast carcinoma: relationship with tumour differentiation and steroid receptors.
Breast Neoplasms
Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients.
Breast Neoplasms
Implication of Xenobiotic Metabolizing Enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and NAT2) polymorphisms in breast carcinoma.
Breast Neoplasms
In vitro evidence suggesting that the toll-like receptor 7 and 8 agonist resiquimod (R-848) unlikely affects drug levels of co-administered compounds.
Breast Neoplasms
In-Depth Characterization of EpiIntestinal Microtissue as a Model for Intestinal Drug Absorption and Metabolism in Human.
Breast Neoplasms
Influence of CYP2D6 and CYP3A4 Phenotypes, Drug Interactions, and Vitamin D Status on Tamoxifen Biotransformation.
Breast Neoplasms
Influence of CYP2D6 polymorphisms on serum levels of tamoxifen metabolites in Spanish women with breast cancer.
Breast Neoplasms
Interaction Between Cyclosporine and Palbociclib in a Renal Transplant Patient: Case Report and Pharmacokinetic Perspective.
Breast Neoplasms
Lack of association of single-nucleotide polymorphisms in pregnane X receptor, hepatic nuclear factor 4alpha, and constitutive androstane receptor with docetaxel pharmacokinetics.
Breast Neoplasms
Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration in 2017.
Breast Neoplasms
Mechanisms and Predictions of Drug-Drug Interactions of the Hepatitis C Virus Three Direct-Acting Antiviral Regimen: Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir.
Breast Neoplasms
Molecular epidemiology of breast cancer: genetic variation in steroid hormone metabolism.
Breast Neoplasms
Multi-gene and Drug Interaction Approach for Tamoxifen Metabolite Patterns Reveals Possible Involvement of CYP2C9, CYP2C19 and ABCB1.
Breast Neoplasms
NCT01110291: induction of CYP3A activity and lowered exposure to docetaxel in patients with primary breast cancer.
Breast Neoplasms
Novel mutations of CYP3A4 in fine needle aspiration cytology samples of breast cancer patients and its clinical correlations.
Breast Neoplasms
P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability.
Breast Neoplasms
Paclitaxel Nanoparticles Induce Apoptosis and Regulate TXR1, CYP3A4 and CYP2C8 in Breast Cancer and Hepatoma Cells.
Breast Neoplasms
Pairwise combinations of estrogen metabolism genotypes in postmenopausal breast cancer etiology.
Breast Neoplasms
Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma.
Breast Neoplasms
Pharmacogenetic modulation of combined hormone replacement therapy by progesterone-metabolism genotypes in postmenopausal breast cancer risk.
Breast Neoplasms
Pharmacogenetics as Personalized Medicine: Association Investigation of SOD2 rs4880, CYP2C19 rs4244285, and FCGR2A rs1801274 Polymorphisms in a Breast Cancer Population in Iraqi Women.
Breast Neoplasms
Pharmacokinetic Drug-Drug Interaction of Apalutamide, Part 1: Clinical Studies in Healthy Men and Patients with Castration-Resistant Prostate Cancer.
Breast Neoplasms
Pharmacokinetic interaction profile of riociguat, a new soluble guanylate cyclase stimulator, in vitro.
Breast Neoplasms
Pharmacokinetics of cyclophosphamide enantiomers in patients with breast cancer.
Breast Neoplasms
Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects.
Breast Neoplasms
Pharmacokinetics, Pharmacodynamics and Drug-Drug Interactions of New Anti-Migraine Drugs-Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies.
Breast Neoplasms
Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel.
Breast Neoplasms
Polymorphisms in estrogen biosynthesis and metabolism-related genes, ionizing radiation exposure, and risk of breast cancer among US radiologic technologists.
Breast Neoplasms
Polymorphisms of GSTP1 is associated with differences of chemotherapy response and toxicity in breast cancer.
Breast Neoplasms
Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues.
Breast Neoplasms
Predictive pharmacogenetic biomarkers for breast cancer recurrence prevention by simvastatin.
Breast Neoplasms
Preventive medical services not covered by public health insurance at Daiko Medical Center in Japan, 2004-2011.
Breast Neoplasms
Profound reduction in tamoxifen active metabolite endoxifen in a breast cancer patient treated with rifampin prior to initiation of an anti-TNF? biologic for ulcerative colitis: a case report.
Breast Neoplasms
PXR pharmacogenetics: association of haplotypes with hepatic CYP3A4 and ABCB1 messenger RNA expression and doxorubicin clearance in Asian breast cancer patients.
Breast Neoplasms
PXR, CAR and HNF4alpha genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients.
Breast Neoplasms
Reductive amination-assisted quantitation of tamoxifen and its metabolites by liquid phase chromatography tandem mass spectrometry.
Breast Neoplasms
Regioselective hydroxylation of steroid hormones by human cytochromes P450.
Breast Neoplasms
Relationship between CYP3A activity and breast cancer susceptibility in Chinese Han women.
Breast Neoplasms
Relationship between genotypes Sult1a2 and Cyp2d6 and tamoxifen metabolism in breast cancer patients.
Breast Neoplasms
Representation of CYP3A4, CYP3A5 and UGT1A4 Polymorphisms within Croatian Breast Cancer Patients' Population.
Breast Neoplasms
Role of pharmacogenetics on adjuvant chemotherapy-induced neutropenia in Chinese breast cancer patients.
Breast Neoplasms
Role of the CYP3A4-mediated 11,12-epoxyeicosatrienoic acid pathway in the development of tamoxifen-resistant breast cancer.
Breast Neoplasms
Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms.
Breast Neoplasms
Studies on CYP1A1, CYP1B1 and CYP3A4 gene polymorphisms in breast cancer patients.
Breast Neoplasms
Studies on the role of metabolic activation in tyrosine kinase inhibitor-dependent hepatotoxicity: induction of CYP3A4 enhances the cytotoxicity of lapatinib in HepaRG cells.
Breast Neoplasms
SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen.
Breast Neoplasms
Tamoxifen activates CYP3A4 and MDR1 genes through steroid and xenobiotic receptor in breast cancer cells.
Breast Neoplasms
The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy.
Breast Neoplasms
The associations of genetic polymorphisms in CYP1A2 and CYP3A4 with clinical outcomes of breast cancer patients in northern China.
Breast Neoplasms
The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients.
Breast Neoplasms
The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer.
Breast Neoplasms
The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomes.
Breast Neoplasms
The Influence of CYP3A4 Polymorphism in Sex Steroids as a Risk Factor for Breast Cancer.
Breast Neoplasms
The influence of genetic polymorphisms on the efficacy and side effects of anastrozole in postmenopausal breast cancer patients.
Breast Neoplasms
The phospholipidosis-lnducing potential of the chemopotentiating drug, N,N-Diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine (DPPE, tesmilifene) correlates with its stimulation of phosphatidylserine synthesis and exposure on the plasma membrane in MCF-7 breast cancer cells.
Breast Neoplasms
The role of cytochromes p450 and aldo-keto reductases in prognosis of breast carcinoma patients.
Breast Neoplasms
Thiamine transporter gene expression and exogenous thiamine modulate the expression of genes involved in drug and prostaglandin metabolism in breast cancer cells.
Breast Neoplasms
Usefulness of novobiocin as a selective inhibitor of intestinal breast cancer resistance protein (Bcrp) in rats.
Breast Neoplasms
Whole genome amplification of DNA for genotyping pharmacogenetics candidate genes.
Breast Neoplasms
[Genetic polymorphism and variability of steroid hormone metabolism: connection with risk of developing breast neoplasms]
Carcinogenesis
Correlations between CYP3A4 polymorphism and susceptibility to breast cancer in Chinese Han population.
Carcinogenesis
CYP3A4 polymorphisms--potential risk factors for breast and prostate cancer: a HuGE review.
Carcinogenesis
Decreased expression of cytochrome P450 protein in non-malignant colonic tissue of patients with colonic adenoma.
Carcinogenesis
Methylation of the Constitutive Androstane Receptor Is Involved in the Suppression of CYP2C19 in Hepatitis B Virus-Associated Hepatocellular Carcinoma.
Carcinogenesis
Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.
Carcinogenesis
Salvianolic acid B modulates the expression of drug-metabolizing enzymes in HepG2 cells.
Carcinogenesis
The CYP3A4 *1B polymorphism and prostate cancer susceptibility in a Portuguese population.
Carcinogenesis
The frameshift polymorphism CYP3A43_74_delA is associated with poor differentiation of breast tumors.
Carcinogenesis
Tissue-specific regulation of pregnane X receptor in cancer development and therapy.
Carcinogenesis
Transcriptional targets of the chromatin-remodelling factor SMARCA4/BRG1 in lung cancer cells.
Carcinogenesis
Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium.
Carcinoma
Activation of Fas receptor modulates cytochrome P450 3A4 expression in human colon carcinoma cells.
Carcinoma
Association of CYP2C19 *17/*17 Genotype With the Risk of Voriconazole-Associated Squamous Cell Carcinoma.
Carcinoma
Association of Genetic Variants of CYP2C19 and CYP2D6 with Esophageal Squamous Cell Carcinoma Risk in Northern India, Kashmir.
Carcinoma
Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion.
Carcinoma
Cyclin-dependent kinase 2 negatively regulates human pregnane X receptor-mediated CYP3A4 gene expression in HepG2 liver carcinoma cells.
Carcinoma
Differences in cytochrome P450 2C19 (CYP2C19) expression in adjacent normal and tumor tissues in Chinese cancer patients.
Carcinoma
Dual-color fluorescence imaging to monitor CYP3A4 and CYP3A7 expression in human hepatic carcinoma HepG2 and HepaRG cells.
Carcinoma
Effects of herbal medicinal products and food supplements on induction of CYP1A2, CYP3A4 and MDR1 in the human colon carcinoma cell line LS180.
Carcinoma
Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4-dependent pharmacokinetics in humans.
Carcinoma
Expression alterations of cytochromes P4501A1, 2E1, and 3A, and their receptors AhR and PXR caused by 1-octyl-3-methylimidazolium chloride in mouse mammary carcinoma cells.
Carcinoma
Expression of cytochrome P 450 3A enzymes in human lung: a combined RT-PCR and immunohistochemical analysis of normal tissue and lung tumours.
Carcinoma
Flavonoids activate pregnane x receptor-mediated CYP3A4 gene expression by inhibiting cyclin-dependent kinases in HepG2 liver carcinoma cells.
Carcinoma
Gene expression of CYP3A4, ABC-transporters (MDR1 and MRP1-MRP5) and hPXR in three different human colon carcinoma cell lines.
Carcinoma
Identification and characterization of genes associated with human hepatocellular carcinogenesis.
Carcinoma
Immunohistochemical localization of cytochrome P450 3A in human pulmonary carcinomas and normal bronchial tissue.
Carcinoma
Independent and combined effects of environmental factors and CYP2C19 polymorphisms on the risk of esophageal squamous cell carcinoma in Fujian Province of China.
Carcinoma
Inhibitory effect of nitric oxide on the induction of cytochrome P450 3A4 mRNA by 1,25-dihydroxyvitamin D3 in Caco-2 cells.
Carcinoma
Interaction between Alcohol Consumption and CYP 2C19 Gene Polymorphism in Relation to Oesophageal Squamous Cell Carcinoma.
Carcinoma
Interaction between CYP 2C19*3 polymorphism and smoking in relation to laryngeal carcinoma in the Chinese Han population.
Carcinoma
Loss of CYP3A7 gene induction by 1,25-dihydroxyvitamin D3 is caused by less binding of VDR to the proximal ER6 in CYP3A7 gene.
Carcinoma
Modulation of CYP3A4 expression by ceramide in human colon carcinoma HT-29 cells.
Carcinoma
P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans.
Carcinoma
Pharmacokinetics of sunitinib in combination with fluoroquinolones in rabbit model.
Carcinoma
Protein phosphatase 2Cbetal regulates human pregnane X receptor-mediated CYP3A4 gene expression in HepG2 liver carcinoma cells.
Carcinoma
PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide.
Carcinoma
Role of human pregnane X receptor in tamoxifen- and 4-hydroxytamoxifen-mediated CYP3A4 induction in primary human hepatocytes and LS174T cells.
Carcinoma
Study the polymorphism of CYP3A5 and CYP3A4 loci in Iranian population with laryngeal squamous cell carcinoma.
Carcinoma
Sunitinib for metastatic renal cell cancer patients: observational study highlighting the risk of important drug-drug interactions.
Carcinoma
Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma.
Carcinoma, Hepatocellular
A cell-based reporter gene assay for determining induction of CYP3A4 in a high-volume system.
Carcinoma, Hepatocellular
A Fibroblast Growth Factor 21-Pregnane X Receptor Pathway Downregulates Hepatic CYP3A4 in Nonalcoholic Fatty Liver Disease.
Carcinoma, Hepatocellular
A Pharmacokinetic Interaction Study of Sorafenib and Iced Teas in Rats Using UPLC-MS/MS: An Illustration of Beverage-Drug Interaction.
Carcinoma, Hepatocellular
A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma.
Carcinoma, Hepatocellular
A PXR reporter gene assay in a stable cell culture system: CYP3A4 and CYP2B6 induction by pesticides.
Carcinoma, Hepatocellular
A two-dimensional multiwell cell culture method for the production of CYP3A4-expressing hepatocyte-like cells from HepaRG cells.
Carcinoma, Hepatocellular
Activation of the steroid and xenobiotic receptor (human pregnane X receptor) by nontaxane microtubule-stabilizing agents.
Carcinoma, Hepatocellular
Alisol B 23-acetate from the rhizomes of Alisma orientale is a natural agonist of the human pregnane X receptor.
Carcinoma, Hepatocellular
Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid.
Carcinoma, Hepatocellular
Biotransformation of 17 beta-hydroxy-11 beta-(4-dimethylaminophenyl)17 alpha-1-propynyl-estra-4,9-dien-3-one (RU486) in rat hepatoma variants.
Carcinoma, Hepatocellular
Cis-Nerolidol Induces Endoplasmic Reticulum Stress and Cell Death in Human Hepatocellular Carcinoma Cells through Extensive CYP2C19 and CYP1A2 Oxidation.
Carcinoma, Hepatocellular
Cloning and functional expression of a first inducible avian cytochrome P450 of the CYP3A subfamily (CYP3A37).
Carcinoma, Hepatocellular
Comparative analysis of human CYP3A4 and rat CYP3A1 induction and relevant gene expression by bisphenol A and diethylstilbestrol: Implications for toxicity testing paradigms.
Carcinoma, Hepatocellular
Correlation of PPM1A Downregulation with CYP3A4 Repression in the Tumor Liver Tissue of Hepatocellular Carcinoma Patients.
Carcinoma, Hepatocellular
CYP2C19 Genotype Could be a Predictive Factor for Aggressive Manifestations of Hepatocellular Carcinoma Related with Chronic Hepatitis B Infection in Thailand.
Carcinoma, Hepatocellular
CYP3A Activity and Expression in Nonalcoholic Fatty Liver Disease.
Carcinoma, Hepatocellular
CYP3A4 catalytic activity is induced in confluent Huh7 hepatoma cells.
Carcinoma, Hepatocellular
CYP3A4 inducible model for in vitro analysis of human drug metabolism using a bioartificial liver.
Carcinoma, Hepatocellular
CYP3A4-dependent cellular response does not relate to CYP3A4-catalysed metabolites of C-1748 and C-1305 acridine antitumor agents in HepG2 cells.
Carcinoma, Hepatocellular
CYP450 enzyme-specific enantioselective species-specific response for metalaxyl in in vitro hepatic cells.
Carcinoma, Hepatocellular
Cytochromes P450 (CYP) in the Poeciliopsis lucida hepatocellular carcinoma cell line (PLHC-1): dose- and time-dependent glucocorticoid potentiation of CYP1A induction without induction of CYP3A.
Carcinoma, Hepatocellular
Cytotoxic effects of benzbromarone and its 1'-hydroxy metabolite in human hepatocarcinoma FLC4 cells cultured on micro-space cell culture plates.
Carcinoma, Hepatocellular
Cytotoxicity of 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione (DCPT) and analogues in wild type and CYP3A4 stably transfected HepG2 cells.
Carcinoma, Hepatocellular
Development of a Highly Sensitive Cytotoxicity Assay System for CYP3A4-Mediated Metabolic Activation.
Carcinoma, Hepatocellular
Differences in cytochrome P450 2C19 (CYP2C19) expression in adjacent normal and tumor tissues in Chinese cancer patients.
Carcinoma, Hepatocellular
Drug-metabolising enzymes are down-regulated by hypoxia in differentiated human hepatoma HepaRG cells: HIF-1alpha involvement in CYP3A4 repression.
Carcinoma, Hepatocellular
Effects of cytokines on CYP3A4 expression and reversal of the effects by anti-cytokine agents in the three-dimensionally cultured human hepatoma cell line FLC-4.
Carcinoma, Hepatocellular
Enhanced anti-cancer activity by menthol in HepG2 cells exposed to paclitaxel and vincristine: possible involvement of CYP3A4 downregulation.
Carcinoma, Hepatocellular
ER stress reliever enhances functionalities of in vitro cultured hepatocytes.
Carcinoma, Hepatocellular
Evaluation of CYP3A4 inhibition and hepatotoxicity using DMSO-treated human hepatoma HuH-7 cells.
Carcinoma, Hepatocellular
Evaluation of genipin on human cytochrome P450 isoenzymes and P-glycoprotein in vitro.
Carcinoma, Hepatocellular
Fucoxanthin Attenuates Rifampin-Induced Cytochrome P450 3A4 (CYP3A4) and Multiple Drug Resistance 1 (MDR1) Gene Expression Through Pregnane X Receptor (PXR)-Mediated Pathways in Human Hepatoma HepG2 and Colon Adenocarcinoma LS174T Cells.
Carcinoma, Hepatocellular
Genotype analysis of the CYP2C19 gene in HCV-seropositive patients with cirrhosis and hepatocellular carcinoma.
Carcinoma, Hepatocellular
Histone deacetylase inhibitor stimulate CYP3A4 proximal promoter activity in HepG2 cells.
Carcinoma, Hepatocellular
Human hepatoma cell lines on gas foaming templated alginate scaffolds for in vitro drug-drug interaction and metabolism studies.
Carcinoma, Hepatocellular
Identification and characterization of genes associated with human hepatocellular carcinogenesis.
Carcinoma, Hepatocellular
Identification of a novel polymorphic enhancer of the human CYP3A4 gene.
Carcinoma, Hepatocellular
Immunohistochemical markers of CYP3A4 and CYP3A7: a new tool towards personalized pharmacotherapy of hepatocellular carcinoma.
Carcinoma, Hepatocellular
Impact of transcription factor profile and chromatin conformation on human hepatocyte CYP3A gene expression.
Carcinoma, Hepatocellular
Increased CYP3A4 copy number in TONG/HCC cells but not in DNA from other humans.
Carcinoma, Hepatocellular
Increased expression of drug-metabolizing enzymes in human hepatocarcinoma FLC-4 cells cultured on micro-space cell culture plates.
Carcinoma, Hepatocellular
Induced CYP3A4 expression in confluent Huh7 hepatoma cells as a result of decreased cell proliferation and subsequent pregnane X receptor activation.
Carcinoma, Hepatocellular
Interactions of pharmaceuticals and other xenobiotics on hepatic pregnane X receptor and cytochrome P450 3A signaling pathway in rainbow trout (Oncorhynchus mykiss).
Carcinoma, Hepatocellular
Janus kinase-dependent regulation of drug detoxifying protein expression by interleukin-22 in human hepatic cells.
Carcinoma, Hepatocellular
Metabolic Susceptibility of 2-Chlorothioxanthone and Its Toxic Effects on mRNA and Protein Expression and Activities of Human CYP1A2 and CYP3A4 Enzymes.
Carcinoma, Hepatocellular
Methylation of the Constitutive Androstane Receptor Is Involved in the Suppression of CYP2C19 in Hepatitis B Virus-Associated Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Modulation of CYP3A4 activity and induction of apoptosis, necrosis and senescence by the anti-tumour imidazoacridinone C-1311 in human hepatoma cells.
Carcinoma, Hepatocellular
Modulation of pregnane X receptor (PXR) and constitutive androstane receptor (CAR) activation by ursolic acid (UA) attenuates rifampin-isoniazid cytotoxicity.
Carcinoma, Hepatocellular
Multiparametric characterization by flow cytometry of flow-sorted subpopulations of a human hepatoma cell line useful for drug research.
Carcinoma, Hepatocellular
Novel naphthyloxy derivatives - Potent histamine H3 receptor ligands. Synthesis and pharmacological evaluation.
Carcinoma, Hepatocellular
Overexpression of CYP3A4, but not CYP2D6, promotes hypoxic response and cell growth of Hep3B cells.
Carcinoma, Hepatocellular
Paclitaxel Nanoparticles Induce Apoptosis and Regulate TXR1, CYP3A4 and CYP2C8 in Breast Cancer and Hepatoma Cells.
Carcinoma, Hepatocellular
Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma.
Carcinoma, Hepatocellular
Phase I study of tivantinib in Japanese patients with advanced hepatocellular carcinoma; distinctive PK profiles from other solid tumors.
Carcinoma, Hepatocellular
Polymorphic Variants of Cytochrome P450: Relevance to Cancer and Other Diseases.
Carcinoma, Hepatocellular
Population pharmacokinetics modeling and analysis of foretinib in adult patients with advanced solid tumors.
Carcinoma, Hepatocellular
Pungent ginger components modulates human cytochrome P450 enzymes in vitro.
Carcinoma, Hepatocellular
Regulation of CYP2C19 expression by estrogen receptor {alpha}: implications for estrogen-dependent inhibition of drug metabolism.
Carcinoma, Hepatocellular
Relative receptor expression is a determinant in xenobiotic-mediated CYP3A induction in rat and human cells.
Carcinoma, Hepatocellular
Retinoids activate the RXR/SXR-mediated pathway and induce the endogenous CYP3A4 activity in Huh7 human hepatoma cells.
Carcinoma, Hepatocellular
Retinoids induce cytochrome P450 3A4 through RXR/VDR-mediated pathway.
Carcinoma, Hepatocellular
Role of CYP3A4 in the regulation of the aryl hydrocarbon receptor by omeprazole sulphide.
Carcinoma, Hepatocellular
Role of hepatocyte nuclear factor 3 gamma in the expression of human CYP2C genes.
Carcinoma, Hepatocellular
Roles of CYP3A4, CYP3A5 and CYP2C8 drug-metabolizing enzymes in cellular cytostatic resistance.
Carcinoma, Hepatocellular
Saikosaponins and the deglycosylated metabolites exert liver meridian guiding effect through PXR/CYP3A4 inhibition.
Carcinoma, Hepatocellular
Selective induction of the CYP3A family by endosulfan and DNA-adduct formation in different hepatic and hepatoma cells.
Carcinoma, Hepatocellular
Signal transduction-mediated activation of the aryl hydrocarbon receptor in rat hepatoma H4IIE cells.
Carcinoma, Hepatocellular
Silybin and dehydrosilybin inhibit cytochrome P450 1A1 catalytic activity: A study in human keratinocytes and human hepatoma cells.
Carcinoma, Hepatocellular
Technical pentabromodiphenyl ether and hexabromocyclododecane as activators of the pregnane-X-receptor (PXR).
Carcinoma, Hepatocellular
The down-regulation of the CYP2C19 gene is associated with aggressive tumor potential and the poorer recurrence-free survival of hepatocellular carcinoma.
Carcinoma, Hepatocellular
The effect of interferon-? on the expression of cytochrome P450 3A4 in human hepatoma cells.
Carcinoma, Hepatocellular
The prognostic value of differentially expressed CYP3A subfamily members for hepatocellular carcinoma.
Carcinoma, Hepatocellular
The Synergistic Antitumor Effect of Tanshinone IIA Plus Adriamycin on Human Hepatocellular Carcinoma Xenograft in BALB/C Nude Mice and Their Influences on Cytochrome P450 CYP3A4 In Vivo.
Carcinoma, Hepatocellular
The transcription factor GATA-4 regulates cytochrome P4502C19 gene expression.
Carcinoma, Hepatocellular
Tumor Microenvironment Alters Chemoresistance of Hepatocellular Carcinoma Through CYP3A4 Metabolic Activity.
Carcinoma, Hepatocellular
Up-regulating CYP3A4 expression in C3A cells by transfection with a novel chimeric regulator of hPXR-p53-AD.
Carcinoma, Hepatocellular
Up-regulation of CYP expression in hepatoma cells stably transfected by chimeric nuclear receptors.
Carcinoma, Hepatocellular
Urinary 6 beta-hydroxycortisol excretion in Hong Kong Chinese patients with hepatocellular carcinoma and other chronic liver diseases.
Carcinoma, Non-Small-Cell Lung
CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
CYP3A4 genetic variants are associated with susceptibility of non-small cell lung cancer in a Shaanxi Han population.
Carcinoma, Non-Small-Cell Lung
Drug interaction between erlotinib and phenytoin for brain metastases in a patient with nonsmall cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Erlotinib treatment induces cytochrome P450 3A activity in non-small cell lung cancer patients.
Carcinoma, Non-Small-Cell Lung
Molecular docking of chemotherapeutic agents to CYP3A4 in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer using the CYP3A Inhibitor Cobicistat.
Carcinoma, Non-Small-Cell Lung
The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib.
Carcinoma, Non-Small-Cell Lung
Therapeutic effects and adverse drug reactions are affected by icotinib exposure and CYP2C19 and EGFR genotypes in Chinese non-small cell lung cancer patients.
Carcinoma, Renal Cell
Antitumour prodrug development using cytochrome P450 (CYP) mediated activation.
Carcinoma, Renal Cell
Pharmacokinetics of sunitinib in combination with fluoroquinolones in rabbit model.
Carcinoma, Renal Cell
Sunitinib for metastatic renal cell cancer patients: observational study highlighting the risk of important drug-drug interactions.
Carcinoma, Renal Cell
Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma.
Carcinoma, Squamous Cell
Association of CYP2C19 *17/*17 Genotype With the Risk of Voriconazole-Associated Squamous Cell Carcinoma.
Cardiomyopathies
Severe acute cardiomyopathy associated with venlafaxine overdose and possible role of CYP2D6 and CYP2C19 polymorphisms.
Cardiotoxicity
Bortezomib: new indication. Second-line treatment of myeloma: limited efficacy, major risks.
Cardiotoxicity
CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system.
Cardiotoxicity
Functional characteristics of CYP3A4 allelic variants on the metabolism of loperamide in vitro.
Cardiotoxicity
Pharmaceutical Characterization of MyoNovin, a Novel Skeletal Muscle Regenerator: in silico, in vitro and in vivo Studies.
Cardiotoxicity
The enhancement of cardiac toxicity by concomitant administration of Berberine and macrolides.
Cardiotoxicity
The enhancement of cardiotoxicity that results from inhibiton of CYP 3A4 activity and hERG channel by berberine in combination with statins.
Cardiovascular Diseases
A functional polymorphism in the CYP3A4 gene is associated with increased risk of coronary heart disease in the Chinese Han population.
Cardiovascular Diseases
Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients.
Cardiovascular Diseases
Association between CYP2C19 gene polymorphisms and lipid metabolism in Chinese patients with ischemic stroke.
Cardiovascular Diseases
Association of CYP2C19*2 and *3 genetic variants with essential hypertension in Koreans.
Cardiovascular Diseases
Association of CYP3A4*1G and CYP3A5*3 With the 1-year Outcome of Acute Ischemic Stroke in the Han Chinese Population.
Cardiovascular Diseases
Coding SNPs in hsa-miR-1343-3p and hsa-miR-6783-3p target sites of CYP2C19 modulates clopidogrel response in individuals with cardiovascular diseases.
Cardiovascular Diseases
Correlation between the CYP2C19 phenotype status and the results of three different platelet function tests in cardiovascular disease patients receiving antiplatelet therapy: an emphasis on newly introduced platelet function analyzer-200 P2Y test.
Cardiovascular Diseases
CYP2C19 genotype-guided antiplatelet therapy: promises and pitfalls.
Cardiovascular Diseases
Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease.
Cardiovascular Diseases
Influence of CYP2C19 polymorphisms on platelet reactivity and clinical outcomes in ischemic stroke patients treated with clopidogrel.
Cardiovascular Diseases
Influence of cytochrome 2C19 allelic variants on on-treatment platelet reactivity evaluated by five different platelet function tests.
Cardiovascular Diseases
Pantoprazole does not interact with nifedipine in man under steady-state conditions.
Cardiovascular Diseases
Prevalence and types of genetic polymorphisms of CYP2C19 and their effects on platelet aggregation inhibition by clopidogrel.
Cardiovascular Diseases
The clinical significance of statins-macrolides interaction: comprehensive review of in vivo studies, case reports, and population studies.
Cardiovascular Diseases
The influence of genetic polymorphism of Cyp2c19 isoenzyme on the pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases.
Cardiovascular Diseases
Tolerability and safety of eletriptan in the treatment of migraine: a comprehensive review.
Cardiovascular Diseases
[Relationship between ATP-binding cassette subfamily B member 1 and cytochrome P450 2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with acute coronary syndrome].
Carotid Stenosis
CYP2C19 Loss-of-Function Associated with First-Time Ischemic Stroke in Non-surgical Asymptomatic Carotid Artery Stenosis During Clopidogrel Therapy.
Celiac Disease
Decreased intestinal CYP3A in celiac disease: reversal after successful gluten-free diet: a potential source of interindividual variability in first-pass drug metabolism.
Central Nervous System Diseases
Disseminated Scedosporium prolificans infection in an 'extensive metaboliser': navigating the minefield of drug interactions and pharmacogenomics.
Cerebral Hemorrhage
Genetic factors for ischemic and hemorrhagic stroke in Japanese individuals.
Cerebral Infarction
Anti-Platelet Therapy in Mild Cerebral Infarction Patients on the Basis of CYP2C19 Metabolizer Status.
Cerebral Infarction
Correlation study of CYP2C19 gene polymorphism and clopidogrel resistance in Han Chinese patients with cerebral infarction in Guizhou region.
Cerebral Infarction
Genetic factors for ischemic and hemorrhagic stroke in Japanese individuals.
Cerebral Infarction
[Correlation between CYP2C19 Gene Polymorphism and Elderly Cerebral Infarction].
Cerebrovascular Disorders
Analysis of the CYP2C19 genetic polymorphism in Han and Uyghur patients with cardiovascular and cerebrovascular diseases in the Kashi area of Xinjiang.
Cerebrovascular Disorders
Cytochrome P450 2C19 Polymorphism is Associated with Reduced Clopidogrel Response in Cerebrovascular Disease.
Cerebrovascular Disorders
Effects of CYP2C19 and P2Y12 Gene Polymorphisms on Clinical Results of Patients Using Clopidogrel after Acute Ischemic Cerebrovascular Disease.
Cerebrovascular Disorders
Potential Usefulness of Clopidogrel Pharmacogenetics in Cerebral Endovascular Procedures and Carotid Artery Stenting.
Cerebrovascular Disorders
Reduced Clopidogrel Metabolism in a Multiethnic Population: Prevalence and Rates of Recurrent Cerebrovascular Events.
Cerebrovascular Disorders
Switching between ticagrelor and clopidogrel in patients who underwent percutaneous coronary intervention: insight into contemporary practice in Chinese patients.
Chemical and Drug Induced Liver Injury
Association of CYP2C19 and UGT1A4 polymorphisms with voriconazole-induced liver injury.
Chemical and Drug Induced Liver Injury
Lack of association between genetic polymorphisms of CYP3A4, CYP2C9, CYP2C19 and anti-tuberculosis drug-induced liver injury in community-based Chinese population.
Chemical and Drug Induced Liver Injury
Modeling of Hepatic Drug Metabolism and Responses in CYP2C19 Poor Metabolizer Using Genetically Manipulated Human iPS cells.
Chemical and Drug Induced Liver Injury
Reactive metabolite activation by CYP2C19-mediated rhein hepatotoxicity.
Cholangiocarcinoma
Inhibitory Activities of Thai Medicinal Plants with Promising Activities Against Malaria and Cholangiocarcinoma on Human Cytochrome P450.
Cholestasis
Feed-forward regulation of bile acid detoxification by CYP3A4: studies in humanized transgenic mice.
Cholestasis
Impaired Hepatic Adaptation to Chronic Cholestasis induced by Primary Sclerosing Cholangitis.
Cholestasis
Ligand diversity of human and chimpanzee CYP3A4: Activation of human CYP3A4 by lithocholic acid results from positive selection.
Cholestasis
Non-uniformity of Changes in Drug-Metabolizing Enzymes and Transporters in Liver Cirrhosis: Implications for Drug Dosage Adjustment.
Cholestasis
Optimization of the HepaRG cell model for drug metabolism and toxicity studies.
Cholestasis
Pregnane X receptor and constitutive androstane receptor modulate differently CYP3A-mediated metabolism in early- and late-stage cholestasis.
Cholestasis
Pregnane X receptor mediated-transcription regulation of CYP3A by glycyrrhizin: a possible mechanism for its hepatoprotective property against lithocholic acid-induced injury.
Cholestasis
Regulation of CYP3A4 by the bile acid receptor FXR: evidence for functional binding sites in the CYP3A4 gene.
Cholestasis
Rifampicin induction of CYP3A4 requires pregnane X receptor cross talk with hepatocyte nuclear factor 4alpha and coactivators, and suppression of small heterodimer partner gene expression.
Cholestasis
The role of CYP3A4 in the biotransformation of bile acids and therapeutic implication for cholestasis.
Cholestasis, Intrahepatic
[Association between polymorphisms of CYP17 and CYP3A4 genes and intrahepatic cholestasis of pregnancy in Chengdu]
Cocarcinogenesis
Biomarkers of effect in evaluating dithianon cocarcinogenesis: selective induction and suppression of murine CYP3A isoform.
Coinfection
Comparative study of the effects of anti-tuberculosis drugs and antiretroviral drugs on CYP3A4 and P-glycoprotein.
Coinfection
Data on pilot assessment of efficacy of artemether lumefantrine when co-administered with ciprofloxacin in malaria-typhoid co-infected patients.
Coinfection
Inhibitory Potential of Twenty Five Anti-tuberculosis Drugs on CYP Activities in Human Liver Microsomes.
Coinfection
Potentiation of methoxymorpholinyl doxorubicin antitumor activity by P450 3A4 gene transfer.
Coinfection
Prevalence and risk factors for efavirenz-based antiretroviral treatment-associated severe vitamin D deficiency: A prospective cohort study.
Coinfection
Ritonavir Greatly Impairs CYP3A Activity in HIV Infection With Chronic Viral Hepatitis.
Coinfection
Ritonavir greatly impairs CYP3A activity in HIV infection with chronic viral hepatitis.
Colitis
Decreased drug penetration in inflamed tissue related to changed mucosal metabolism in experimental colitis.
Colitis
Dextran sulfate sodium-induced colitis and ginseng intervention altered oral pharmacokinetics of cyclosporine A in rats.
Colitis
Downregulation of CYP3A and P-glycoprotein in the secondary inflammatory response of mice with dextran sulfate sodium-induced colitis and its contribution to cyclosporine A blood concentrations.
Colitis
Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial).
Colitis
Selective effects of a therapeutic protein targeting tumor necrosis factor-alpha on cytochrome P450 regulation during infectious colitis: Implications for disease-dependent drug-drug interactions.
Colitis, Ulcerative
Serum derived from ulcerative colitis mouse changes the metabolism of the fluorescent substrate by P450 depending on the degree of disease progression.
Colonic Neoplasms
19nor-1,25-dihydroxyvitamin D2 specifically induces CYP3A9 in rat intestine more strongly than 1,25-dihydroxyvitamin D3 in vivo and in vitro.
Colonic Neoplasms
3-Hydroxyflavone and structural analogues differentially activate pregnane X receptor: Implication for inflammatory bowel disease.
Colonic Neoplasms
Activation of Fas receptor modulates cytochrome P450 3A4 expression in human colon carcinoma cells.
Colonic Neoplasms
Curcumin: a novel nutritionally derived ligand of the vitamin D receptor with implications for colon cancer chemoprevention.
Colonic Neoplasms
Detoxication of vinca alkaloids by human P450 CYP3A4-mediated metabolism: implications for the development of drug resistance.
Colonic Neoplasms
Differential activation of pregnane X receptor by carnosic acid, carnosol, ursolic acid, and rosmarinic acid.
Colonic Neoplasms
Drug membrane transporters and CYP3A4 are affected by hypericin, hyperforin or aristoforin in colon adenocarcinoma cells.
Colonic Neoplasms
Human PXR-mediated induction of intestinal CYP3A4 attenuates 1?,25-dihydroxyvitamin D? function in human colon adenocarcinoma LS180 cells.
Colonic Neoplasms
Induction of CYP3A4 by 1 alpha,25-dihydroxyvitamin D3 is human cell line-specific and is unlikely to involve pregnane X receptor.
Colonic Neoplasms
Intestinal human colon adenocarcinoma cell line LS180 is an excellent model to study pregnane X receptor, but not constitutive androstane receptor, mediated CYP3A4 and multidrug resistance transporter 1 induction: studies with anti-human immunodeficiency virus protease inhibitors.
Colonic Neoplasms
Liganded VDR induces CYP3A4 in small intestinal and colon cancer cells via DR3 and ER6 vitamin D responsive elements.
Colonic Neoplasms
Milk thistle's active components silybin and isosilybin: novel inhibitors of PXR-mediated CYP3A4 induction.
Colonic Neoplasms
Overexpression of CYP3A4 in a COLO 205 Colon Cancer Stem Cell Model in vitro.
Colonic Neoplasms
Polymorphic Variants of Cytochrome P450: Relevance to Cancer and Other Diseases.
Colonic Neoplasms
Tissue-specific regulation of pregnane X receptor in cancer development and therapy.
Colonic Neoplasms
Vitamin D Enhances the Efficacy of Irinotecan through miR-627-Mediated Inhibition of Intratumoral Drug Metabolism.
Colorectal Neoplasms
A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer.
Colorectal Neoplasms
Acquired resistance to the anticancer drug paclitaxel is associated with induction of cytochrome P450 2C8.
Colorectal Neoplasms
CYP2C19 polymorphisms in patients with gastric and colorectal carcinoma.
Colorectal Neoplasms
Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy.
Colorectal Neoplasms
Expression Patterns of Xenobiotic-Metabolizing Enzymes in Tumor and Adjacent Normal Mucosa Tissues among Patients with Colorectal Cancer: The ColoCare Study.
Colorectal Neoplasms
Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients.
Colorectal Neoplasms
Genetic Variations in the Xenobiotic-Metabolizing Enzymes CYP1A1, CYP1A2, CYP2C9, CYP2C19 and Susceptibility to Colorectal Cancer Among Turkish People.
Colorectal Neoplasms
Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients.
Colorectal Neoplasms
Polymorphisms in the cytochrome P450 genes CYP1A2, CYP1B1, CYP3A4, CYP3A5, CYP11A1, CYP17A1, CYP19A1 and colorectal cancer risk.
Communicable Diseases
Immunization and Drug Metabolizing Enzymes: Focus on Hepatic Cytochrome P450 3A.
Confusion
An East Asian Perspective on the Interaction between Proton Pump Inhibitors and Clopidogrel.
Conjunctivitis, Allergic
Ritonavir and Topical Ocular Corticosteroid Induced Cushing's Syndrome in an Adolescent with HIV-1 Infection.
Connective Tissue Diseases
Effect of CYP3A5 and ABCB1 polymorphisms on the interaction between tacrolimus and itraconazole in patients with connective tissue disease.
Coronary Artery Disease
A study on the impact of CYP2C19 genotype and platelet reactivity assay on patients undergoing PCI.
Coronary Artery Disease
Association between cytochrome P450 2C19 polymorphism and clinical outcomes in Chinese patients with coronary artery disease.
Coronary Artery Disease
Association of CYP2C19 Loss-of-Function Alleles with Major Adverse Cardiovascular Events of Clopidogrel in Stable Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention: Meta-analysis.
Coronary Artery Disease
Association of CYP2C19, CYP3A5 and GPIIb/IIIa gene polymorphisms with Aspirin and Clopidogrel Resistance in a cohort of Indian patients with Coronary Artery Disease.
Coronary Artery Disease
Calcium-channel blockers reduce the antiplatelet effect of clopidogrel.
Coronary Artery Disease
Can prasugrel decrease the extent of periprocedural myocardial injury during elective PCI?
Coronary Artery Disease
Changes in CYP2C19 enzyme activity evaluated by the [(13)C]-pantoprazole breath test after co-administration of clopidogrel and proton pump inhibitors following percutaneous coronary intervention and correlation to platelet reactivity.
Coronary Artery Disease
Clinical Value of CYP2C19 Genetic Testing for Guiding the Antiplatelet Therapy in a Chinese Population.
Coronary Artery Disease
Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease.
Coronary Artery Disease
Clopidogrel preventive effect based on cytochrome P450 2C19 genotype in ischaemic stroke: protocol for multicentre observational study.
Coronary Artery Disease
Comparison of the effect of CYP2C19 polymorphism on clinical outcome between acute coronary syndrome and stable angina.
Coronary Artery Disease
CYP 450 2C19 polymorphisms in Indian patients with coronary artery disease.
Coronary Artery Disease
CYP2C19 activity and cardiovascular risk factors in patients with an acute coronary syndrome.
Coronary Artery Disease
CYP2C19 and ABCB1 genetic polymorphisms correlate with the recurrence of ischemic cardiovascular adverse events after clopidogrel treatment.
Coronary Artery Disease
CYP2C19 genotype and adverse cardiovascular outcomes after stent implantation in clopidogrel-treated Asian populations: A systematic review and meta-analysis.
Coronary Artery Disease
CYP2C19 pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: A meta-analysis of randomized clinical trials.
Coronary Artery Disease
CYP2C19, PON1, and ABCB1 gene polymorphisms in Han and Uygur populations with coronary artery disease in Northwestern Xinjiang, China, From 2014 Through 2019.
Coronary Artery Disease
Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: A meta-analysis based on 23,035 subjects.
Coronary Artery Disease
Cytochrome P450 2C19 Polymorphism is Associated with Reduced Clopidogrel Response in Cerebrovascular Disease.
Coronary Artery Disease
Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine.
Coronary Artery Disease
Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y12 Inhibitor Therapy: A Meta-Analysis.
Coronary Artery Disease
Effects of CYP2C19 Polymorphism on Endothelial Function, Arterial Stiffness and Inflammation in Coronary Artery Disease Patients Under Clopidogrel Treatment.
Coronary Artery Disease
Efficacy and safety of clopidogrel versus prasugrel and ticagrelor for coronary artery disease treatment in patients with CYP2C19 LoF alleles: a systemic review and meta-analysis.
Coronary Artery Disease
Enhanced active metabolite generation and platelet inhibitionwith prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways.
Coronary Artery Disease
Exome sequencing of extreme clopidogrel response phenotypes identifies B4GALT2 as a determinant of on-treatment platelet reactivity.
Coronary Artery Disease
Gender differences in impact of CYP2C19 polymorphism on development of coronary artery disease.
Coronary Artery Disease
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease.
Coronary Artery Disease
Impact of CYP2C19 polymorphism and smoking on response to clopidogrel in patients with stable coronary artery disease.
Coronary Artery Disease
Impact of CYP2C19 polymorphism on clinical outcome following coronary stenting is more important in non-diabetic than diabetic patients.
Coronary Artery Disease
Implementation and evaluation of a CYP2C19 genotype-guided antiplatelet therapy algorithm in high-risk coronary artery disease patients.
Coronary Artery Disease
Implementing a pharmacogenetic-driven algorithm to guide dual antiplatelet therapy (DAPT) in Caribbean Hispanics: protocol for a non-randomised clinical trial.
Coronary Artery Disease
Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease.
Coronary Artery Disease
Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel.
Coronary Artery Disease
Meta-Analysis of Cytochrome P450 2C19 Polymorphism and Risk of Adverse Clinical Outcomes Among Coronary Artery Disease Patients of Different Ethnic Groups Treated With Clopidogrel.
Coronary Artery Disease
Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients.
Coronary Artery Disease
Physiologically-Based Pharmacokinetic-Pharmacodynamics Model Characterizing CYP2C19 Polymorphisms to Predict Clopidogrel Pharmacokinetics and Its Anti-Platelet Aggregation Effect Following Oral Administration to Coronary Artery Disease Patients With or Without Diabetes.
Coronary Artery Disease
Risk of major adverse cardiovascular events for concomitant use of clopidogrel and proton pump inhibitors in patients inheriting CYP2C19 loss-of-function alleles: meta-analysis.
Coronary Artery Disease
Risk of stroke in CYP2C19 LoF polymorphism carrier coronary artery disease patients undergoing clopidogrel therapy: An ethnicity-based updated meta-analysis.
Coronary Artery Disease
Suboptimal response to clopidogrel: a genetic risk factor for recurrent ischaemic stroke.
Coronary Artery Disease
Switching between ticagrelor and clopidogrel in patients who underwent percutaneous coronary intervention: insight into contemporary practice in Chinese patients.
Coronary Artery Disease
The CYP2C19 genotype does not impact the long-term prognosis of patients with coronary artery disease.
Coronary Artery Disease
The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease.
Coronary Artery Disease
The effect of CYP2C19 genetic polymorphism and non-genetic factors on clopidogrel platelets inhibition in East Asian coronary artery disease patients.
Coronary Artery Disease
The impact of CYP2C19 genotype on cardiovascular events and platelet reactivity in patients with coronary artery disease receiving clopidogrel.
Coronary Artery Disease
The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy.
Coronary Artery Disease
The Triangulation WIthin a STudy (TWIST) framework for causal inference within pharmacogenetic research.
Coronary Artery Disease
Translational pharmacogenetics and risk management in the cardiovascular arena: CYP3A5*3 model for gene-based drug selection.
Coronary Artery Disease
[Influence of CYP2C19 gene polymorphisms on the efficacy of clopidogrel treatment for the prevention of ischemic stroke following coronary stent implantation].
Coronary Artery Disease
[The possibility of selecting optimal antiplatelet therapy in patients with coronary heart disease in terms of CYP2C19 polymorphism].
Coronary Disease
A functional polymorphism in the CYP3A4 gene is associated with increased risk of coronary heart disease in the Chinese Han population.
Coronary Disease
Association of cytochrome P450 2C19 polymorphisms with coronary heart disease risk: A protocol for systematic review and meta analysis.
Coronary Disease
Comment on Xie et al.: The effects of CES1A2 A(-816)C and CYP2C19 loss-of-function polymorphisms on clopidogrel response variability among Chinese patients with coronary heart disease.
Coronary Disease
CYP2C19 activity and cardiovascular risk factors in patients with an acute coronary syndrome.
Coronary Disease
CYP2C19 polymorphisms and coronary heart disease risk factors synergistically impact clopidogrel response variety after percutaneous coronary intervention.
Coronary Disease
Genotype Frequencies of CYP2C19, P2Y12 and GPIIIa Polymorphisms in Coronary Heart Disease Patients of Han Ethnicity, and Their Impact on Clopidogrel Responsiveness.
Coronary Disease
Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy.
Coronary Disease
Impact of esomeprazole on platelet reactivity and clinical outcome according to CYP2C19 genotype in coronary heart disease patients during dual antiplatelet therapy.
Coronary Disease
Influence of
CYP2C19
genotype on antiplatelet treatment outcomes after percutaneous coronary intervention in patients with coronary heart disease.
Coronary Disease
Polymorphisms of CYP2C8, CYP2C9 and CYP2C19 and risk of coronary heart disease in Russian population.
Coronary Disease
Positive Clinical Response to Clopidogrel is Independent of Paraoxonase 1 Q192R and CYP2C19 Genetic Variants.
Coronary Disease
The effects of CES1A2 A(-816)C and CYP2C19 loss-of-function polymorphisms on clopidogrel response variability among Chinese patients with coronary heart disease.
Coronary Disease
The Effects of CYP2C19 genotype on the susceptibility for nephrosis in cardio-cerebral vascular disease treated by anticoagulation.
Coronary Disease
Using Workflow Modeling to Identify Areas to Improve Genetic Test Processes in the University of Maryland Translational Pharmacogenomics Project.
Coronary Disease
[Association of ITGB3, P2RY12, and CYP2C19 gene polymorphisms with platelet functional activity in patients with coronary heart disease during dual antiplatelet therapy].
Coronary Disease
[Prevalence of CYP2C19 gene mutations in patients with coronary heart disease and its biological activation effect in clopidogrel antiplatelet response].
Coronary Disease
[The possibility of selecting optimal antiplatelet therapy in patients with coronary heart disease in terms of CYP2C19 polymorphism].
COVID-19
CYP2D6 and CYP3A4 variants influence the risk and outcome of COVID-19 infection among rheumatoid arthritis patients maintained on hydroxychloroquine.
COVID-19
Impact of SARS-CoV-2 Infection (COVID-19) on Cytochromes P450 Activity Assessed by the Geneva Cocktail.
COVID-19
Inhibition of drug-metabolizing enzymes by Qingfei Paidu decoction: Implication of herb-drug interactions in COVID-19 pharmacotherapy.
COVID-19
Physiologically Based Pharmacokinetic Modelling to Investigate the Impact of the Cytokine Storm on CYP3A Drug Pharmacokinetics in COVID-19 Patients.
COVID-19
Prediction of potential drug interactions between repurposed COVID-19 and antitubercular drugs: an integrational approach of drug information software and computational techniques data.
Craniocerebral Trauma
Head injury and cytochrome P-450 enzymes. Differential effect on mRNA and protein expression in the Fischer-344 rat.
Crohn Disease
Crohn's Disease Is Associated with Decreased CYP3A4 and P-Glycoprotein Protein Expression.
Crohn Disease
Effect of Crohn's Disease on Villous Length and CYP3A4 Expression in the Pediatric Small Intestine.
Crohn Disease
Effect of high-dose metronidazole on pharmacokinetics of oral budesonide and vice versa: a double drug interaction study.
Crohn Disease
Impact of inflammation on the duodenal mRNA expression of CYP3A and P-glycoprotein in children with Crohn's disease.
Cryptorchidism
Association of variants in genes involved in environmental chemical metabolism and risk of cryptorchidism and hypospadias.
Cushing Syndrome
Acute development of Cushing syndrome in an HIV-infected child on atazanavir/ritonavir based antiretroviral therapy.
Cushing Syndrome
Fluticasone furoate induced iatrogenic Cushing syndrome in a pediatric patient receiving anti-retroviral therapy.
Cushing Syndrome
Iatrogenic Cushing syndrome following lumbar medial branch block in a patient with HIV on ritonavir and darunavir.
Cushing Syndrome
IATROGENIC CUSHING SYNDROME IN AN HIV-INFECTED PATIENT SECONDARY TO CONCOMITANT THERAPY WITH GENVOYA AND EPIDURAL TRIAMCINOLONE.
Cushing Syndrome
Iatrogenic Cushing's syndrome due to drug interaction between glucocorticoids and the ritonavir or cobicistat containing HIV therapies.
Cushing Syndrome
Ritonavir and Topical Ocular Corticosteroid Induced Cushing's Syndrome in an Adolescent with HIV-1 Infection.
Cushing Syndrome
Triamcinolone and ritonavir leading to drug-induced Cushing syndrome and adrenal suppression: description of a new case and review of the literature.
Cushing Syndrome
Troglitazone induces CYP3A4 activity leading to falsely abnormal dexamethasone suppression test.
Cystic Fibrosis
Cytochrome P450 3A4 induction: lumacaftor versus ivacaftor potentially resulting in significantly reduced plasma concentration of ivacaftor.
Cystic Fibrosis
Disposition of drugs in cystic fibrosis. V. In vivo CYP2C9 activity as probed by (S)-warfarin is not enhanced in cystic fibrosis.
Cystic Fibrosis
Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients.
Cystic Fibrosis
Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosis.
Cystic Fibrosis
Impact of CYP3A5 phenotype on tacrolimus concentrations after sublingual and oral administration in lung transplant.
Cystic Fibrosis
Pharmacokinetic variability of clarithromycin and differences in CYP3A4 activity in patients with cystic fibrosis.
Death, Sudden, Cardiac
Prolongation of the QT interval related to cisapride-diltiazem interaction.
Dehydration
Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4.
Dehydration
Mechanism of cytochrome P4503A4- and 2D6-catalyzed dehydrogenation of ezlopitant as probed with isotope effects using five deuterated analogs.
Delirium
Extreme Duration of Diazepam-Associated Sedation in a Patient With Alcohol Delirium and CYP2C19 Polymorphisms.
Dementia
Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial).
Dementia
Influence of Pathogenic and Metabolic Genes on the Pharmacogenetics of Mood Disorders in Alzheimer's Disease.
Dementia
Pharmacogenomics of Cognitive Dysfunction and Neuropsychiatric Disorders in Dementia.
Dermatitis
Trichloroethylene-induced hypersensitivity dermatitis was associated with hepatic metabolic enzyme genes and immune-related genes.
Dermatitis, Atopic
Evaluation of Potential Disease-Mediated Drug-Drug Interaction in Patients With Moderate-to-Severe Atopic Dermatitis Receiving Dupilumab.
Diabetes Mellitus
Association of polymorphisms of ABCA1 and ROS1 with hypertension in Japanese individuals.
Diabetes Mellitus
Contribution of cytochrome P450 isoforms to gliquidone metabolism in rats and human.
Diabetes Mellitus
CYP2C19 activity and cardiovascular risk factors in patients with an acute coronary syndrome.
Diabetes Mellitus
Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 Trial.
Diabetes Mellitus
Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus.
Diabetes Mellitus
Evaluation of changes in cytochrome P450 2C19 activity in type 2 diabetic rats before and after treatment, by using isolated perfused liver model.
Diabetes Mellitus
Expression of xenobiotic and steroid hormone metabolizing enzymes in hepatocellular tumors of the non-cirrhotic liver.
Diabetes Mellitus
Impact of CYP2C19 polymorphism on clinical outcome following coronary stenting is more important in non-diabetic than diabetic patients.
Diabetes Mellitus
Influence of CYP2C19 genotype on the pharmacokinetics of R483, a CYP2C19 substrate, in healthy subjects and type 2 diabetes patients.
Diabetes Mellitus
Lack of Potential Pharmacokinetic and Pharmacodynamic Interactions Between Piragliatin, a Glucokinase Activator, and Simvastatin in Patients With Type 2 Diabetes Mellitus.
Diabetes Mellitus
Nonalcoholic Fatty Liver Disease and Diabetes Are Associated with Decreased CYP3A4 Protein Expression and Activity in Human Liver.
Diabetes Mellitus
Opposite effect of diabetes mellitus induced by streptozotocin on oral and intravenous pharmacokinetics of verapamil in rats.
Diabetes Mellitus
Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention.
Diabetes Mellitus
Should CYP2C19 Genotyping Be Recommended as a Straight Forward Approach to Optimize Clopidogrel Utilization in Patients with Ischemic Stroke Complicated by Type 2 Diabetes Mellitus?
Diabetes Mellitus
The effects of polymorphisms in CYP2C19, ATP-binding cassette transporter B1, and paraoxonase-1 on clopidogrel treatment of Uygur patients following percutaneous coronary intervention.
Diabetes Mellitus
[Variable extent of platelet responsiveness to clopidogrel inhibition: "clopidogrel resistance"?]
Diabetes Mellitus, Type 2
Association of a polymorphism of CYP3A4 with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
CYP2C19 activity and cardiovascular risk factors in patients with an acute coronary syndrome.
Diabetes Mellitus, Type 2
Evaluating the effect of type 2 diabetes mellitus on CYP450 enzymes and P-gp activities, before and after glycemic control: A protocol for a case-control pharmacokinetic study.
Diabetes Mellitus, Type 2
Exploratory effects of a strong CYP3A inhibitor (ketoconazole), a strong CYP3A inducer (rifampicin), and concomitant ethanol on piragliatin pharmacokinetics and pharmacodynamics in type 2 diabetic patients.
Diabetes Mellitus, Type 2
Influence of CYP2C19 genotype on the pharmacokinetics of R483, a CYP2C19 substrate, in healthy subjects and type 2 diabetes patients.
Diabetes Mellitus, Type 2
Lack of Potential Pharmacokinetic and Pharmacodynamic Interactions Between Piragliatin, a Glucokinase Activator, and Simvastatin in Patients With Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Modulation of CYP3a expression and activity in mice models of type 1 and type 2 diabetes.
Diabetes Mellitus, Type 2
Should CYP2C19 Genotyping Be Recommended as a Straight Forward Approach to Optimize Clopidogrel Utilization in Patients with Ischemic Stroke Complicated by Type 2 Diabetes Mellitus?
Diabetes Mellitus, Type 2
Structural and mechanistic insights into the interaction of cytochrome P4503A4 with bromoergocryptine, a type I ligand.
Diabetes Mellitus, Type 2
Thiazolidinediones for type 2 diabetes. No evidence exists that pioglitazone induces hepatic cytochrome P450 isoform CYP3A4.
Diabetes Mellitus, Type 2
Tissue Specific Modulation of cyp2c and cyp3a mRNA Levels and Activities by Diet-Induced Obesity in Mice: The Impact of Type 2 Diabetes on Drug Metabolizing Enzymes in Liver and Extra-Hepatic Tissues.
Diabetes Mellitus, Type 2
Use of 4?-Hydroxycholesterol Plasma Concentrations as an Endogenous Biomarker of CYP3A Activity: Clinical Validation in Individuals With Type 2 Diabetes.
Diabetic Retinopathy
Sex differences in the effect of cytochrome P450 2C19 polymorphisms on the risk of diabetic retinopathy: a retrospective longitudinal study in Japanese patients with type 2 diabetes.
Digestive System Neoplasms
Functional polymorphisms in the CYP2C19 gene contribute to digestive system cancer risk: evidence from 11,042 subjects.
Disorders of Excessive Somnolence
Persistent Hypersomnolence Following Clobazam in a Child With Epilepsy and Undiagnosed CYP2C19 Polymorphism.
Drug Resistant Epilepsy
Evidence of polymorphic CYP2C19 involvement in the human metabolism of N-desmethylclobazam.
Drug Resistant Epilepsy
Influence of genetic variants of CYP2D6, CYP2C9, CYP2C19 and CYP3A4 on antiepileptic drug metabolism in pediatric patients with refractory epilepsy.
Drug Resistant Epilepsy
Possible role of CYP2C9 & CYP2C19 single nucleotide polymorphisms in drug refractory epilepsy.
Drug-Related Side Effects and Adverse Reactions
ABCG2 gene polymorphisms as risk factors for atorvastatin adverse reactions: a case-control study.
Drug-Related Side Effects and Adverse Reactions
Alterations of Histone Modifications Contribute to Pregnane X Receptor-Mediated Induction of CYP3A4 by Rifampicin.
Drug-Related Side Effects and Adverse Reactions
Associations of CYP2C9 and CYP2C19 Pharmacogenetic Variation with Phenytoin-Induced Cutaneous Adverse Drug Reactions.
Drug-Related Side Effects and Adverse Reactions
Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease.
Drug-Related Side Effects and Adverse Reactions
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy.
Drug-Related Side Effects and Adverse Reactions
Correlation of CYP2B6, CYP2C19, ABCC4 and SOD2 genotype with outcomes in allogeneic blood and marrow transplant patients.
Drug-Related Side Effects and Adverse Reactions
Current Approaches for Investigating and Predicting Cytochrome P450 3A4-Ligand Interactions.
Drug-Related Side Effects and Adverse Reactions
CYP2C19 polymorphism in relation to the pharmacotherapy optimization of commonly used drugs.
Drug-Related Side Effects and Adverse Reactions
CYP2C9 and CYP2C19 Allele and Haplotype Distributions in Four Mestizo Populations from Western Mexico: An Interethnic Comparative Study.
Drug-Related Side Effects and Adverse Reactions
CYP2D6 *6/*6 genotype and drug interactions as cause of haloperidol-induced extrapyramidal symptoms.
Drug-Related Side Effects and Adverse Reactions
CYP2D6 and CYP2C19 genotypes and amitriptyline metabolite ratios in a series of medicolegal autopsies.
Drug-Related Side Effects and Adverse Reactions
Development and validation of a method for the simultaneous quantification of endogenous steroids metabolized by CYP3A.
Drug-Related Side Effects and Adverse Reactions
Distribution of CYP2D6 and CYP2C19 Polymorphisms Associated with Poor Metabolizer Phenotype in Five Amerindian Groups and Western Mestizos from Mexico.
Drug-Related Side Effects and Adverse Reactions
Does obtaining CYP2D6 and CYP2C19 pharmacogenetic testing predict antidepressant response or adverse drug reactions?
Drug-Related Side Effects and Adverse Reactions
Drug metabolism genotypes and their association with adverse drug reactions in selected populations: a pilot study of methodology.
Drug-Related Side Effects and Adverse Reactions
Effect of concomitant treatment with a CYP3A4 inhibitor and a calcium channel blocker.
Drug-Related Side Effects and Adverse Reactions
Effect of cytochrome P450 3A4 inhibitor ketoconazole on risperidone pharmacokinetics in healthy volunteers.
Drug-Related Side Effects and Adverse Reactions
Effect of Microbial Short-Chain Fatty Acids on CYP3A4-Mediated Metabolic Activation of Human Pluripotent Stem Cell-Derived Liver Organoids.
Drug-Related Side Effects and Adverse Reactions
Effects of 27 CYP3A4 protein variants on saxagliptin metabolism in vitro.
Drug-Related Side Effects and Adverse Reactions
Genetic variability of CYP2C19 in a Mexican population: contribution to the knowledge of the inheritance pattern of CYP2C19*17 to develop the ultrarapid metabolizer phenotype.
Drug-Related Side Effects and Adverse Reactions
Genetics and Extracellular Vesicles of Pediatrics Sleep Disordered Breathing and Epilepsy.
Drug-Related Side Effects and Adverse Reactions
High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme.
Drug-Related Side Effects and Adverse Reactions
In vitro functional analysis of 24 novel CYP2C19 variants recently found in the Chinese Han population.
Drug-Related Side Effects and Adverse Reactions
Influence of CYP2C19 Genotypes on the Occurrence of Adverse Drug Reactions of Voriconazole among Hematological Patients after Allo-HSCT.
Drug-Related Side Effects and Adverse Reactions
Inhibition of cytochrome P450 3A: relevant drug interactions in gastroenterology.
Drug-Related Side Effects and Adverse Reactions
Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis.
Drug-Related Side Effects and Adverse Reactions
Pharmacogenetic Prediction of Individual Variability in Drug Response Based on CYP2D6, CYP2C9 and CYP2C19 Genetic Polymorphisms.
Drug-Related Side Effects and Adverse Reactions
Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance.
Drug-Related Side Effects and Adverse Reactions
Polymorphisms and phenotypic analysis of cytochrome P450 3A4 in the Uygur population in northwest China.
Drug-Related Side Effects and Adverse Reactions
Pomegranate Juice does not Affect the Bioavailability of Cyclosporine in Healthy Thai Volunteers.
Drug-Related Side Effects and Adverse Reactions
Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
Drug-Related Side Effects and Adverse Reactions
Potential Mechanisms of Hematological Adverse Drug Reactions in Patients Receiving Clozapine in Combination With Proton Pump Inhibitors.
Drug-Related Side Effects and Adverse Reactions
Reduction in hepatic drug metabolizing CYP3A4 activities caused by P450 oxidoreductase mutations identified in patients with disordered steroid metabolism.
Drug-Related Side Effects and Adverse Reactions
The enhancement of cardiotoxicity that results from inhibiton of CYP 3A4 activity and hERG channel by berberine in combination with statins.
Drug-Related Side Effects and Adverse Reactions
The influence of CYP3A5 polymorphisms on haloperidol treatment in patients with alcohol addiction.
Drug-Related Side Effects and Adverse Reactions
The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions.
Drug-Related Side Effects and Adverse Reactions
Therapeutic effects and adverse drug reactions are affected by icotinib exposure and CYP2C19 and EGFR genotypes in Chinese non-small cell lung cancer patients.
Drug-Related Side Effects and Adverse Reactions
Voriconazole Metabolism, Toxicity, and the Effect of Cytochrome P450 2C19 Genotype.
Drug-Related Side Effects and Adverse Reactions
[Cytochrome P-450 3A4--the most important arena for drug interactions in the body]
Duodenal Ulcer
Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient.
Duodenal Ulcer
Genetic polymorphism of CYP2C19 & therapeutic response to proton pump inhibitors.
Duodenal Ulcer
Modeling the cost-effectiveness of ilaprazole versus omeprazole for the treatment of newly diagnosed duodenal ulcer patients in China.
Duodenal Ulcer
Polymorphisms and the pocketbook: the cost-effectiveness of cytochrome P450 2C19 genotyping in the eradication of Helicobacter pylori infection associated with duodenal ulcer.
Dyslipidemias
Assessment of the CYP3A-mediated drug interaction potential of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy volunteers.
Dyslipidemias
CYP2C19 activity and cardiovascular risk factors in patients with an acute coronary syndrome.
Dyslipidemias
Gender differences in impact of CYP2C19 polymorphism on development of coronary artery disease.
Dyslipidemias
Genetic and non-genetic factors responsible for antiplatelet effects of clopidogrel in Japanese patients undergoing coronary stent implantation: an algorithm to predict on-clopidogrel platelet reactivity.
Dyslipidemias
Rhabdomyolysis in an HIV-Infected Patient on Anti-Retroviral Therapy Precipitated by High-Dose Pravastatin.
Dyslipidemias
Statin-Induced Myotoxicity: Pharmacokinetic Differences among Statins and the Risk of Rhabdomyolysis, with Particular Reference to Pitavastatin.
Dyslipidemias
The effects of polymorphisms in CYP2C19, ATP-binding cassette transporter B1, and paraoxonase-1 on clopidogrel treatment of Uygur patients following percutaneous coronary intervention.
Endocrine System Diseases
Separate and interactive regulation of cytochrome P450 3A4 by triiodothyronine, dexamethasone, and growth hormone in cultured hepatocytes.
Endometrial Neoplasms
Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use.
Endometrial Neoplasms
Down-regulation of pregnane X receptor contributes to cell growth inhibition and apoptosis by anticancer agents in endometrial cancer cells.
Endometrial Neoplasms
Studies on CYP1A1, CYP1B1 and CYP3A4 gene polymorphisms in breast cancer patients.
Endometrial Neoplasms
The pregnane X receptor regulates gene expression in a ligand- and promoter-selective fashion.
Endometrial Neoplasms
Tissue-specific regulation of pregnane X receptor in cancer development and therapy.
Endometriosis
Common variants in the CYP2C19 gene are associated with susceptibility to endometriosis.
Endometriosis
High-density fine-mapping of a chromosome 10q26 linkage peak suggests association between endometriosis and variants close to CYP2C19.
Endometriosis
Is cytochrome P450 3A4 regulated by menstrual cycle hormones in control endometrium and endometriosis?
Endometriosis
Polymorphic Variants of Cytochrome P450: Relevance to Cancer and Other Diseases.
Endometriosis
Role of cytochrome P450 2C19 polymorphisms and body mass index in endometriosis: A case-control study.
Endometriosis
TGF-? Induces Endometriotic Progression via a Noncanonical, KLF11-Mediated Mechanism.
Endometriosis
[Influence of CYP3A4/5 polymorphisms in the pharmacokinetics of levonorgestrel: a pilot study].
Endophthalmitis
Disseminated Scedosporium prolificans infection in an 'extensive metaboliser': navigating the minefield of drug interactions and pharmacogenomics.
Endotoxemia
Lipopolysaccharide and cecal ligation/puncture differentially affect the subcellular distribution of the pregnane X receptor but consistently cause suppression of its target genes CYP3A.
Enterocolitis
Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial).
Eosinophilia
CYP2C19 and STAT6 Variants Influence the Outcome of Proton Pump Inhibitor Therapy in Pediatric Eosinophilic Esophagitis.
Eosinophilia
Long-Term Loss of Response in Proton Pump Inhibitor-Responsive Esophageal Eosinophilia Is Uncommon and Influenced by CYP2C19 Genotype and Rhinoconjunctivitis.
Eosinophilic Esophagitis
CYP2C19 and STAT6 Variants Influence the Outcome of Proton Pump Inhibitor Therapy in Pediatric Eosinophilic Esophagitis.
Epilepsies, Myoclonic
Effect of CYP2C19 polymorphisms on stiripentol administration in Japanese cases of Dravet syndrome.
Epilepsies, Myoclonic
Impact of CYP2C19 phenotypes on clinical efficacy of stiripentol in Japanese patients with Dravet syndrome.
Epilepsy
An association between the rs1799853 and rs1057910 polymorphisms of CYP2C9, the rs4244285 polymorphism of CYP2C19 and the prevalence rates of drug-resistant epilepsy in children.
Epilepsy
Association of ABCB1, CYP3A4, EPHX1, FAS, SCN1A, MICA, and BAG6 polymorphisms with the risk of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Chinese Han patients with epilepsy.
Epilepsy
Association of polymorphisms of CYP2C9, CYP2C19, and ABCB1, and activity of P-glycoprotein with response to anti-epileptic drugs.
Epilepsy
Associations between CYP3A4, CYP3A5 and SCN1A polymorphisms and carbamazepine metabolism in epilepsy: A meta-analysis.
Epilepsy
CYP2C19 polymorphism effect on phenobarbitone. Pharmacokinetics in Japanese patients with epilepsy: analysis by population pharmacokinetics.
Epilepsy
CYP2C9 (*2&*3) and CYP2C19 (*2&*3) polymorphisms among children with nonlesional epilepsy: a single-center study.
Epilepsy
CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy.
Epilepsy
Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms.
Epilepsy
Effect of CYP2C19 polymorphisms on the clinical outcome of low-dose clobazam therapy in Japanese patients with epilepsy.
Epilepsy
Effect of CYP2C19, UGT1A8, and UGT2B7 on valproic acid clearance in children with epilepsy: a population pharmacokinetic model.
Epilepsy
Effects of CYP2C19 and P450 Oxidoreductase Polymorphisms on the Population Pharmacokinetics of Clobazam and N-Desmethylclobazam in Japanese Patients With Epilepsy.
Epilepsy
Effects of EPHX1, SCN1A and CYP3A4 genetic polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy.
Epilepsy
Effects of polymorphisms in six candidate genes on phenytoin maintenance therapy in Han Chinese patients.
Epilepsy
Genetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsy.
Epilepsy
Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy.
Epilepsy
Genetic profile of patients with epilepsy on first-line antiepileptic drugs and potential directions for personalized treatment.
Epilepsy
Genetics and Extracellular Vesicles of Pediatrics Sleep Disordered Breathing and Epilepsy.
Epilepsy
Impact of CYP2C19 and CYP2C9 gene polymorphisms on sodium valproate plasma concentration in patients with epilepsy.
Epilepsy
Impact of Drug Interactions on Clobazam and N-Desmethylclobazam Concentrations in Pediatric Patients With Epilepsy.
Epilepsy
Individualized phenytoin therapy for Japanese pediatric patients with epilepsy based on CYP2C9 and CYP2C19 genotypes.
Epilepsy
Influence of age and co-medication on the steady-state pharmacokinetics of valproic acid in Tunisian patients with epilepsy.
Epilepsy
Influence of CYP2C19 polymorphism and concomitant antiepileptic drugs on serum clobazam and N-desmethyl clobazam concentrations in patients with epilepsy.
Epilepsy
Influence of genetic variants of CYP2D6, CYP2C9, CYP2C19 and CYP3A4 on antiepileptic drug metabolism in pediatric patients with refractory epilepsy.
Epilepsy
Influence of Renal Function on Pharmacokinetics of Antiepileptic Drugs Metabolized by CYP3A4 in a Patient With Renal Impairment.
Epilepsy
Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants.
Epilepsy
Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms.
Epilepsy
Neurovascular Drug Biotransformation Machinery in Focal Human Epilepsies: Brain CYP3A4 Correlates with Seizure Frequency and Antiepileptic Drug Therapy.
Epilepsy
Non-response to antiepileptic pharmacotherapy is associated with the ABCC2 -24C>T polymorphism in young and adult patients with epilepsy.
Epilepsy
Persistent Hypersomnolence Following Clobazam in a Child With Epilepsy and Undiagnosed CYP2C19 Polymorphism.
Epilepsy
Pharmacogenetic evaluation of ABCB1, Cyp2C9, Cyp2C19 and methylene tetrahydrofolate reductase polymorphisms in teratogenicity of anti-epileptic drugs in women with epilepsy.
Epilepsy
Possible role of CYP2C9 & CYP2C19 single nucleotide polymorphisms in drug refractory epilepsy.
Epilepsy
Presence of allele CYP3A4*16 does not have any bearing on carbamazepine-induced adverse drug reactions in North Indian people with epilepsy.
Epilepsy
The Effect of Genetic Polymorphisms of Cytochrome P450 CYP2C9, CYP2C19, and CYP2D6 on Drug-Resistant Epilepsy in Turkish Children.
Epilepsy
The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics.
Epilepsy
[Association between genetic polymorphisms of CYP2C19 and CYP2C9 and phenytoin serum concentration]
Epilepsy
[Development of rapid genotyping methods for single nucleotide polymorphisms of cytochrome P450 2C9 (CYP2C9) and cytochrome P450 2C19 (CYP2C19) and their clinical application in pediatric patients with epilepsy].
Epilepsy, Frontal Lobe
Influence of Renal Function on Pharmacokinetics of Antiepileptic Drugs Metabolized by CYP3A4 in a Patient With Renal Impairment.
Epistaxis
Efficacy of local budesonide therapy in the management of persistent hyposmia in COVID-19 patients without signs of severity: A structured summary of a study protocol for a randomised controlled trial.
Erectile Dysfunction
Sildenafil and furosemide associated ototoxicity: consideration of drug-drug interactions, synergy, and broader clinical relevance.
Erythema Nodosum
NR3C1, ABCB1, TNF and CYP2C19 polymorphisms association with the response to the treatment of erythema nodosum leprosum.
Esophageal Neoplasms
Frequencies of poor metabolizers of cytochrome P450 2C19 in esophagus cancer, stomach cancer, lung cancer and bladder cancer in Chinese population.
Esophageal Squamous Cell Carcinoma
Association of Genetic Variants of CYP2C19 and CYP2D6 with Esophageal Squamous Cell Carcinoma Risk in Northern India, Kashmir.
Esophageal Squamous Cell Carcinoma
Independent and combined effects of environmental factors and CYP2C19 polymorphisms on the risk of esophageal squamous cell carcinoma in Fujian Province of China.
Esophageal Squamous Cell Carcinoma
Interaction between Alcohol Consumption and CYP 2C19 Gene Polymorphism in Relation to Oesophageal Squamous Cell Carcinoma.
Esophagitis
Factors associated with residual gastroesophageal reflux disease symptoms in patients receiving proton pump inhibitor maintenance therapy.
Esophagitis
Genetic polymorphisms of CYP2C19 and IL1B have no influence on esomeprazole treatment for mild erosive esophagitis.
Esophagitis
Pharmacogenomics fail to explain proton pump inhibitor refractory esophagitis in pediatric esophageal atresia.
Esophagitis
Role of cytochrome P450 2C19 genetic polymorphisms in the therapeutic efficacy of omeprazole in Iranian patients with erosive reflux esophagitis.
Esophagitis, Peptic
A multicentre randomised trial to compare the efficacy of omeprazole versus rabeprazole in early symptom relief in patients with reflux esophagitis.
Esophagitis, Peptic
CYP2C19 Genotypes Determine the Efficacy of On-demand Therapy of Pantoprazole for Reflux Esophagitis as Los-Angeles Grade C & D.
Esophagitis, Peptic
Cytochrome P450 2C19 polymorphism influences the preventive effect of lansoprazole on the recurrence of erosive reflux esophagitis.
Esophagitis, Peptic
Genetic polymorphisms of CYP2C19 and IL1B have no influence on esomeprazole treatment for mild erosive esophagitis.
Esophagitis, Peptic
Influences of CYP2C19 polymorphism on recurrence of reflux esophagitis during proton pump inhibitor maintenance therapy.
Esophagitis, Peptic
Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis.
Esophagitis, Peptic
Role of cytochrome P450 2C19 genetic polymorphisms in the therapeutic efficacy of omeprazole in Iranian patients with erosive reflux esophagitis.
Esophagitis, Peptic
Therapeutic effects of 10 mg/day rabeprazole administration on reflux esophagitis was not influenced by the CYP2C19 polymorphism.
Essential Hypertension
Effects of genetic factors on the pharmacokinetics and pharmacodynamics of amlodipine in primary hypertensive patients.
Exanthema
Clarithromycin co-administration does not increase irinotecan (CPT-11) toxicity in colorectal cancer patients.
Familial Mediterranean Fever
Lack of an effect of CYP3A4 and MDR1 gene polymorphisms on colchicine pharmacogenetics in the treatment of Familial Mediterranean fever.
Fatty Liver
Curcumin regulates endogenous and exogenous metabolism via Nrf2-FXR-LXR pathway in NAFLD mice.
Fatty Liver
Decreased CYP3a Expression and Activity in Guinea Pig Models of Diet-Induced Metabolic Syndrome: Is Fatty Liver Infiltration Involved?
Fatty Liver
Non-uniformity of Changes in Drug-Metabolizing Enzymes and Transporters in Liver Cirrhosis: Implications for Drug Dosage Adjustment.
Fatty Liver
Serum Alanine Transaminase Total Bilirubin Concentrations Predict CYP3A Activity as Measured by Midazolam and 1'-Hydroxylation.
Fatty Liver
Silybin Restored CYP3A Expression through the Sirtuin 2/Nuclear Factor ?-B Pathway in Mouse Nonalcoholic Fatty Liver Disease.
Fatty Liver, Alcoholic
A new approach to drug therapy in non-alcoholic steatohepatitis (NASH).
Febrile Neutropenia
Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma.
Febrile Neutropenia
Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel.
Foot Ulcer
Effects of Radix Astragali and Radix Rehmanniae, the components of an anti-diabetic foot ulcer herbal formula, on metabolism of model CYP1A2, CYP2C9, CYP2D6, CYP2E1 and CYP3A4 probe substrates in pooled human liver microsomes and specific CYP isoforms.
Gastritis
Effects of the CYP2C19 Genetic Polymorphism on Gastritis, Peptic Ulcer Disease, Peptic Ulcer Bleeding and Gastric Cancer.
Gastritis
First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype.
Gastritis
Importance of CYP2C19 genetic polymorphism in the eradication of Helicobacter pylori in north Indians.
Gastritis
Poor metabolizer genotype status of CYP2C19 is a risk factor for developing gastric cancer in Japanese patients with Helicobacter pylori infection.
Gastritis
Prediction of progression of chronic atrophic gastritis with Helicobacter pylori and poor prognosis of gastric cancer by CYP3A4.
Gastritis
Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers.
Gastritis, Atrophic
Prediction of progression of chronic atrophic gastritis with Helicobacter pylori and poor prognosis of gastric cancer by CYP3A4.
Gastroesophageal Reflux
Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19.
Gastroesophageal Reflux
Association between CYP2C19 extensive metabolizer phenotype and childhood anti-reflux surgery following failed proton pump inhibitor medication treatment.
Gastroesophageal Reflux
Association Between CYP2C19*17 Alleles and pH Probe Testing Outcomes in Children With Symptomatic Gastroesophageal Reflux.
Gastroesophageal Reflux
Characteristics of Refractory Gastroesophageal Reflux Disease (GERD) Symptoms -Is Switching Proton Pump Inhibitors Based on the Patient's CYP2C19 Genotype an Effective Management Strategy?
Gastroesophageal Reflux
Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.
Gastroesophageal Reflux
Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastr?c pH in extensive metabolizer patients with gastroesophageal reflux disease.
Gastroesophageal Reflux
CYP2C19 genotype is associated with symptomatic recurrence of GERD during maintenance therapy with low-dose lansoprazole.
Gastroesophageal Reflux
CYP2C19 genotype variability in patients with refractory gastroesophageal reflux after per-oral endoscopic myotomy (POEM).
Gastroesophageal Reflux
CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms.
Gastroesophageal Reflux
CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor.
Gastroesophageal Reflux
Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole.
Gastroesophageal Reflux
Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data.
Gastroesophageal Reflux
Factors associated with residual gastroesophageal reflux disease symptoms in patients receiving proton pump inhibitor maintenance therapy.
Gastroesophageal Reflux
Genetic polymorphism of CYP2C19 & therapeutic response to proton pump inhibitors.
Gastroesophageal Reflux
Genotype tailored treatment of mild symptomatic acid reflux in children with uncontrolled asthma (GenARA): Rationale and methods.
Gastroesophageal Reflux
Individualized Therapy for Gastroesophageal Reflux Disease: Potential Impact of Pharmacogenetic Testing based on CYP2C19.
Gastroesophageal Reflux
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Gastroesophageal Reflux
Influences of CYP2C19 polymorphism on recurrence of reflux esophagitis during proton pump inhibitor maintenance therapy.
Gastroesophageal Reflux
Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism.
Gastroesophageal Reflux
Pharmacogenetics of the proton pump inhibitors: a systematic review.
Gastroesophageal Reflux
Plasma concentration of rabeprazole after 8-week administration in gastroesophageal reflux disease patients and intragastric pH elevation.
Gastroesophageal Reflux
Prolongation of the QT interval related to cisapride-diltiazem interaction.
Gastroesophageal Reflux
Putting Out the Fire: The Relationship of Pharmacogenetics and Proton Pump Inhibitors for the Treatment of Gastroesophageal Reflux Disease.
Gastroesophageal Reflux
Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis.
Gastroesophageal Reflux
The effect of proton pump inhibitors on the CYP2C19 enzyme activity evaluated by the pantoprazole-(13)C breath test in GERD patients: clinical relevance for personalized medicine.
Gastroesophageal Reflux
[Comparative effectiveness of the antisecretory action of rabeprazole and esomeprazole in people with rapid metabolism of proton pump inhibitors]
Gastroesophageal Reflux
[Influence of CYP2C19 polymorphism and Helicobacter pylori status on the antisecretory effect of omeprazole in gastroesophageal reflux disease]
Gastroesophageal Reflux
[Pathogenesis and treatment of refractory gastroesophageal reflux disease in Japanese patients]
Gastrointestinal Diseases
Effect of azole antifungals ketoconazole and fluconazole on the pharmacokinetics of dexloxiglumide.
Gastrointestinal Diseases
Use of Pharmacogenomics to Guide Proton Pump Inhibitor Therapy in Clinical Practice.
Gastrointestinal Neoplasms
High CYP2C19 phenotypic variability in gastrointestinal cancer patients.
Gastrointestinal Stromal Tumors
Human hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation.
Gastrointestinal Stromal Tumors
Pharmacokinetics of sunitinib in combination with fluoroquinolones in rabbit model.
Gastrointestinal Stromal Tumors
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.
Gaucher Disease
Metabolizing profile of the cytochrome pathway CYP2D6, CYP3A4 and the ABCB 1 transporter in Spanish patients affected by Gaucher disease.
Gingival Hyperplasia
Association of galactose single-point test levels and phenytoin metabolic polymorphisms with gingival hyperplasia in patients receiving long-term phenytoin therapy.
Glioblastoma
MGMT- and P450 3A-inhibitors do not sensitize glioblastoma cell cultures against nitrosoureas.
Gliosarcoma
Potentiation of methoxymorpholinyl doxorubicin antitumor activity by P450 3A4 gene transfer.
glucose-6-phosphate dehydrogenase (nadp+) deficiency
Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial).
Glucosephosphate Dehydrogenase Deficiency
Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial).
Glycogen Storage Disease
Detection of single nucleotide substitution by competitive allele-specific short oligonucleotide hybridization (CASSOH) with immunochromatographic strip.
Gout
Differential Reversible and Irreversible Interactions between Benzbromarone and Human Cytochrome P450s 3A4 and 3A5.
Graft vs Host Disease
Comparative effects of fluconazole, posaconazole, and isavuconazole upon tacrolimus and cyclosporine serum concentrations.
Graft vs Host Disease
Impact of CYP3A5, POR, and CYP2C19 Polymorphisms on Trough Concentration to Dose Ratio of Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplantation.
Gynecomastia
Studies on the interactions between drug and estrogen. II. On the inhibitory effect of 29 drugs reported to induce gynecomastia on the oxidation of estradiol at C-2 or C-17.
Gynecomastia
Studies on the interactions between drugs and estrogen: analytical method for prediction system of gynecomastia induced by drugs on the inhibitory metabolism of estradiol using Escherichia coli coexpressing human CYP3A4 with human NADPH-cytochrome P450 reductase.
Heart Diseases
Comment on Xie et al.: The effects of CES1A2 A(-816)C and CYP2C19 loss-of-function polymorphisms on clopidogrel response variability among Chinese patients with coronary heart disease.
Heart Diseases
CYP2C19 Loss-of-Function is Associated with Increased Risk of Ischemic Stroke after Transient Ischemic Attack in Intracranial Atherosclerotic Disease.
Heart Diseases
Distribution of CYP2C19, ABCB1 and PON1 polymorphisms in Chinese Han, Hui, Uygur and Kazak patients with coronary atherosclerotic heart disease.
Heart Diseases
Erythromycin, QTc interval prolongation, and torsade de pointes: Case reports, major risk factors and illness severity.
Heart Diseases
Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes.
Heart Diseases
Methadone-associated long QT syndrome: improving pharmacotherapy for dependence on illegal opioids and lessons learned for pharmacology.
Heart Diseases
[Impact of CYP2C19 genotype and platelet function on clinical outcome in coronary atherosclerotic heart diseases patients received clopidogrel post percutaneous coronary intervention].
Heart Diseases
[Maximal initial dose of simvastatin causing acute renal failure through rhabdomyolysis: risk factors, pathomechanism and therapy related to a case]
Heart Failure
CYP3A4 genotype is associated with sildenafil concentrations in patients with heart failure with preserved ejection fraction.
Heart Failure
Impact of CYP3A5 genotype on tolvaptan pharmacokinetics and their relationships with endogenous markers of CYP3A activity and serum sodium level in heart failure patients.
Heart Failure
Nonlinear mixed effects model analysis of the pharmacokinetics of metoprolol in routinely treated Japanese patients.
Heart Failure
Tolvaptan administration does not affect steady state amiodarone concentrations in patients with cardiac arrhythmias.
Hemangioma
Cytochrome P450 isoform genotyping in poor propranolol responders for hemangioma treatment.
Hematologic Neoplasms
CYP2C19 genotypes in a population of healthy volunteers and in children with hematological malignancies in Gaza Strip.
Hematologic Neoplasms
Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug-drug interaction predictions using a PBPK approach.
Hematologic Neoplasms
Effect of CYP3A4, CYP3A5, and ABCB1 Polymorphisms on Intravenous Tacrolimus Exposure and Adverse Events in Adult Allogeneic Stem Cell Transplant Patients.
Hematologic Neoplasms
Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin's Lymphoma.
Hematologic Neoplasms
Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients.
Hepatic Insufficiency
Altered cytokine profile under control of the serotonergic system determines the regulation of CYP2C11 and CYP3A isoforms.
Hepatic Insufficiency
Differential Effect of Liver Cirrhosis on the Pregnane X Receptor-Mediated Induction of CYP3A1 and 3A2 in the Rat.
Hepatic Insufficiency
Pharmacokinetic evaluation of eszopiclone: clinical and therapeutic implications.
Hepatic Insufficiency
Physiologically-Based Pharmacokinetic Modeling for Optimal Dosage Prediction of Quinine Coadministered With Ritonavir-Boosted Lopinavir.
Hepatic Insufficiency
Sildenafil (Viagra) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current.
Hepatitis
Individuals having variant genotypes of cytochrome P450 2C19 are at increased risk of developing primary liver cancer in Han populations, without infection with the hepatitis virus.
Hepatitis
Inhibition of cytochrome P450 3A: relevant drug interactions in gastroenterology.
Hepatitis
Overexpression of cytochrome P-450 isoforms involved in aflatoxin B1 bioactivation in human liver with cirrhosis and hepatitis.
Hepatitis
Ritonavir Greatly Impairs CYP3A Activity in HIV Infection With Chronic Viral Hepatitis.
Hepatitis
Ritonavir greatly impairs CYP3A activity in HIV infection with chronic viral hepatitis.
Hepatitis B
A New Approach of Mitigating CYP3A4 Induction Led to the Discovery of Potent Hepatitis B Virus (HBV) Capsid Inhibitor with Optimal ADMET Profiles.
Hepatitis B
Impact of hepatitis B virus (HBV) infection on platelet response to clopidogrel in patients undergoing coronary stent implantation.
Hepatitis B
Methylation of the Constitutive Androstane Receptor Is Involved in the Suppression of CYP2C19 in Hepatitis B Virus-Associated Hepatocellular Carcinoma.
Hepatitis B
Single-nucleotide polymorphism genotyping using a novel multiplexed electrochemical biosensor with nonfouling surface.
Hepatitis B, Chronic
CYP2C19 Genotype Could be a Predictive Factor for Aggressive Manifestations of Hepatocellular Carcinoma Related with Chronic Hepatitis B Infection in Thailand.
Hepatitis B, Chronic
Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial).
Hepatitis C
ABCB1, CYP2B6, and CYP3A4 genetic polymorphisms do not affect methadone maintenance treatment in HCV-positive patients.
Hepatitis C
Drug-Drug Interactions between Direct Oral Anticoagulants and Hepatitis C Direct-Acting Antiviral Agents: Looking for Evidence Through a Systematic Review.
Hepatitis C
Drug-Drug Interactions Between HMG-CoA Reductase Inhibitors (Statins) and Antiviral Protease Inhibitors.
Hepatitis C
Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin.
Hepatitis C
Effects of omeprazole and ritonavir on absorption and elimination of the hepatitis C virus NS5A inhibitor GSK2336805 in healthy adults.
Hepatitis C
Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in real world hepatitis C patients.
Hepatitis C
Pharmacokinetic Evaluation of the Interaction Between the HCV Protease Inhibitor Boceprevir and the HMG-CoA Reductase Inhibitors Atorvastatin and Pravastatin.
Hepatitis C
Pharmacokinetics of the co-administration of boceprevir and St John's wort to male and female healthy volunteers.
Hepatitis C
Successful telaprevir treatment in combination of cyclosporine against recurrence of hepatitis C in the Japanese liver transplant patients.
Hepatitis C
The Pharmacokinetic Interaction Between an Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone and the HCV Protease Inhibitor Telaprevir.
Hepatitis C, Chronic
Effect of interferon alpha-ribavirin bitherapy on cytochrome P450 1A2 and 2D6 and N-acetyltransferase-2 activities in patients with chronic active hepatitis C.
Hepatitis C, Chronic
Immunoreactivity to various human cytochrome P450 proteins of sera from patients with autoimmune hepatitis, chronic hepatitis B, and chronic hepatitis C.
Hepatitis, Chronic
In vivo metabolic activity of CYP2C19 and CYP3A in relation to CYP2C19 genetic polymorphism in chronic liver disease.
Hepatoblastoma
Bioluminescence Measurement of Time-Dependent Dynamic Changes of CYP-Mediated Cytotoxicity in CYP-Expressing Luminescent HepG2 Cells.
Hepatoblastoma
Cytotoxicity of chloroacetanilide herbicide alachlor in HepG2 cells independent of CYP3A4 and CYP3A7.
Hepatoblastoma
Development of an in vitro reporter gene assay to assess xenobiotic induction of the human CYP3A4 gene.
Hepatoblastoma
Inhibition of CYP3A4 by 6',7'-dihydroxybergamottin in human CYP3A4 over-expressed hepG2 cells.
Hepatoblastoma
Tamoxifen cytotoxicity in hepatoblastoma cells stably transfected with human CYP3A4.
Hepatoblastoma
Threshold for antiproliferative and proapoptotic activity of ttaxol in HepG2 cells expressing human CYP3A4: effect of P-glycoprotein transporters.
Hepatolenticular Degeneration
Hepatic drug-metabolizing enzymes and drug transporters in Wilson's disease patients with liver failure.
Hepatomegaly
Coordinate regulation of xenobiotic and bile acid homeostasis by pregnane X receptor.
Hepatomegaly
Quantitative structure-activity relationships in a series of endogenous and synthetic steroids exhibiting induction of CYP3A activity and hepatomegaly associated with increased DNA synthesis.
Herpes Zoster
Molecular Analysis of Endocrine Disruption in Hornyhead Turbot at Wastewater Outfalls in Southern California Using a Second Generation Multi-Species Microarray.
HIV Infections
A human immunodeficiency virus protease inhibitor is a novel functional inhibitor of human pregnane X receptor.
HIV Infections
Drug-drug interactions in the treatment of HIV infection: focus on pharmacokinetic enhancement through CYP3A inhibition.
HIV Infections
Is there a place for drug combination strategies using clinical pharmacology attributes?--review of current trends in research.
HIV Infections
Nanocapsules embedded in microparticles for enhanced oral bioavailability and efficacy of Lopinavir as an anti-AIDS drug.
HIV Infections
Physiologically-Based Pharmacokinetic Modeling for Optimal Dosage Prediction of Quinine Coadministered With Ritonavir-Boosted Lopinavir.
HIV Infections
Ritonavir Greatly Impairs CYP3A Activity in HIV Infection With Chronic Viral Hepatitis.
HIV Infections
Ritonavir greatly impairs CYP3A activity in HIV infection with chronic viral hepatitis.
HIV Infections
[Implications of antiretroviral therapy in oral medicine--a review of literature]
HIV Seropositivity
MDR1 and CYP3A4 polymorphisms are associated with HIV seropositivity in Israeli patients but do not influence the course of HIV disease.
Hodgkin Disease
Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma.
Hodgkin Disease
Pharmacogenetic study in Hodgkin's lymphomas reveals the impact of UGT1A1 polymorphisms on patient's prognosis.
Hypercholesterolemia
A pharmacokinetic drug-drug interaction model of simvastatin and verapamil in humans.
Hypercholesterolemia
Association of polymorphisms of ABCA1 and ROS1 with hypertension in Japanese individuals.
Hypercholesterolemia
Associations between the genotypes and phenotype of CYP3A and the lipid response to simvastatin in Chinese patients with hypercholesterolemia.
Hypercholesterolemia
Comparison of endothelial function in the carotid artery between normal and short-term hypercholesterolemic rabbits.
Hypercholesterolemia
CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia.
Hypercholesterolemia
No effect of CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) on lipid-lowering response to statins in Greek patients with primary hypercholesterolemia.
Hypercholesterolemia
Statin-Induced Myotoxicity: Pharmacokinetic Differences among Statins and the Risk of Rhabdomyolysis, with Particular Reference to Pitavastatin.
Hyperglycemia
Long-term exposure to abnormal glucose levels alters drug metabolism pathways and insulin sensitivity in primary human hepatocytes.
Hyperglycinemia, Nonketotic
Detection of single nucleotide substitution by competitive allele-specific short oligonucleotide hybridization (CASSOH) with immunochromatographic strip.
Hyperkalemia
Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
Hyperkalemia
Risks of Adverse Events Following Coprescription of Statins and Calcium Channel Blockers: A Nationwide Population-Based Study.
Hyperlipidemias
Pharmacokinetics and Pharmacodynamic Herb-Drug Interaction of Piperine with Atorvastatin in Rats.
Hypersensitivity
Anticonvulsant usage is associated with an increased risk of procarbazine hypersensitivity reactions in patients with brain tumors.
Hypersensitivity
Efficacy of local budesonide therapy in the management of persistent hyposmia in COVID-19 patients without signs of severity: A structured summary of a study protocol for a randomised controlled trial.
Hypersensitivity
Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial).
Hypersensitivity
Human anti-endoplasmic reticulum autoantibodies produced in aromatic anticonvulsant hypersensitivity reactions recognise rodent CYP3A proteins and a similarly regulated human P450 enzyme(s)
Hypersensitivity
Trichloroethylene-induced hypersensitivity dermatitis was associated with hepatic metabolic enzyme genes and immune-related genes.
Hypertension
Antihypertensive Effect Of Amlodipine In Co-Administration With Omeprazole In Patients With Hypertension And Acid-Related Disorders: Cytochrome P450-Associated Aspects.
Hypertension
Association between CYP3A4 gene rs4646437 polymorphism and the risk of hypertension in Chinese population: a case-control study.
Hypertension
Association of CYP2C19 variants and epoxyeicosatrienoic acids on patients with microvascular angina.
Hypertension
Association of genetic polymorphisms of CYP 2C19 with hypertension in a Chinese Han population.
Hypertension
Association of polymorphisms of ABCA1 and ROS1 with hypertension in Japanese individuals.
Hypertension
Augmented arterial pressure responses to cyclosporine in spontaneously hypertensive rats. Role of cytochrome P-450 3A.
Hypertension
Biphenyl/diphenyl ether renin inhibitors: Filling the S1 pocket of renin via the S3 pocket.
Hypertension
Correlation study of CYP2C19 gene polymorphism and clopidogrel resistance in Han Chinese patients with cerebral infarction in Guizhou region.
Hypertension
CYP2C19 activity and cardiovascular risk factors in patients with an acute coronary syndrome.
Hypertension
CYP2C19 genotype is an independent predictor of Adverse Cardiovascular Outcome in Iraqi Patients on Clopidogrel Post Percutaneous Coronary Intervention.
Hypertension
CYP2C19 Loss-of-Function is Associated with Increased Risk of Ischemic Stroke after Transient Ischemic Attack in Intracranial Atherosclerotic Disease.
Hypertension
CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease.
Hypertension
Functional characterization of CYP2C19 variants in nebivolol 4-hydroxlation in vitro.
Hypertension
Functional polymorphisms in the CYP3A4, CYP3A5, and CYP21A2 genes in the risk for hypertension in pregnancy.
Hypertension
Gender Differences in the Impact of CYP2C19 Polymorphisms and Low-Grade Inflammation on Coronary Microvascular Disorder.
Hypertension
Genetic predictors of glucocorticoid-induced hypertension in children with acute lymphoblastic leukemia.
Hypertension
Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection.
Hypertension
Incorporation of Gene-Environment Interaction Terms Improved the Predictive Accuracy of Tacrolimus Stable Dose Algorithms in Chinese Adult Renal Transplant Recipients.
Hypertension
Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma.
Hypertension
Pharmacokinetic drug-drug interaction of calcium channel blockers with cyclosporine in hematopoietic stem cell transplant children.
Hypertension
Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma.
Hypertension
Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans.
Hypertension
Relationships between endogenous CYP3A markers and plasma amlodipine exposure and metabolism in early postpartum and non-peripartum women with hypertension.
Hypertension
Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren.
Hypertension
Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma.
Hypertension
The effects of polymorphisms in CYP2C19, ATP-binding cassette transporter B1, and paraoxonase-1 on clopidogrel treatment of Uygur patients following percutaneous coronary intervention.
Hypertension
The Impact of CYP2C19 Loss-of-Function Polymorphisms, Clinical, and Demographic Variables on Platelet Response to Clopidogrel Evaluated Using Impedance Aggregometry.
Hypertension
[Maximal initial dose of simvastatin causing acute renal failure through rhabdomyolysis: risk factors, pathomechanism and therapy related to a case]
Hypertension, Portal
Overexpression of P-glycoprotein, MRP2, and CYP3A4 impairs intestinal absorption of octreotide in rats with portal hypertension.
Hypertension, Pulmonary
Sildenafil and furosemide associated ototoxicity: consideration of drug-drug interactions, synergy, and broader clinical relevance.
Hypoglycemia
The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.
Hypokalemia
Methadone-associated long QT syndrome: improving pharmacotherapy for dependence on illegal opioids and lessons learned for pharmacology.
Hypokalemia
Severe hypokalemia due to a possible drug-drug interaction between vinblastine and antiretrovirals in a HIV-infected patient with Hodgkin's lymphoma.
Hypospadias
Association of variants in genes involved in environmental chemical metabolism and risk of cryptorchidism and hypospadias.
Hypospadias
Dysregulated expression of androgen metabolism genes and genetic analysis in hypospadias.
Hypotension
Ergotism and factitious hypotension associated with interaction of ergotamine with CYP3A4 inhibitors.
Hypotension
Inhibition of cytochrome P450 3A: relevant drug interactions in gastroenterology.
Hypotension
Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.
Ileus
Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial).
Immune Reconstitution Inflammatory Syndrome
How best to approach endocrine evaluation in patients with HIV in the era of combined antiretroviral therapy?
Infections
A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism.
Infections
A Rapid and Accurate Method to Evaluate Helicobacter pylori Infection, Clarithromycin Resistance, and CYP2C19 Genotypes Simultaneously From Gastric Juice.
Infections
Adverse drug reactions due to drug-drug interactions with proton pump inhibitors: assessment of systematic reviews with AMSTAR method.
Infections
An in vitro drug-induced hepatotoxicity screening system using CYP3A4-expressing and gamma-glutamylcysteine synthetase knockdown cells.
Infections
Antibiotic resistance and CYP2C19 polymorphisms affect the efficacy of concomitant therapies for Helicobacter pylori infection: an open-label, randomized, single-centre clinical trial.
Infections
Application of Visual Gene Clip-Based Tailored Therapy for the Eradication of Helicobacter pylori.
Infections
Association of CYP2C19, TNF-?, NOD1, NOD2, and PPAR? polymorphisms with peptic ulcer disease enhanced by Helicobacter pylori infection.
Infections
Broad but distinct role of pregnane x receptor on the expression of individual cytochrome p450s in human hepatocytes.
Infections
Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19.
Infections
Correlation of CYP2C19 genetic polymorphisms with helicobacter pylori eradication in patients with cirrhosis and peptic ulcer.
Infections
Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient.
Infections
Cure rate of Helicobacter pylori infection in Egyptian children related to CYP2C19 gene polymorphism.
Infections
Cyclophosphamide treatment-induced leukopenia rates in ANCA-associated vasculitis are influenced by variant CYP450 2C9 genotypes.
Infections
CYP2C19 genotype and phenotype determined with omeprazole in patients with acid-related disorders with and without Helicobacter pylori infection.
Infections
CYP2C19 Genotype Could be a Predictive Factor for Aggressive Manifestations of Hepatocellular Carcinoma Related with Chronic Hepatitis B Infection in Thailand.
Infections
CYP2C19 Genotype, CagA Genotype and Antibiotic Resistant
Strain of Helicobacter pylori Infection
Infections
CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori.
Infections
CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection.
Infections
CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor.
Infections
CYP2C19 Phenotype and Risk of Proton Pump Inhibitor-Associated Infections.
Infections
CYP2D6 and CYP3A4 variants influence the risk and outcome of COVID-19 infection among rheumatoid arthritis patients maintained on hydroxychloroquine.
Infections
Cytochrome P450 2C19 polymorphism influences the preventive effect of lansoprazole on the recurrence of erosive reflux esophagitis.
Infections
Cytochrome P450 3A4 and P-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea.
Infections
Cytokines influence mRNA expression of cytochrome P450 3A4 and MDRI in intestinal cells.
Infections
Development of a highly reproducible system to evaluate inhibition of cytochrome P450 3A4 activity by natural medicines.
Infections
Differences in the Serum 4?-hydroxycholesterol Levels of Patients with Chronic HCV Infection: A Possible Impact on the Efficacy and Safety of IFN-free Treatment.
Infections
Disseminated Scedosporium prolificans infection in an 'extensive metaboliser': navigating the minefield of drug interactions and pharmacogenomics.
Infections
Downregulation of Hepatic Cytochrome P450 3A in Mice Infected with Babesia microti.
Infections
Dual proton pump inhibitor plus amoxicillin as an empiric anti-H. pylori therapy: studies from the United States.
Infections
Effect of bacterial and host factors on Helicobacter pylori eradication therapy.
Infections
Effect of cyclosporine a and polymorphisms in CYP2C19 and ABCC2 on the concentration of voriconazole in patients undergoing allogeneic hematopoietic stem cell transplantation.
Infections
Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection.
Infections
Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.
Infections
Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin.
Infections
Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer.
Infections
Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
Infections
Effect of ketoconazole, a cytochrome P450 inhibitor, on the efficacy of quinine and halofantrine against Schistosoma mansoni in mice.
Infections
Effect of the CYP2C19 polymorphism on the eradication rate of Helicobacter pylori infection by 7-day triple therapy with regular proton pump inhibitor dosage.
Infections
Effects of CYP2C19 and MDR1 genotype on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxycillin and clarithromycin.
Infections
Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan.
Infections
Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials.
Infections
Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole.
Infections
Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin.
Infections
Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study in Chinese adults.
Infections
Efficacy of a triple therapy with rabeprazole, amoxicillin, and faropenem as second-line treatment after failure of initial Helicobacter pylori eradication therapy.
Infections
Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism.
Infections
Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype.
Infections
Enhancement of CYP3A4 activity in Hep G2 cells by lentiviral transfection of hepatocyte nuclear factor-1 alpha.
Infections
Evaluation of the HC-04 cell line as an in vitro model for mechanistic assessment of changes in hepatic cytochrome P450 3A during adenovirus infection.
Infections
Factors associated with healing of artificial ulcer after endoscopic submucosal dissection with reference to Helicobacter pylori infection, CYP2C19 genotype, and tumor location: Multicenter randomized trial.
Infections
Gastric Juice-Based Real-Time PCR for Tailored Helicobacter Pylori Treatment: A Practical Approach.
Infections
Gene expression profiling of porcine mammary epithelial cells after challenge with Escherichia coli and Staphylococcus aureus in vitro.
Infections
Genotype analysis of the CYP2C19 gene in HCV-seropositive patients with cirrhosis and hepatocellular carcinoma.
Infections
High Effective of 14-Day High-Dose PPI- Bismuth-Containing Quadruple Therapy with Probiotics Supplement for Helicobacter Pylori Eradication: A Double Blinded-Randomized Placebo-Controlled Study.
Infections
High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin.
Infections
Immunization and Drug Metabolizing Enzymes: Focus on Hepatic Cytochrome P450 3A.
Infections
Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan.
Infections
Impact of hepatitis B virus (HBV) infection on platelet response to clopidogrel in patients undergoing coronary stent implantation.
Infections
In Vitro Model for a Drug Assessment of Cytochrome P450 Family 3 Subfamily A Member 4 Substrates Using Human Induced Pluripotent Stem Cells and Genome Editing Technology.
Infections
Individuals having variant genotypes of cytochrome P450 2C19 are at increased risk of developing primary liver cancer in Han populations, without infection with the hepatitis virus.
Infections
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Infections
Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection.
Infections
Integrin Receptors Play a Key Role in the Regulation of Hepatic Cytochrome P450 3A.
Infections
Long-term virus-induced alterations of CYP3A-mediated drug metabolism: a look at the virology, immunology and molecular biology of a multi-faceted problem.
Infections
Lower expression of HNF4? and PGC1? might impair rifampicin-mediated CYP3A4 induction under conditions where PXR overexpressed in human fetal liver cells.
Infections
Metabolism of Diazepam and Ethosuximide in rats with malaria and endotoxin-induced fever.
Infections
Metronidazole leads to enhanced uptake of imatinib in brain, liver and kidney without affecting its plasma pharmacokinetics in mice.
Infections
Microarray-Based Detection and Clinical Evaluation for Helicobacter pylori Resistance to Clarithromycin or Levofloxacin and the Genotype of CYP2C19 in 1083 Patients.
Infections
Modulation of hepatic cytochrome P450 during Listeria monocytogenes infection of the brain.
Infections
Novel Implementation of Genotype-Guided Proton Pump Inhibitor Medication Therapy in Children: A Pilot, Randomized, Multisite Pragmatic Trial.
Infections
Optimal dose of intravenous pantoprazole in patients with peptic ulcer bleeding requiring endoscopic hemostasis in Korea.
Infections
Pharmacokinetic- pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pylori.
Infections
Polymorphisms and the pocketbook: the cost-effectiveness of cytochrome P450 2C19 genotyping in the eradication of Helicobacter pylori infection associated with duodenal ulcer.
Infections
Polymorphisms in the host CYP2C19 gene and antibiotic-resistance attributes of Helicobacter pylori isolates influence the outcome of triple therapy.
Infections
Poor metabolizer genotype status of CYP2C19 is a risk factor for developing gastric cancer in Japanese patients with Helicobacter pylori infection.
Infections
Prevention of gastric mucosal injury induced by anti-platelet drugs by famotidine.
Infections
Rabeprazole can overcome the impact of CYP2C19 polymorphism on quadruple therapy.
Infections
Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.
Infections
Rhabdomyolysis in an HIV-Infected Patient on Anti-Retroviral Therapy Precipitated by High-Dose Pravastatin.
Infections
Ritonavir and Topical Ocular Corticosteroid Induced Cushing's Syndrome in an Adolescent with HIV-1 Infection.
Infections
Small-Cell Lung Cancer Comorbid with Pulmonary Mycobacterium avium Infection: A Case Report.
Infections
Study of the Urinary Ratio of 6 beta-Hydroxycortisol/Cortisol as a Biomarker of CYP3A4 Activity in Egyptian Patients with Chronic Liver Diseases.
Infections
The dual therapy with 4 times daily dosing of rabeprazole and amoxicillin as the 3rd rescue regimen for eradication of H. pylori.
Infections
The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism.
Infections
The Effects of Switching to Vonoprazan, a Novel Potassium-Competitive Acid Blocker, on Gastric Acidity and Reflux Patterns in Patients with Erosive Esophagitis Refractory to Proton Pump Inhibitors.
Infections
Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers.
Infections
Value of preemptive CYP2C19 genotyping in allogeneic stem cell transplant patients considered for pentamidine administration.
Infections
Worsening pneumonitis due to a pharmacokinetic drug-drug interaction between everolimus and voriconazole in a renal transplant patient.
Infections
[Effect of CYP2C19 gene polymorphism on eradication treatment efficacy of Helicobacter pylori infection]
Infections
[Effect of CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with rabeprazole-based triple therapy in Chinese]
Infections
[Effectiveness of eradication regimen based on the bacterial susceptibility and CYP2C19 genotype in children with refractory Helicobacter pylori infection].
Infections
[High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy: CYP2C19 polymorphism]
Infections
[Influence of CYP2C19 polymorphism and Helicobacter pylori status on the antisecretory effect of omeprazole in gastroesophageal reflux disease]
Infections
[Pathogenesis and treatment of refractory gastroesophageal reflux disease in Japanese patients]
Infections
[Polymorphism of cytochrome P-450 gene in the light of Helicobacter pylori eradication efficiency]
Infections
[Susceptibility to antibiotics and drug metabolism in patients with H. pylori infection refractory to the initial treatment--therapeutic strategy based on susceptibility to CAM and CYP2C19 polymorphism]
Infertility
Interactions between urinary 4-tert-octylphenol levels and metabolism enzyme gene variants on idiopathic male infertility.
Inflammatory Bowel Diseases
Artemisinin protects against dextran sulfate-sodium-induced inflammatory bowel disease, which is associated with activation of the pregnane X receptor.
Inflammatory Bowel Diseases
Assessment of Disease-Related Therapeutic Protein Drug-Drug Interaction for Etrolizumab in Patients With Moderately to Severely Active Ulcerative Colitis.
Inflammatory Bowel Diseases
Effect of high-dose metronidazole on pharmacokinetics of oral budesonide and vice versa: a double drug interaction study.
Inflammatory Bowel Diseases
Influence of CYP3A4, CYP3A5, and ABCB1 genotype and expression on budesonide pharmacokinetics: a possible role of intestinal CYP3A4 expression.
Influenza, Human
Effect of age and degree of immune activation on cytochrome P450 3A4 activity after influenza immunization.
Insulin Resistance
Long-term exposure to abnormal glucose levels alters drug metabolism pathways and insulin sensitivity in primary human hepatocytes.
Intestinal Diseases
Decreased intestinal CYP3A in celiac disease: reversal after successful gluten-free diet: a potential source of interindividual variability in first-pass drug metabolism.
Intestinal Neoplasms
Indole microbial intestinal metabolites expand the repertoire of ligands and agonists of the human pregnane X receptor.
Intracranial Aneurysm
Acute stent thrombosis after stent-assisted coiling in an intracranial aneurysm patient carrying two reduced-function CYP2C19 alleles: A case report.
Intracranial Aneurysm
Influence of CYP2C19 genetic polymorphisms on clinical outcomes of intracranial aneurysms treated with stent-assisted coiling.
Invasive Fungal Infections
A prospective observational study of CYP2C19 polymorphisms and voriconazole plasma level in adult Thai patients with invasive aspergillosis.
Invasive Fungal Infections
Correlation of CYP2C19 genotype with plasma voriconazole exposure in South-western Chinese Han patients with invasive fungal infections.
Invasive Fungal Infections
Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug-drug interaction predictions using a PBPK approach.
Invasive Fungal Infections
Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections.
Invasive Fungal Infections
Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections.
Invasive Fungal Infections
Impact of CYP2C19 genotype on voriconazole exposure and effect of voriconazole on the activity of CYP3A in patients with haematological malignancies.
Invasive Fungal Infections
Impact of CYP2C19, CYP3A4, ABCB1, and FMO3 genotypes on plasma voriconazole in Thai patients with invasive fungal infections.
Invasive Fungal Infections
Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections.
Invasive Fungal Infections
Population Pharmacokinetics of Voriconazole and CYP2C19 Polymorphisms for Optimizing Dosing Regimens in Renal Transplant Recipients.
Invasive Fungal Infections
Risk Factors for Voriconazole-Associated Hepatotoxicity in Patients in the Intensive Care Unit.
Invasive Fungal Infections
[The polymorphism of cytochrome P(450) 2C19 gene in patients with invasive fungal infections.]
Iron Deficiencies
Effect of intravenous iron supplementation on hepatic cytochrome P450 3A4 activity in hemodialysis patients: A prospective, open-label study.
Irritable Bowel Syndrome
Role of serum amitriptyline concentration and CYP2C19 polymorphism in predicting the response to low-dose amitriptyline in irritable bowel syndrome.
Ischemic Attack, Transient
A pharmacoepidemiology study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention.
Ischemic Attack, Transient
Antiplatelet effect of ticagrelor with aspirin in acute minor stroke and transient ischemic attack stratified by CYP2C19 metabolizer status: subgroup analysis of the PRINCE trial.
Ischemic Attack, Transient
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Ischemic Attack, Transient
Cost-effectiveness of CYP2C19 genotyping to guide antiplatelet therapy for acute minor stroke and high-risk transient ischemic attack.
Ischemic Attack, Transient
CYP2C19 Loss-of-Function is Associated with Increased Risk of Ischemic Stroke after Transient Ischemic Attack in Intracranial Atherosclerotic Disease.
Ischemic Attack, Transient
Efficacy and safety of CYP2C19 genotype in stroke or transient ischemic attack patients treated with clopidogrel monotherapy or clopidogrel plus aspirin: Protocol for a systemic review and meta-analysis.
Ischemic Attack, Transient
Efficacy of Clopidogrel-Aspirin Therapy for Stroke Does Not Exist in CYP2C19 Loss-of-Function Allele Noncarriers With Overweight/Obesity.
Ischemic Attack, Transient
Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy.
Ischemic Stroke
Association between CYP2C19 gene polymorphisms and lipid metabolism in Chinese patients with ischemic stroke.
Ischemic Stroke
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Ischemic Stroke
Association between genetic polymorphisms of cytochrome P450 2C19 and the risk of cerebral ischemic stroke in Chinese.
Ischemic Stroke
Association of CYP2C19 Polymorphisms With Clopidogrel Reactivity and Clinical Outcomes in Chronic Ischemic Stroke.
Ischemic Stroke
Association of CYP2C19 Polymorphisms with the Clinical Efficacy of Clopidogrel Therapy in Patients Undergoing Carotid Artery Stenting in Asia.
Ischemic Stroke
Association of CYP3A4*1G and CYP3A5*3 With the 1-year Outcome of Acute Ischemic Stroke in the Han Chinese Population.
Ischemic Stroke
Associations of CYP3A4, NR1I2, CYP2C19 and P2RY12 polymorphisms with clopidogrel resistance in Chinese patients with ischemic stroke.
Ischemic Stroke
Body weight, CYP2C19, and P2Y12 receptor polymorphisms relate to clopidogrel resistance in a cohort of Chinese ischemic stroke patients with aspirin intolerance.
Ischemic Stroke
Clopidogrel preventive effect based on cytochrome P450 2C19 genotype in ischaemic stroke: protocol for multicentre observational study.
Ischemic Stroke
Cost Effectiveness of Genotype-Guided Antiplatelet Therapy in Asian Ischemic Stroke Patients: Ticagrelor as an Alternative to Clopidogrel in Patients with CYP2C19 Loss of Function Mutations.
Ischemic Stroke
CYP2C19 Genotype-Guided Antiplatelet Therapy Among Asian Patients with Ischaemic Stroke.
Ischemic Stroke
CYP2C19 Loss-of-Function Associated with First-Time Ischemic Stroke in Non-surgical Asymptomatic Carotid Artery Stenosis During Clopidogrel Therapy.
Ischemic Stroke
CYP2C19 Loss-of-Function is Associated with Increased Risk of Ischemic Stroke after Transient Ischemic Attack in Intracranial Atherosclerotic Disease.
Ischemic Stroke
CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China.
Ischemic Stroke
CYP3A4 and CYP11A1 variants are risk factors for ischemic stroke: a case control study.
Ischemic Stroke
Dual therapy with clopidogrel and aspirin prevents early neurological deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles.
Ischemic Stroke
Effect of CYP2C19*2 and *3 on clinical outcome in ischemic stroke patients treated with clopidogrel.
Ischemic Stroke
Effectiveness and safety of high dose clopidogrel plus aspirin in ischemic stroke patients with the single CYP2C19 loss-of-function allele: a randomized trial.
Ischemic Stroke
Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis.
Ischemic Stroke
Influence of CYP2C19 polymorphisms on platelet reactivity and clinical outcomes in ischemic stroke patients treated with clopidogrel.
Ischemic Stroke
Influence of Genetic Polymorphisms on Clopidogrel Response and Clinical Outcomes in Patients with Acute Ischemic Stroke CYP2C19 Genotype on Clopidogrel Response.
Ischemic Stroke
Interaction of CYP2C19, P2Y12, and GPIIIa Variants Associates With Efficacy of Clopidogrel and Adverse Events on Patients With Ischemic Stroke.
Ischemic Stroke
Investigating CYP2C19 loss-of-function allele statuses and their association with stroke of different etiologies in a Taiwanese population.
Ischemic Stroke
Ischemic stroke and myocardial ischemia in clopidogrel users and the association with CYP2C19 loss-of-function homozygocity: a real-world study.
Ischemic Stroke
Non-vitamin K Oral Anticoagulants and Anti-seizure Medications: A Retrospective Cohort Study.
Ischemic Stroke
Pharmacogenetics of CYP2C19 genetic polymorphism on clopidogrel response in patients with ischemic stroke from Saudi Arabia.
Ischemic Stroke
Prevalence of CYP2C19*2 carriers in Saudi ischemic stroke patients and the suitability of using genotyping to guide antiplatelet therapy in a university hospital setup.
Ischemic Stroke
Protocol for the comparison of triflusal and clopidogrel in secondary prevention of stroke based on cytochrome P450 2C19 genotyping (MASETRO study): A multicenter, randomized, open-label, parallel-group trial.
Ischemic Stroke
Risks of Adverse Events Following Coprescription of Statins and Calcium Channel Blockers: A Nationwide Population-Based Study.
Ischemic Stroke
Should CYP2C19 Genotyping Be Recommended as a Straight Forward Approach to Optimize Clopidogrel Utilization in Patients with Ischemic Stroke Complicated by Type 2 Diabetes Mellitus?
Ischemic Stroke
The correlation between recurrent risk and CYP2C19 gene polymorphisms in patients with ischemic stroke treated with clopidogrel for prevention.
Ischemic Stroke
The secondary prevention of stroke according to cytochrome P450 2C19 genotype in patients with acute large-artery atherosclerosis stroke.
Ischemic Stroke
[Association of CYP2C19 gene polymorphisms with long-term recurrent risk of ischemic stroke among ethnic Han Chinese from Fujian].
Ischemic Stroke
[Genetic and non-genetic factors of laboratory resistance to clopidogrel in patients with ischemic stroke].
Ischemic Stroke
[Influence of CYP2C19 gene polymorphisms on the efficacy of clopidogrel treatment for the prevention of ischemic stroke following coronary stent implantation].
Kidney Diseases
CYP2C19 genotype has prognostic value in specific populations following coronary stenting.
Kidney Diseases
CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney diseases and epileptic patients.
Kidney Diseases
CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease.
Kidney Diseases
Down-regulation of hepatic CYP3A and CYP2C mediated metabolism in rats with moderate chronic kidney disease.
Kidney Failure, Chronic
Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease.
Kidney Failure, Chronic
Chronic Inhibition of CYP3A is Temporarily Reduced by Each Hemodialysis Session in Patients With End-Stage Renal Disease.
Kidney Failure, Chronic
Colchicine-induced acute myopathy in a patient with concomitant use of simvastatin.
Kidney Failure, Chronic
CYP3A5 polymorphism affects the increase in CYP3A activity after living kidney transplantation in patients with end stage renal disease.
Kidney Failure, Chronic
Effect of uremic serum and uremic toxins on drug metabolism in human microsomes.
Kidney Failure, Chronic
Effects of decreased vitamin D and accumulated uremic toxin on human CYP3A4 activity in patients with end-stage renal disease.
Kidney Failure, Chronic
End-stage renal disease reduces the expression of drug-metabolizing cytochrome P450s.
Kidney Failure, Chronic
Physiologically-Based Pharmacokinetic Modeling for Optimal Dosage Prediction of Quinine Coadministered With Ritonavir-Boosted Lopinavir.
Kidney Failure, Chronic
Significant increase in plasma 4?-hydroxycholesterol concentration in patients after kidney transplantation.
Kidney Neoplasms
Ritonavir acts synergistically with panobinostat to enhance histone acetylation and inhibit renal cancer growth.
lactase deficiency
Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial).
Leishmaniasis, Visceral
Impact of visceral leishmaniasis and curative chemotherapy on cytochrome P450 activity in Brazilian patients.
Leprosy
Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen's disease patients.
Leukemia
Association of CYP3A4 genotype with detection of Vgamma/Jbeta trans-rearrangements in the peripheral blood leukocytes of pediatric cancer patients undergoing chemotherapy for ALL.
Leukemia
Clinically Relevant Cytochrome P450 3A4 Induction Mechanisms and Drug Screening in Three-Dimensional Spheroid Cultures of Primary Human Hepatocytes.
Leukemia
Effects of cytochrome P450 family 3 subfamily A member 5 gene polymorphisms on daunorubicin metabolism and adverse reactions in patients with acute leukemia.
Leukemia
Frequency and prognostic significant of CYP3A4-A-290G polymorphism in acute myeloid leukemia.
Leukemia
Polymorphisms in CYP1B1, CYP3A5, GSTT1, and SULT1A1 Are Associated with Early Age Acute Leukemia.
Leukemia
Stimulation of human monocytic THP-1 cells by metabolic activation of hepatotoxic drugs.
Leukemia
The constitutive androstane receptor is a novel therapeutic target facilitating cyclophosphamide-based treatment of hematopoietic malignancies.
Leukemia
[The relationship between cytochrome P450, subfamily IIIA, polypeptide 5 gene and drug resistance in leukemia cell lines]
Leukemia, Erythroblastic, Acute
Changes in the expression of cytochrome P450 genes in hemin-induced differentiated K562 cells.
Leukemia, Erythroblastic, Acute
Oxidative stress induces GSTP1 and CYP3A4 expression in the human erythroleukemia cell line, K562.
Leukemia, Lymphocytic, Chronic, B-Cell
Cytochrome P450 Allele CYP3A7*1C Associates with Adverse Outcomes in Chronic Lymphocytic Leukemia, Breast, and Lung Cancer.
Leukemia, Lymphocytic, Chronic, B-Cell
Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice.
Leukemia, Lymphocytic, Chronic, B-Cell
Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Association of Genetic Polymorphisms in the Influx Transporter SLCO1B3 and the Efflux Transporter ABCB1 With Imatinib Pharmacokinetics in Patients With Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cytochrome P450 2C19 gene polymorphisms (CYP2C19*2 and CYP2C19*3) in chronic myeloid leukemia patients: in vitro and in silico studies.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Effects of polymorphisms in NR1I2, CYP3A4, and ABC transporters on the steady-state plasma trough concentrations of bosutinib in Japanese patient with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Evaluation of the effect of multiple doses of rifampin on the pharmacokinetics and safety of ponatinib in healthy subjects.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Human hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Potential interactions between HIV drugs, ritonavir and efavirenz and anticancer drug, nilotinib-a study in primary cultures of human hepatocytes that is applicable to HIV patients with cancer.
Leukemia, Myeloid, Acute
Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/ myelodysplastic syndrome and de novo acute myeloid leukemia.
Leukemia, Myeloid, Acute
Budget Impact Analysis of CYP2C19 Genotyping to Target Voriconazole Prophylaxis During Induction-Consolidation Therapy in Acute Myeloid Leukemia (AML) in The United States.
Leukemia, Myeloid, Acute
Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms.
Leukemia, Myeloid, Acute
Management of Venetoclax-Posaconazole Interaction in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments.
Leukemia, Myeloid, Acute
Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia.
Leukemia, Myeloid, Acute
Role of CYP3A4 in bone marrow microenvironment-mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors.
Leukopenia
Association Study Among Candidate Genetic Polymorphisms and Chemotherapy-Related Severe Toxicity in Testicular Cancer Patients.
Leukopenia
Pharmacokinetics of eribulin mesylate in patients with solid tumors receiving repeated oral rifampicin.
Lipodystrophy
How best to approach endocrine evaluation in patients with HIV in the era of combined antiretroviral therapy?
Liver Cirrhosis
CYP3A activity in severe liver cirrhosis correlates with Child-Pugh and Model for End-Stage Liver Disease (MELD) scores.
Liver Cirrhosis
Different alterations of cytochrome P450 3A4 isoform and its gene expression in livers of patients with chronic liver diseases.
Liver Cirrhosis
Effects of zedoary turmeric oil on P450 activities in rats with liver cirrhosis induced by thioacetamide.
Liver Cirrhosis
Intestinal first pass metabolism of midazolam in liver cirrhosis --effect of grapefruit juice.
Liver Cirrhosis
Overexpression of P-glycoprotein, MRP2, and CYP3A4 impairs intestinal absorption of octreotide in rats with portal hypertension.
Liver Cirrhosis
Population Pharmacokinetics of Voriconazole and Optimization of Dosage Regimens Based on Monte Carlo Simulation in Patients With Liver Cirrhosis.
Liver Cirrhosis
Reduced urinary 6beta-hydroxycortisol to cortisol ratios in patients with liver cirrhosis.
Liver Cirrhosis
Risk of Colchicine-Associated Myopathy in Gout: Influence of Concomitant Use of Statin.
Liver Cirrhosis
Study of the Urinary Ratio of 6 beta-Hydroxycortisol/Cortisol as a Biomarker of CYP3A4 Activity in Egyptian Patients with Chronic Liver Diseases.
Liver Cirrhosis
The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes.
Liver Cirrhosis
[Effect of Fuzheng Huayu recipe on CYP450 isozymes in normal and liver fibrosis rats].
Liver Cirrhosis
[Study on CYP1A2, CYP2C9/10 and CYP2C19 activities in rats to create liver cirrhosis by using multi-factor complex].
Liver Cirrhosis, Alcoholic
Abundance of Phase 1 and 2 Drug-Metabolizing Enzymes in Alcoholic and Hepatitis C Cirrhotic Livers: A Quantitative Targeted Proteomics Study.
Liver Cirrhosis, Biliary
Differential alteration of cytochrome P450 isoenzymes in two experimental models of cirrhosis.
Liver Diseases
A Fibroblast Growth Factor 21-Pregnane X Receptor Pathway Downregulates Hepatic CYP3A4 in Nonalcoholic Fatty Liver Disease.
Liver Diseases
Blood concentration of pantoprazole sodium is significantly high in hepatogenic peptic ulcer patients, especially those with a poor CYP2C19 metabolism.
Liver Diseases
Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence.
Liver Diseases
CYP2C19 Polymorphisms and Therapeutic Drug Monitoring of Voriconazole: Are We Ready for Clinical Implementation of Pharmacogenomics?
Liver Diseases
CYP3A activity in severe liver cirrhosis correlates with Child-Pugh and Model for End-Stage Liver Disease (MELD) scores.
Liver Diseases
CYP3A suppression during diet-induced nonalcoholic fatty liver disease is independent of PXR regulation.
Liver Diseases
Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans.
Liver Diseases
Different alterations of cytochrome P450 3A4 isoform and its gene expression in livers of patients with chronic liver diseases.
Liver Diseases
Differential effects of hepatic cirrhosis on the intrinsic clearances of sorafenib and imatinib by CYPs in human liver.
Liver Diseases
Effects of 18alpha-glycyrrhizin on the pharmacodynamics and pharmacokinetics of glibenclamide in alloxan-induced diabetic rats.
Liver Diseases
Establishment of an ex Vivo Model of Nonalcoholic Fatty Liver Disease Using a Tissue-Engineered Liver.
Liver Diseases
Impaired irinotecan biotransformation in hepatic microsomal fractions from patients with chronic liver disease.
Liver Diseases
In vivo metabolic activity of CYP2C19 and CYP3A in relation to CYP2C19 genetic polymorphism in chronic liver disease.
Liver Diseases
Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: hypothesis with implications for personalized medicine.
Liver Diseases
Influence of clinicopathological variables on CYP protein expression in human liver.
Liver Diseases
Longitudinal analysis of the effect of inflammation on voriconazole trough concentrations.
Liver Diseases
Nonalcoholic Fatty Liver Disease and Diabetes Are Associated with Decreased CYP3A4 Protein Expression and Activity in Human Liver.
Liver Diseases
Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment.
Liver Diseases
Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurements.
Liver Diseases
Population Pharmacokinetic/Pharmacodynamic Analyses of Avatrombopag in Patients With Chronic Liver Disease and Optimal Dose Adjustment Guide With Concomitantly Administered CYP3A and CYP2C9 Inhibitors.
Liver Diseases
Prevalence of CYP2C19 Genetic Polymorphism among Normal People and Patients with Hepatic Diseases.
Liver Diseases
Rapid Onset of Iatrogenic Adrenal Insufficiency in a Patient with Cystic Fibrosis-Related Liver Disease Treated with Inhaled Corticosteroids and a Moderate CYP3A4 Inhibitor.
Liver Diseases
Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping: possible effect of age, liver disease and length of therapy.
Liver Diseases
Selective effect of liver disease on the activities of specific metabolizing enzymes: investigation of cytochromes P450 2C19 and 2D6.
Liver Diseases
Serum Alanine Transaminase Total Bilirubin Concentrations Predict CYP3A Activity as Measured by Midazolam and 1'-Hydroxylation.
Liver Diseases
Silybin Restored CYP3A Expression through the Sirtuin 2/Nuclear Factor ?-B Pathway in Mouse Nonalcoholic Fatty Liver Disease.
Liver Diseases
Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease.
Liver Diseases
Study of the Urinary Ratio of 6 beta-Hydroxycortisol/Cortisol as a Biomarker of CYP3A4 Activity in Egyptian Patients with Chronic Liver Diseases.
Liver Diseases
The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics.
Liver Diseases
Urinary 6 beta-hydroxycortisol excretion in Hong Kong Chinese patients with hepatocellular carcinoma and other chronic liver diseases.
Liver Diseases
Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.
Liver Diseases, Alcoholic
Polymorphic Variants of Cytochrome P450: Relevance to Cancer and Other Diseases.
Liver Diseases, Alcoholic
Respective roles of human cytochrome P-4502E1, 1A2, and 3A4 in the hepatic microsomal ethanol oxidizing system.
Liver Failure
Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial).
Liver Failure
Identification and Characterization of a Defective CYP3A4 Genotype in a Kidney Transplant Patient With Severely Diminished Tacrolimus Clearance.
Liver Failure
Methadone-associated long QT syndrome: improving pharmacotherapy for dependence on illegal opioids and lessons learned for pharmacology.
Liver Failure
Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients.
Liver Failure
Tolterodine: a new antimuscarinic agent for the treatment of the overactive bladder.
Liver Failure, Acute
In vitro evaluation of hepatotoxic drugs in human hepatocytes from multiple donors: Identification of P450 activity as a potential risk factor for drug-induced liver injuries.
Liver Neoplasms
Development of an oncogenic dedifferentiation SOX signature with prognostic significance in hepatocellular carcinoma.
Liver Neoplasms
Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients.
Liver Neoplasms
Individuals having variant genotypes of cytochrome P450 2C19 are at increased risk of developing primary liver cancer in Han populations, without infection with the hepatitis virus.
Liver Neoplasms
[Liver Tissue-specific Genes IGFALS,CYP3A4,SLC22A1 and CYP2E1 May be Associated with Poor Prognosis of Liver Cancer].
Long QT Syndrome
Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial).
Long QT Syndrome
Optimizing drug selection in psychopharmacology based on 40 significant CYP2C19- and CYP2D6-biased adverse drug reactions of selective serotonin reuptake inhibitors.
Lung Diseases, Interstitial
Gefitinib: new preparation. Non small-cell lung cancer: stricter assessment needed.
Lung Neoplasms
Association of CYP3A4, CYP3A5 polymorphisms with lung cancer risk in Bangladeshi population.
Lung Neoplasms
CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer.
Lung Neoplasms
CYP3A4 genetic variants are associated with susceptibility of non-small cell lung cancer in a Shaanxi Han population.
Lung Neoplasms
Cytochrome P450 Allele CYP3A7*1C Associates with Adverse Outcomes in Chronic Lymphocytic Leukemia, Breast, and Lung Cancer.
Lung Neoplasms
Drug interaction between erlotinib and phenytoin for brain metastases in a patient with nonsmall cell lung cancer.
Lung Neoplasms
Erlotinib treatment induces cytochrome P450 3A activity in non-small cell lung cancer patients.
Lung Neoplasms
Frequencies of poor metabolizers of cytochrome P450 2C19 in esophagus cancer, stomach cancer, lung cancer and bladder cancer in Chinese population.
Lung Neoplasms
Gefitinib: new preparation. Non small-cell lung cancer: stricter assessment needed.
Lung Neoplasms
Immunohistochemical localization of cytochrome P450 3A in human pulmonary carcinomas and normal bronchial tissue.
Lung Neoplasms
Induction of cytochrome P450 3A4 by docetaxel in peripheral mononuclear cells and its expression in lung cancer.
Lung Neoplasms
Interaction between smoking and CYP2C19*3 polymorphism increased risk of lung cancer in a Chinese population.
Lung Neoplasms
Molecular docking of chemotherapeutic agents to CYP3A4 in non-small cell lung cancer.
Lung Neoplasms
Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer using the CYP3A Inhibitor Cobicistat.
Lung Neoplasms
The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose.
Lung Neoplasms
The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib.
Lung Neoplasms
The Rationale for Repurposing Sildenafil as an Adjuvant to Lung Cancer Treatment.
Lung Neoplasms
Therapeutic effects and adverse drug reactions are affected by icotinib exposure and CYP2C19 and EGFR genotypes in Chinese non-small cell lung cancer patients.
Lung Neoplasms
Transcriptional targets of the chromatin-remodelling factor SMARCA4/BRG1 in lung cancer cells.
Lupus Erythematosus, Systemic
CYP2C19 genotype does not represent a genetic predisposition in idiopathic systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Cytochrome P450 Polymorphism as a Predictor of Ovarian Toxicity to Pulse Cyclophosphamide in Systemic Lupus Erythematosus.
Lupus Erythematosus, Systemic
Cytochrome P450 polymorphism as a predictor of ovarian toxicity to pulse cyclophosphamide in systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Genetic markers in CYP2C19 and CYP2B6 for prediction of cyclophosphamide's 4-hydroxylation, efficacy and side effects in Chinese patients with systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Pharmacogenetics of cyclophosphamide and CYP2C19 polymorphism in Thai systemic lupus erythematosus.
Lupus Erythematosus, Systemic
The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomes.
Lupus Nephritis
Epistatic interactions among CYP2C19*2, CYP3A4 and GSTP1 on the cyclophosphamide therapy in lupus nephritis patients.
Lymphoma
Effect of the Cytochrome P450 2C19 Inhibitor Omeprazole on the Pharmacokinetics and Safety Profile of Bortezomib in Patients with Advanced Solid Tumours, Non-Hodgkin's Lymphoma or Multiple Myeloma.
Lymphoma
Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers.
Lymphoma
Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis.
Lymphoma
Expression of CYP3A4 as a predictor of response to chemotherapy in peripheral T-cell lymphomas.
Lymphoma
Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer using the CYP3A Inhibitor Cobicistat.
Lymphoma
Pharmacogenetic study in Hodgkin's lymphomas reveals the impact of UGT1A1 polymorphisms on patient's prognosis.
Lymphoma, B-Cell
Development of an alternative zebrafish model for drug-induced intestinal toxicity.
Lymphoma, Mantle-Cell
Effect of the Cytochrome P450 2C19 Inhibitor Omeprazole on the Pharmacokinetics and Safety Profile of Bortezomib in Patients with Advanced Solid Tumours, Non-Hodgkin's Lymphoma or Multiple Myeloma.
Lymphoma, Non-Hodgkin
Cytochrome P450 Genetic Variations Can Predict mRNA Expression, Cyclophosphamide 4-Hydroxylation, and Treatment Outcomes in Chinese Patients With Non-Hodgkin's Lymphoma.
Lymphoma, Non-Hodgkin
Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma.
Lymphoma, Non-Hodgkin
[Activity and induction of CYP2B, CYP2C, and CYP3A in tissues of cyclophosphane-sensitive and resistant neoplasms and the liver of neoplasm-carrying mice]
Lymphoma, T-Cell
Expression of CYP3A4 as a predictor of response to chemotherapy in peripheral T-cell lymphomas.
Lymphoma, T-Cell, Peripheral
Expression of CYP3A4 as a predictor of response to chemotherapy in peripheral T-cell lymphomas.
Lymphopenia
Association Study Among Candidate Genetic Polymorphisms and Chemotherapy-Related Severe Toxicity in Testicular Cancer Patients.
Macular Degeneration
Associations between Rs4244285 and Rs762551 gene polymorphisms and age-related macular degeneration.
Malabsorption Syndromes
Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial).
Malaria
Analysis of Sepik populations of Papua New Guinea suggests an increase of CYP2C19 null allele frequencies during the colonization of Melanesia.
Malaria
CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients.
Malaria
Cytochrome P450 CYP2C19 genotypes in Nigerian sickle-cell disease patients and normal controls.
Malaria
Development of a paediatric physiologically based pharmacokinetic model to assess the impact of drug-drug interactions in tuberculosis co-infected malaria subjects: A case study with artemether-lumefantrine and the CYP3A4-inducer rifampicin.
Malaria
Effect of fluconazole on the pharmacokinetics of halofantrine in healthy volunteers.
Malaria
Effects of genetic variation at the CYP2C19/CYP2C9 locus on pharmacokinetics of chlorcycloguanil in adult Gambians.
Malaria
Influence of a Nigerian honey on CYP3A4 biotransformation of quinine in healthy volunteers.
Malaria
Inhibitory Activities of Thai Medicinal Plants with Promising Activities Against Malaria and Cholangiocarcinoma on Human Cytochrome P450.
Malaria
Metabolism of Diazepam and Ethosuximide in rats with malaria and endotoxin-induced fever.
Malaria
Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects.
Malaria
Physiologically-Based Pharmacokinetic Modeling for Optimal Dosage Prediction of Quinine Coadministered With Ritonavir-Boosted Lopinavir.
Malaria
Proguanil disposition and toxicity in malaria patients from Vanuatu with high frequencies of CYP2C19 mutations.
Malaria
Role of specific cytochrome P450 isoforms in the conversion of phenoxypropoxybiguanide analogs in human liver microsomes to potent antimalarial dihydrotriazines.
Malaria, Falciparum
Analysis of Sepik populations of Papua New Guinea suggests an increase of CYP2C19 null allele frequencies during the colonization of Melanesia.
Malaria, Vivax
Impact of Plasmodium vivax malaria and antimalarial treatment on cytochrome P450 activity in Brazilian patients.
Malnutrition
Effect of protein and calorie malnutrition on drug metabolism in rat - in vitro.
medium-chain acyl-coa dehydrogenase deficiency
Detection of single nucleotide substitution by competitive allele-specific short oligonucleotide hybridization (CASSOH) with immunochromatographic strip.
Medulloblastoma
Hypoxia increases chemoresistance in human medulloblastoma DAOY cells via hypoxia?inducible factor 1??mediated downregulation of the CYP2B6, CYP3A4 and CYP3A5 enzymes and inhibition of cell proliferation.
Melanoma
Antiproliferative Activity of Non-Calcemic Vitamin D Analogs on Human Melanoma Lines in Relation to VDR and PDIA3 Receptors.
Melanoma
Effects of pharmacogenetic variants on vemurafenib-related toxicities in patients with melanoma.
Melanoma
Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study.
Melanoma
Microarray Analysis of Differentially-Expressed Genes Encoding CYP450 and Phase II Drug Metabolizing Enzymes in Psoriasis and Melanoma.
Melanosis
Histopathology of melanosis coli and determination of its associated genes by comparative analysis of expression microarrays.
Metabolic Syndrome
Age-dependent features of CYP3A, CYP2C, and CYP2E1 functioning at metabolic syndrome.
Metabolic Syndrome
Decreased CYP3a Expression and Activity in Guinea Pig Models of Diet-Induced Metabolic Syndrome: Is Fatty Liver Infiltration Involved?
Metabolic Syndrome
Genetic risk for metabolic syndrome: examination of candidate gene polymorphisms related to lipid metabolism in Japanese people.
Metabolic Syndrome
Genetic variation at the CYP2C19 gene associated with metabolic syndrome susceptibility in a South Portuguese population: results from the pilot study of the European Health Examination Survey in Portugal.
Metabolic Syndrome
Specific Inhibition of the Distribution of Lobeglitazone to the Liver by Atorvastatin in Rats: Evidence for a Rat Organic Anion Transporting Polypeptide 1B2-Mediated Interaction in Hepatic Transport.
Metrorrhagia
Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug.
Microvascular Angina
Association of CYP2C19 variants and epoxyeicosatrienoic acids on patients with microvascular angina.
Microvascular Angina
CYP2C19 variants and epoxyeicosatrienoic acids in patients with microvascular angina.
Migraine Disorders
Association of MDR1, CYP2D6, and CYP2C19 gene polymorphisms with prophylactic migraine treatment response.
Migraine Disorders
Lack of drug interaction between the migraine drug MAP0004 (orally inhaled dihydroergotamine) and a CYP3A4 inhibitor in humans.
Migraine Disorders
The pharmacokinetics of sumatriptan when administered with clarithromycin in healthy volunteers.
Miosis
A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans.
Miosis
Alfentanil-induced miosis clearance as a liver CYP3A4 and 3A5 activity measure in healthy volunteers: improvement of experimental conditions.
Miosis
Concurrent Assessment of Hepatic and Intestinal Cytochrome P450 3A Activities Using Deuterated Alfentanil.
Miosis
Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
Miosis
Mechanism of Ritonavir Changes in Methadone Pharmacokinetics and Pharmacodynamics: II. Ritonavir Effects on CYP3A and P-Glycoprotein Activities.
Miosis
Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities.
Miosis
Paradoxical role of cytochrome P450 3A in the bioactivation and clinical effects of levo-alpha-acetylmethadol: importance of clinical investigations to validate in vitro drug metabolism studies.
Miosis
Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimal and noninvasive probes for hepatic and first-pass CYP3A induction.
Miosis
Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity.
Movement Disorders
Sustained Impairment of Lurasidone Clearance After Discontinuation of Posaconazole: Impact of Obesity, and Implications for Patient Safety.
Multiple Myeloma
Bortezomib: new indication. Second-line treatment of myeloma: limited efficacy, major risks.
Multiple Myeloma
CYP2C19 genotype-phenotype discordance in patients with multiple myeloma leads to an acquired loss of drug-metabolising activity.
Multiple Myeloma
Effect of CYP2C19 and CYP3A4 gene polymorphisms on the efficacy of bortezomib-based regimens in patients with multiple myeloma.
Multiple Myeloma
Effect of the Cytochrome P450 2C19 Inhibitor Omeprazole on the Pharmacokinetics and Safety Profile of Bortezomib in Patients with Advanced Solid Tumours, Non-Hodgkin's Lymphoma or Multiple Myeloma.
Multiple Myeloma
Human bone marrow niche chemoprotection mediated by cytochrome P450 enzymes.
Multiple Myeloma
Influence of genetic polymorphisms in CYP3A4, CYP3A5, GSTP1, GSTM1, GSTT1 and MDR1 genes on survival and therapy-related toxicity in multiple myeloma.
Multiple Myeloma
No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma.
Multiple Myeloma
Polymorphisms of CYP2C19 gene are associated with the efficacy of thalidomide based regimens in multiple myeloma.
Multiple Myeloma
[Antiangiogenic Activity of Thalidomide In Vitro Mediated by Cytochrome CYP2C19.]
Multiple Myeloma
[Effect of CYP2C19 gene polymorphism on efficacy of thalidomide-based regimens for the treatment of multiple myeloma]
Multiple Sclerosis
Interferon-beta treatment in patients with multiple sclerosis does not alter CYP2C19 or CYP2D6 activity.
Multiple Sclerosis
Therapeutic protein-drug interaction assessment for daclizumab high-yield process in patients with multiple sclerosis using a cocktail approach.
Muscular Diseases
A case of simvastatin-induced myopathy with SLCO1B1 genetic predisposition and co-ingestion of linagliptin and Stevia rebaudiana.
Muscular Diseases
Acute myopathy in a patient with concomitant use of pravastatin and colchicine.
Muscular Diseases
Clinical implications of pharmacogenetic variation on the effects of statins.
Muscular Diseases
Colchicine-induced acute myopathy in a patient with concomitant use of simvastatin.
Muscular Diseases
Effect of thyroid hormone status and concomitant medication on statin induced adverse effects in hyperlipidemic patients.
Muscular Diseases
Ranolazine-induced Elevation of Creatinine Kinase in the Absence of Statin Usage.
Muscular Diseases
Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage.
Muscular Diseases
Rhabdomyolysis in association with simvastatin and dosage increment in clarithromycin.
Muscular Diseases
Risk of Colchicine-Associated Myopathy in Gout: Influence of Concomitant Use of Statin.
Muscular Diseases
Simvastatin-induced myopathy, the role of interaction with diltiazem and genetic predisposition.
Muscular Diseases
Statins and skeletal muscles toxicity: from clinical trials to everyday practice.
Muscular Diseases
The influence of high-dose simvastatin and diltiazem on myocardium in rabbits: a haemodynamic study.
Muscular Diseases
The influence of simvastatin at high dose and diltiazem on myocardium in rabbits, the biochemical study.
Muscular Diseases
Treatment of the elderly with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors: focus on drug interactions.
Mycoses
Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes.
Mycoses
Pharmacokinetics of Cyclosporine a Conversion from Twice-Daily Infusion to Oral Administration in Allogeneic Hematopoietic Stem Cell Transplantation.
Mycoses
Prospective CYP2C19-Guided Voriconazole Prophylaxis in Neutropenic AML Patients Reduces the Incidence of Subtherapeutic Antifungal Plasma Concentrations.
Myelodysplastic Syndromes
Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/ myelodysplastic syndrome and de novo acute myeloid leukemia.
Myocardial Infarction
A pharmacoepidemiology study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention.
Myocardial Infarction
Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel.
Myocardial Infarction
Association of CYP2C19 Genotype With Periprocedural Myocardial Infarction After Uneventful Stent Implantation in Chinese Patients Receiving Clopidogrel Pretreatment.
Myocardial Infarction
Association of CYP2C19 Loss-of-Function Alleles with Major Adverse Cardiovascular Events of Clopidogrel in Stable Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention: Meta-analysis.
Myocardial Infarction
Association with CYP2C19 polymorphisms and Clopidogrel in treatment of elderly stroke patients.
Myocardial Infarction
Bedside testing of CYP2C19 vs. conventional clopidogrel treatment to guide antiplatelet therapy in ST-segment elevation myocardial infarction patients.
Myocardial Infarction
Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study.
Myocardial Infarction
Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction.
Myocardial Infarction
Clopidogrel preventive effect based on cytochrome P450 2C19 genotype in ischaemic stroke: protocol for multicentre observational study.
Myocardial Infarction
Cost Effectiveness of a CYP2C19 Genotype-Guided Strategy in Patients with Acute Myocardial Infarction: Results from the POPular Genetics Trial.
Myocardial Infarction
Cost-Effectiveness and Cost-Utility Analysis of the Use of Clopidogrel and Pantoprazole in Comparison with Clopidogrel and Omeprazole for the Secondary Prevention of Myocardial Infarction in Iran.
Myocardial Infarction
Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary intervention.
Myocardial Infarction
CYP2C19 and CYP3A4 Activity and ADP-induced Platelet Reactivity in Prasugrel- or Ticagrelor-treated STEMI Patients: Monocentric Study in PRAGUE-18 Trial Participants.
Myocardial Infarction
CYP2C19 genotype is an independent predictor of Adverse Cardiovascular Outcome in Iraqi Patients on Clopidogrel Post Percutaneous Coronary Intervention.
Myocardial Infarction
CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study.
Myocardial Infarction
CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis.
Myocardial Infarction
CYP2C19 phenotype, stent thrombosis, myocardial infarction, and mortality in patients with coronary stent placement in a Chinese population.
Myocardial Infarction
CYP2C19 Poor Metabolizer Is Associated with Clinical Outcome of Clopidogrel Therapy in Acute Myocardial Infarction but Not Stable Angina.
Myocardial Infarction
Cytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome.
Myocardial Infarction
Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin.
Myocardial Infarction
Effect of CYP2C19*2 and *3 on clinical outcome in ischemic stroke patients treated with clopidogrel.
Myocardial Infarction
Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial.
Myocardial Infarction
Effect of paraoxonase-1 polymorphism on clinical outcomes in patients treated with clopidogrel after an acute myocardial infarction.
Myocardial Infarction
Financial Analysis of CYP2C19 Genotyping in Patients Receiving Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention.
Myocardial Infarction
Genetic determinants of response to clopidogrel and cardiovascular events.
Myocardial Infarction
Genetic testing for CYP450 polymorphisms to predict response to clopidogrel: current evidence and test availability. Application: pharmacogenomics.
Myocardial Infarction
Implementation of a pharmacogenetic management service for postmyocardial infarction care in a community pharmacy.
Myocardial Infarction
Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study.
Myocardial Infarction
Ischemic stroke and myocardial ischemia in clopidogrel users and the association with CYP2C19 loss-of-function homozygocity: a real-world study.
Myocardial Infarction
Meta-Analysis of Cytochrome P450 2C19 Polymorphism and Risk of Adverse Clinical Outcomes Among Coronary Artery Disease Patients of Different Ethnic Groups Treated With Clopidogrel.
Myocardial Infarction
Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data.
Myocardial Infarction
Predicting clopidogrel response using DNA samples linked to an electronic health record.
Myocardial Infarction
Reduced number of cardiovascular events and increased cost-effectiveness by genotype-guided antiplatelet therapy in patients undergoing percutaneous coronary interventions in the Netherlands.
Myocardial Infarction
Risks of Adverse Events Following Coprescription of Statins and Calcium Channel Blockers: A Nationwide Population-Based Study.
Myocardial Infarction
Routine CYP2C19 Genotyping to Adjust Thienopyridine Treatment After Primary PCI for STEMI: Results of the GIANT Study.
Myocardial Infarction
Study design and rationale for Optimal aNtiplatelet pharmacotherapy guided by bedSIDE genetic or functional TESTing in elective percutaneous coronary intervention patients (ONSIDE TEST): a prospective, open-label, randomised parallel-group multicentre tri.
Myocardial Infarction
Tailored Adjunctive Cilostazol Therapy Based on CYP2C19 Genotyping in Patients With Acute Myocardial Infarction?- The CALDERA-GENE Study.
Myocardial Infarction
The efficacy and safety of CYP2C19 genotype-guided antiplatelet therapy compared with conventional antiplatelet therapy in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials.
Myocardial Infarction
The Impact of CYP2C19 Loss-of-Function Polymorphisms, Clinical, and Demographic Variables on Platelet Response to Clopidogrel Evaluated Using Impedance Aggregometry.
Myocardial Infarction
Variant recurrent risk among stroke patients with different CYP2C19 phenotypes and treated with clopidogrel.
Myocardial Infarction
[Association of CYP2C19 and CYP3A5 gene polymorphisms with myocardial infarction].
Myocardial Infarction
[CYP2C19 gene polymorphism in patients with myocardial infarction who use clopidogrel].
Myocardial Infarction
[Impact of CYP2C19 genotypes on antiplatelet therapy among Chinese patients with acute myocardial infarction after percutaneous coronary intervention].
Myocardial Ischemia
Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population.
Myocardial Ischemia
Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection.
Myocardial Ischemia
Ischemic stroke and myocardial ischemia in clopidogrel users and the association with CYP2C19 loss-of-function homozygocity: a real-world study.
Myocardial Ischemia
The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease.
Myocardial Ischemia
Tolerability and safety of eletriptan in the treatment of migraine: a comprehensive review.
Myoclonus
Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors.
Myotoxicity
Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.
Myotoxicity
Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.
Nasopharyngeal Carcinoma
The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients.
Nasopharyngeal Neoplasms
Polymorphic Variants of Cytochrome P450: Relevance to Cancer and Other Diseases.
Neoplasm Metastasis
Association of CYP2C19*2 and ALDH1A1*1/*2 variants with disease outcome in breast cancer patients: results of a global screening array.
Neoplasm Metastasis
CYP genes in osteosarcoma: Their role in tumorigenesis, pulmonary metastatic microenvironment and treatment response.
Neoplasm Metastasis
CYP3A isoforms in Ewing's sarcoma tumours: an immunohistochemical study with clinical correlation.
Neoplasm Metastasis
CYP3A4 expression to predict treatment response to docetaxel for metastasis and recurrence of primary breast cancer.
Neoplasm Metastasis
Differential expression of drug metabolizing enzymes in primary and secondary liver neoplasm: immunohistochemical characterization of cytochrome P4503A and glutathione-S-transferase.
Neoplasm Metastasis
Factors affecting high-grade hepatotoxicity of tyrosine kinase inhibitors in cancer patients: a multi-center observational study.
Neoplasm Metastasis
Genetic polymorphisms and response to 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients.
Neoplasm Metastasis
N,N-diethyl-2-[4-(phenylmethyl) phenoxy] ethanamine (DPPE; tesmilifene), a chemopotentiating agent with hormetic effects on DNA synthesis in vitro, may improve survival in patients with metastatic breast cancer.
Neoplasm Metastasis
Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer.
Neoplasm Metastasis
Population pharmacokinetics meta-analysis of plitidepsin (Aplidin((R))) in cancer subjects.
Neoplasm Metastasis
Relationship between CYP3A activity and breast cancer susceptibility in Chinese Han women.
Neoplasm Metastasis
Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study.
Neoplasm Metastasis
Therapeutic effects and adverse drug reactions are affected by icotinib exposure and CYP2C19 and EGFR genotypes in Chinese non-small cell lung cancer patients.
Neoplasms
4?-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes.
Neoplasms
A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871.
Neoplasms
A drug-drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies.
Neoplasms
A genetic polymorphism of CYP2C19 is associated with susceptibility to biliary tract cancer.
Neoplasms
A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111).
Neoplasms
A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer.
Neoplasms
A Physiologically-Based Pharmacokinetic Modeling Approach To Predict Drug-Drug Interactions of Sonidegib (LDE225) with Perpetrators of CYP3A in Cancer Patients.
Neoplasms
A Review of CYP3A Drug-Drug Interaction Studies: Practical Guidelines for Patients Using Targeted Oral Anticancer Drugs.
Neoplasms
A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes.
Neoplasms
Abemaciclib Does Not Have a Clinically Meaningful Effect on Pharmacokinetics of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 Substrates in Patients with Cancer.
Neoplasms
Altered cytochrome 2E1 and 3A P450-dependent drug metabolism in advanced ovarian cancer correlates to tumour-associated inflammation.
Neoplasms
An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified cooperstown 5+1 cocktail in patients with advanced solid tumors.
Neoplasms
An Open-Label Phase 1 Study to Determine the Effect of Lenvatinib on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, in Patients with Advanced Solid Tumors.
Neoplasms
Analysis of CYP450 gene allelic variants can predict ifosfamide toxicity in Mexican paediatric patients.
Neoplasms
Androgen Metabolism Gene Polymorphisms, Associations with Prostate Cancer Risk and Pathological Characteristics: A Comparative Analysis between South African and Senegalese Men.
Neoplasms
Antitumor activity of methoxymorpholinyl doxorubicin: potentiation by cytochrome P450 3A metabolism.
Neoplasms
Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach.
Neoplasms
Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib.
Neoplasms
Assessment of the involvement of CYP3A in the vitro metabolism of a new modulator of MDR in cancer chemotherapy, OC144-193, by human liver microsomes.
Neoplasms
Association between cytochrome CYP17A1, CYP3A4, and CYP3A43 polymorphisms and prostate cancer risk and aggressiveness in a Korean study population.
Neoplasms
Association between the CYP3A4 and CYP3A5 polymorphisms and cancer risk: a meta-analysis and meta-regression.
Neoplasms
Association of CYP3A4 genotype with detection of Vgamma/Jbeta trans-rearrangements in the peripheral blood leukocytes of pediatric cancer patients undergoing chemotherapy for ALL.
Neoplasms
Association of CYP3A4/5 genotypes and expression with the survival of patients with neuroblastoma.
Neoplasms
Association of Genetic Variants of CYP2C19 and CYP2D6 with Esophageal Squamous Cell Carcinoma Risk in Northern India, Kashmir.
Neoplasms
Associations between smoking, polymorphisms in polycyclic aromatic hydrocarbon (PAH) metabolism and conjugation genes and PAH-DNA adducts in prostate tumors differ by race.
Neoplasms
Camptothecin attenuates cytochrome P450 3A4 induction by blocking the activation of human pregnane X receptor.
Neoplasms
Cancer cachexia raises the plasma concentration of oxymorphone through the reduction of CYP3A but not CYP2D6 in oxycodone-treated patients.
Neoplasms
Clobetasol Propionate Is a Heme-Mediated Selective Inhibitor of Human Cytochrome P450 3A5.
Neoplasms
Correlation of PPM1A Downregulation with CYP3A4 Repression in the Tumor Liver Tissue of Hepatocellular Carcinoma Patients.
Neoplasms
Cyclamen Trochopteranthum: Cytotoxic activity and possible adverse interactions including drugs and carcinogens.
Neoplasms
CYP genes in osteosarcoma: Their role in tumorigenesis, pulmonary metastatic microenvironment and treatment response.
Neoplasms
CYP2C19 genotype-phenotype discordance in patients with multiple myeloma leads to an acquired loss of drug-metabolising activity.
Neoplasms
CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotype.
Neoplasms
CYP3A induction by N-hydroxyformamide tumor necrosis factor-alpha converting enzyme/matrix metalloproteinase inhibitors use of a pregname X receptor activation assay and primary hepatocyte culture for assessing induction potential in humans.
Neoplasms
CYP3A isoforms in Ewing's sarcoma tumours: an immunohistochemical study with clinical correlation.
Neoplasms
CYP3A4 expression to predict treatment response to docetaxel for metastasis and recurrence of primary breast cancer.
Neoplasms
CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin.
Neoplasms
CYP3A4 ubiquitination by gp78 (the tumor autocrine motility factor receptor, AMFR) and CHIP E3 ligases.
Neoplasms
CYP3A4, CYP2C9 and CYP2B6 expression and ifosfamide turnover in breast cancer tissue microsomes.
Neoplasms
CYP3A4-dependent cellular response does not relate to CYP3A4-catalysed metabolites of C-1748 and C-1305 acridine antitumor agents in HepG2 cells.
Neoplasms
CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy.
Neoplasms
CYP3A5*3 and bilirubin predict midazolam population pharmacokinetics in Asian cancer patients.
Neoplasms
Cytochrome P450 2C19 gene polymorphisms (CYP2C19*2 and CYP2C19*3) in chronic myeloid leukemia patients: in vitro and in silico studies.
Neoplasms
Cytochrome P450 Allele CYP3A7*1C Associates with Adverse Outcomes in Chronic Lymphocytic Leukemia, Breast, and Lung Cancer.
Neoplasms
Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture.
Neoplasms
Decreased expression of cytochrome P450 protein in non-malignant colonic tissue of patients with colonic adenoma.
Neoplasms
Deregulating the CYP2C19/Epoxy-Eicosatrienoic Acid-Associated FABP4/FABP5 Signaling Network as a Therapeutic Approach for Metastatic Triple-Negative Breast Cancer.
Neoplasms
Development of a novel, fully-automated genotyping system: principle and applications.
Neoplasms
Development of a real-time in vivo transcription assay: application reveals pregnane X receptor-mediated induction of CYP3A4 by cancer chemotherapeutic agents.
Neoplasms
Development of a Tumour Growth Inhibition Model to Elucidate the Effects of Ritonavir on Intratumoural Metabolism and Anti-tumour Effect of Docetaxel in a Mouse Model for Hereditary Breast Cancer.
Neoplasms
Development of an alternative zebrafish model for drug-induced intestinal toxicity.
Neoplasms
Differences in cytochrome P450 2C19 (CYP2C19) expression in adjacent normal and tumor tissues in Chinese cancer patients.
Neoplasms
Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes.
Neoplasms
Differential effects of cytokines on the inducible expression of CYP1A1, CYP1A2, and CYP3A4 in human hepatocytes in primary culture.
Neoplasms
Differential effects of hepatic cirrhosis on the intrinsic clearances of sorafenib and imatinib by CYPs in human liver.
Neoplasms
Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus.
Neoplasms
Differential expression of cytochrome p450 enzymes in normal and tumor tissues from childhood rhabdomyosarcoma.
Neoplasms
Discovery and optimization of a highly efficacious class of 5-aryl-2-aminopyridines as FMS-like tyrosine kinase 3 (FLT3) inhibitors.
Neoplasms
Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms.
Neoplasms
Disrupted hepatic pentose phosphate pathway directly participates in and indirectly promotes CYP3A reduction: A new strategy for CYP3A-mediated drug hepatotoxicity.
Neoplasms
Down-regulation of pregnane X receptor contributes to cell growth inhibition and apoptosis by anticancer agents in endometrial cancer cells.
Neoplasms
Downregulation of CYP2A6 and CYP2C8 in Tumor Tissues Is Linked to Worse Overall Survival and Recurrence-Free Survival from Hepatocellular Carcinoma.
Neoplasms
Drug interaction between sunitinib and cimetidine and contribution of the efflux transporter ATP-binding cassette C2 to biliary excretion of sunitinib in rats.
Neoplasms
Drug-drug interactions with aprepitant in antiemetic prophylaxis for chemotherapy.
Neoplasms
Effect of Botanical Immunomodulators on Human CYP3A4 Inhibition: Implications for Concurrent Use as Adjuvants in Cancer Therapy.
Neoplasms
Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug-drug interaction study in patients with ALK?+?advanced tumors.
Neoplasms
Effect of Co-administration of Ketoconazole, a Strong CYP3A Inhibitor, on the Pharmacokinetics, Safety and Tolerability of Navitoclax, a First-in-class Oral Bcl-2 Family Inhibitor, in Cancer Patients.
Neoplasms
Effect of coadministration of ketoconazole, a strong CYP3A4 inhibitor, on pharmacokinetics and tolerability of motesanib diphosphate (AMG 706) in patients with advanced solid tumors.
Neoplasms
Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients.
Neoplasms
Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse.
Neoplasms
Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours.
Neoplasms
Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer.
Neoplasms
Effect of genetic polymorphisms in CYP3A4, CYP3A5, and m-TOR on everolimus blood exposure and clinical outcomes in cancer patients.
Neoplasms
Effect of Itraconazole, a Potent CYP3A4 Inhibitor, on the Steady-State Pharmacokinetics of Vemurafenib in Patients With BRAFV600 Mutation-Positive Malignancies.
Neoplasms
Effect of Rifampicin on the Pharmacokinetics of a Single Dose of Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy.
Neoplasms
Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study.
Neoplasms
Effectiveness of human cytochrome P450 3A4 present in liposomal and microsomal nanoparticles in formation of covalent DNA adducts by ellipticine.
Neoplasms
Effects of cytokines on CYP3A4 expression and reversal of the effects by anti-cytokine agents in the three-dimensionally cultured human hepatoma cell line FLC-4.
Neoplasms
Effects of Oral Anorexiant Sibutramine on the Expression of Cytochromes P450s in Human Hepatocytes and Cancer Cell Lines.
Neoplasms
Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors.
Neoplasms
Effects of ready to drink teas on AhR- and PXR-mediated expression of cytochromes P450 CYP1A1 and CYP3A4 in human cancer cell lines and primary human hepatocytes
Neoplasms
Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies.
Neoplasms
Effects of Sorafenib Dose on Acquired Reversible Resistance and Toxicity in Hepatocellular Carcinoma.
Neoplasms
Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis.
Neoplasms
Enantioselective metabolism and cytotoxicity of R-Ifosfamide and S-Ifosfamide by tumor cell-expressed cytochromes P450.
Neoplasms
Evaluation of CYP3A-mediated drug-drug interactions with romidepsin in patients with advanced cancer.
Neoplasms
Evaluation of Drug-Drug Interactions of Rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp Substrates in Patients With an Advanced Solid Tumor.
Neoplasms
Evaluation of the likelihood of a selective CHK1 inhibitor (LY2603618) to inhibit CYP2D6 with desipramine as a probe substrate in cancer patients.
Neoplasms
Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours.
Neoplasms
Everolimus-induced nephrotic syndrome precipitated by interaction with voriconazole in a patient with Hodgkin's lymphoma.
Neoplasms
Expression of CYP3A4 as a predictor of response to chemotherapy in peripheral T-cell lymphomas.
Neoplasms
Expression of cytochrome P 450 3A enzymes in human lung: a combined RT-PCR and immunohistochemical analysis of normal tissue and lung tumours.
Neoplasms
Expression of cytochrome P450 1A1/2 and 3A4 in liver tissues of hepatocellular carcinoma cases and controls from Taiwan and their relationship to hepatitis B virus and aflatoxin B1-and 4-aminobiphenyl-DNA adducts.
Neoplasms
Expression of cytochrome P450 3A4 and its clinical significance in human prostate cancer.
Neoplasms
Expression of cytochromes P450 3A and P-glycoprotein in human large intestine in paired tumour and normal samples.
Neoplasms
Expression of xenobiotic and steroid hormone metabolizing enzymes in hepatocellular tumors of the non-cirrhotic liver.
Neoplasms
Factors associated with healing of artificial ulcer after endoscopic submucosal dissection with reference to Helicobacter pylori infection, CYP2C19 genotype, and tumor location: Multicenter randomized trial.
Neoplasms
Factors involved in phenoconversion of CYP3A using 4?-hydroxycholesterol in stable kidney transplant recipients.
Neoplasms
Formation of a novel topotecan metabolite in the hormone-independent human prostate carcinoma cell lines DU-145 and PC-3.
Neoplasms
Frequencies of poor metabolizers of cytochrome P450 2C19 in esophagus cancer, stomach cancer, lung cancer and bladder cancer in Chinese population.
Neoplasms
Functional polymorphisms in the CYP2C19 gene contribute to digestive system cancer risk: evidence from 11,042 subjects.
Neoplasms
Genetic Polymorphism of CYP2C19 gene in the Stanislas cohort. A link with inflammation.
Neoplasms
Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies.
Neoplasms
Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions.
Neoplasms
Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients.
Neoplasms
Global analysis of gene expression signature and diagnostic/prognostic biomarker identification of hepatocellular carcinoma.
Neoplasms
Heme Binding Biguanides Target Cytochrome P450-Dependent Cancer Cell Mitochondria.
Neoplasms
Human hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation.
Neoplasms
Identification of a less toxic vinca alkaloid derivative for use as a chemotherapeutic agent, based on in silico structural insights and metabolic interactions with CYP3A4 and CYP3A5.
Neoplasms
Identification of DEGs and transcription factors involved in H. pylori-associated inflammation and their relevance with gastric cancer.
Neoplasms
Immunohistochemical localization of cytochrome P450 3A in human pulmonary carcinomas and normal bronchial tissue.
Neoplasms
Immunolocalisation of cytochrome P-450 3A enzymes in human breast carcinoma: relationship with tumour differentiation and steroid receptors.
Neoplasms
Impact of a genetic variant in CYP3A4 on risk and clinical presentation of prostate cancer among white and African-American men.
Neoplasms
Impact of CYP2C19 genotype on voriconazole exposure and effect of voriconazole on the activity of CYP3A in patients with haematological malignancies.
Neoplasms
Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients.
Neoplasms
In silico and in vitro screening for inhibition of cytochrome P450 CYP3A4 by comedications commonly used by patients with cancer.
Neoplasms
In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity at CYP-450.
Neoplasms
In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2).
Neoplasms
In Vitro Approaches to Study Regulation of Hepatic Cytochrome P450 (CYP) 3A Expression by Paclitaxel and Rifampicin.
Neoplasms
In vitro inhibition of CYP3A4 by herbal remedies frequently used by cancer patients.
Neoplasms
In vitro inhibitory effects of ganoderic acid A on human liver cytochrome P450 enzymes.
Neoplasms
Individuals having variant genotypes of cytochrome P450 2C19 are at increased risk of developing primary liver cancer in Han populations, without infection with the hepatitis virus.
Neoplasms
Induction of CYP3A4 by 1 alpha,25-dihydroxyvitamin D3 is human cell line-specific and is unlikely to involve pregnane X receptor.
Neoplasms
Inflammation and altered drug clearance in cancer: transcriptional repression of a human CYP3A4 transgene in tumor-bearing mice.
Neoplasms
Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing.
Neoplasms
Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: hypothesis with implications for personalized medicine.
Neoplasms
Influence of aprepitant and localization of the patch on fentanyl exposure in patients with cancer using transdermal fentanyl.
Neoplasms
Inoculation of human tumor cells alters the basal expression but not the inducibility of Cyp enzymes in tumor-bearing mouse liver.
Neoplasms
Interaction of N-(2-Hydroxypropyl)methacrylamide Copolymer-Doxorubicin Conjugates with Human Liver Microsomal Cytochromes P450: Comparison with Free Doxorubicin.
Neoplasms
Joint effects of inflammation and androgen metabolism on prostate cancer severity.
Neoplasms
Lipid Drug Carriers for Cancer Therapeutics: An Insight into Lymphatic Targeting, P-gp, CYP3A4 Modulation and Bioavailability Enhancement.
Neoplasms
MDR1 not CYP3A4 gene expression is the predominant mechanism of innate drug resistance in pediatric soft tissue sarcoma patients.
Neoplasms
Methylation of the Constitutive Androstane Receptor Is Involved in the Suppression of CYP2C19 in Hepatitis B Virus-Associated Hepatocellular Carcinoma.
Neoplasms
MGMT- and P450 3A-inhibitors do not sensitize glioblastoma cell cultures against nitrosoureas.
Neoplasms
Microarray Analysis of Differentially-Expressed Genes Encoding CYP450 and Phase II Drug Metabolizing Enzymes in Psoriasis and Melanoma.
Neoplasms
Milk thistle's active components silybin and isosilybin: novel inhibitors of PXR-mediated CYP3A4 induction.
Neoplasms
Minor contribution of cytochrome P450 3A activity on fentanyl exposure in palliative care cancer patients.
Neoplasms
Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.
Neoplasms
Modulation of CYP3A4 expression by ceramide in human colon carcinoma HT-29 cells.
Neoplasms
Modulation of multidrug resistance in cancer cells by chelidonine and Chelidonium majus alkaloids.
Neoplasms
Molecular docking of chemotherapeutic agents to CYP3A4 in non-small cell lung cancer.
Neoplasms
More about: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.
Neoplasms
N,N-diethyl-2-[4-(phenylmethyl) phenoxy] ethanamine (DPPE; tesmilifene), a chemopotentiating agent with hormetic effects on DNA synthesis in vitro, may improve survival in patients with metastatic breast cancer.
Neoplasms
N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine (DPPE) a chemopotentiating and cytoprotective agent in clinical trials: interaction with histamine at cytochrome P450 3A4 and other isozymes that metabolize antineoplastic drugs.
Neoplasms
Non-uniformity of Changes in Drug-Metabolizing Enzymes and Transporters in Liver Cirrhosis: Implications for Drug Dosage Adjustment.
Neoplasms
Novel Tetrazole-containing Analogs of Itraconazole as Potent Anti-angiogenic Agents with Reduced CYP3A4 Inhibition.
Neoplasms
Omeprazole and lansoprazole enantiomers induce CYP3A4 in human hepatocytes and cell lines via glucocorticoid receptor and pregnane X receptor axis.
Neoplasms
Optimization of Individual Pharmacotherapy Based on Multiple Evaluations of Patient Data.
Neoplasms
Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel.
Neoplasms
Overcoming vincristine resistance in cancer: Computational design and discovery of piperine-inspired P-glycoprotein inhibitors.
Neoplasms
Overexpression of CYP3A4, but not CYP2D6, promotes hypoxic response and cell growth of Hep3B cells.
Neoplasms
P450 induction alters paclitaxel pharmacokinetics and tissue distribution with multiple dosing.
Neoplasms
Pathway-dependent inhibition of paclitaxel hydroxylation by kinase inhibitors and assessment of drug-drug interaction potentials.
Neoplasms
PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction.
Neoplasms
Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK.
Neoplasms
Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome p450-inducing medications.
Neoplasms
Pharmacokinetics of eribulin mesylate in patients with solid tumors receiving repeated oral rifampicin.
Neoplasms
Pharmacokinetics of Lapatinib, a Nonrenally Cleared Drug, in Patients With End-Stage Renal Disease on Maintenance Hemodialysis.
Neoplasms
Pharmacokinetics of sunitinib in combination with fluoroquinolones in rabbit model.
Neoplasms
Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours.
Neoplasms
Phase I study of tivantinib in Japanese patients with advanced hepatocellular carcinoma; distinctive PK profiles from other solid tumors.
Neoplasms
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.
Neoplasms
Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies.
Neoplasms
Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity.
Neoplasms
Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer.
Neoplasms
Poor Metabolizers at the Cytochrome P450 2C19 Loci Is at Increased Risk of Developing Cancer in Asian Populations.
Neoplasms
Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors.
Neoplasms
Population pharmacokinetics and pharmacogenetics of vincristine in paediatric patients treated for solid tumour diseases.
Neoplasms
Population pharmacokinetics modeling and analysis of foretinib in adult patients with advanced solid tumors.
Neoplasms
Population Pharmacokinetics of Phenytoin Based on NONMEN in Patients with Intracranial Tumor during the First Week of Post-craniotomy.
Neoplasms
Potentiation of methoxymorpholinyl doxorubicin antitumor activity by P450 3A4 gene transfer.
Neoplasms
Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues.
Neoplasms
Prediction of response to docetaxel by immunohistochemical analysis of CYP3A4 expression in human breast cancers.
Neoplasms
Prediction of the drug-drug interaction potential of the ?1-acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib.
Neoplasms
Pregnane X receptor dependent up-regulation of CYP2C9 and CYP3A4 in tumor cells by antitumor acridine agents, C-1748 and C-1305, selectively diminished under hypoxia.
Neoplasms
Prevalence of five pharmacologically most important CYP2C9 and CYP2C19 allelic variants in the population from the Republic of Srpska in Bosnia and Herzegovina.
Neoplasms
Preventive medical services not covered by public health insurance at Daiko Medical Center in Japan, 2004-2011.
Neoplasms
Quantitative assessment of the influence of cytochrome P450 2C19 gene polymorphisms and digestive tract cancer risk.
Neoplasms
Re: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.
Neoplasms
Re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.
Neoplasms
Relationships between oxycodone pharmacokinetics, central symptoms, and serum interleukin-6 in cachectic cancer patients.
Neoplasms
RESPONSE: re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4
Neoplasms
Resveratrol mediated cancer cell apoptosis, and modulation of multidrug resistance proteins and metabolic enzymes.
Neoplasms
Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy.
Neoplasms
Ribociclib enhances infigratinib-induced cancer cell differentiation and delays resistance in FGFR-driven hepatocellular carcinoma.
Neoplasms
Ritonavir inhibits intratumoral docetaxel metabolism and enhances docetaxel antitumor activity in an immunocompetent mouse breast cancer model.
Neoplasms
Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism.
Neoplasms
Role of NF-kappaB in regulation of PXR-mediated gene expression: a mechanism for the suppression of cytochrome P-450 3A4 by proinflammatory agents.
Neoplasms
Self-Assembling Derivative of Hydrocortisone as Glucocorticoid Receptor-Targeted Nanotherapeutics for Synergistic, Combination Therapy against Colorectal Tumor.
Neoplasms
Significant transcriptional down-regulation of the human MDR1 gene by beta-naphthoflavone: a proposed hypothesis linking potent CYP gene induction to MDR1 inhibition.
Neoplasms
Single- and multiple-dose pharmacokinetics, potential for CYP3A inhibition, and food effect in patients with cancer and healthy subjects receiving ipatasertib.
Neoplasms
Stimulation of human monocytic THP-1 cells by metabolic activation of hepatotoxic drugs.
Neoplasms
The antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liver.
Neoplasms
The carotenoid fucoxanthin can sensitize multidrug resistant cancer cells to doxorubicin via induction of apoptosis, inhibition of multidrug resistance proteins and metabolic enzymes.
Neoplasms
The down-regulation of the CYP2C19 gene is associated with aggressive tumor potential and the poorer recurrence-free survival of hepatocellular carcinoma.
Neoplasms
The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics.
Neoplasms
The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors.
Neoplasms
The Effect of CYP3A4 Inhibition or Induction on the Pharmacokinetics and Pharmacodynamics of Orally Administered Ruxolitinib (INCB018424 Phosphate) in Healthy Volunteers.
Neoplasms
The effects of lapatinib on cardiac repolarization: results from a placebo controlled, single sequence, crossover study in patients with advanced solid tumors.
Neoplasms
The effects of lapatinib on CYP3A metabolism of midazolam in patients with advanced cancer.
Neoplasms
The expression of cytochrome P450 enzymes in human breast tumours and normal breast tissue.
Neoplasms
The Expression Profiles of ADME Genes in Human Cancers and Their Associations with Clinical Outcomes.
Neoplasms
The frameshift polymorphism CYP3A43_74_delA is associated with poor differentiation of breast tumors.
Neoplasms
The immunohistochemical localization of drug-metabolizing enzymes in prostate cancer.
Neoplasms
The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomes.
Neoplasms
The modulatory properties of Si Jun Zi Tang enhancing anticancer of gefitinib by an integrating approach.
Neoplasms
The nuclear factor-kappa B pathway regulates cytochrome P450 3A4 protein stability.
Neoplasms
The pharmacokinetics of pamiparib in the presence of a strong CYP3A inhibitor (itraconazole) and strong CYP3A inducer (rifampin) in patients with solid tumors: an open-label, parallel-group phase 1 study.
Neoplasms
The phospholipidosis-lnducing potential of the chemopotentiating drug, N,N-Diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine (DPPE, tesmilifene) correlates with its stimulation of phosphatidylserine synthesis and exposure on the plasma membrane in MCF-7 breast cancer cells.
Neoplasms
The prognostic value of differentially expressed CYP3A subfamily members for hepatocellular carcinoma.
Neoplasms
The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients.
Neoplasms
The role of cytochromes p450 and aldo-keto reductases in prognosis of breast carcinoma patients.
Neoplasms
The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions.
Neoplasms
Therapeutic effects and adverse drug reactions are affected by icotinib exposure and CYP2C19 and EGFR genotypes in Chinese non-small cell lung cancer patients.
Neoplasms
Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer.
Neoplasms
Transcriptional targets of the chromatin-remodelling factor SMARCA4/BRG1 in lung cancer cells.
Neoplasms
Tumor Microenvironment Alters Chemoresistance of Hepatocellular Carcinoma Through CYP3A4 Metabolic Activity.
Neoplasms
Tumor necrosis factor alpha partially contributes to lipopolysaccharide-induced downregulation of CYP3A in fetal liver: Its repression by a low dose LPS pretreatment.
Neoplasms
Tumor-selective drug activation: a GDEPT approach utilizing cytochrome P450 1A1 and AQ4N.
Neoplasms
Unequal prognostic potentials of p53 gain-of-function mutations in human cancers associate with drug-metabolizing activity.
Neoplasms
Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes.
Neoplasms
[Activity and induction of CYP2B, CYP2C, and CYP3A in tissues of cyclophosphane-sensitive and resistant neoplasms and the liver of neoplasm-carrying mice]
Neoplasms
[Effect of jianpi liqi recipe on mRNA expressions of TP, DPD, and CYP3A4 in mice with human gastric cancer transplanted tumor].
Neoplasms
[Interindividual variation of pharmacokinetic disposition of and clinical responses to opioid analgesics in cancer pain patients].
Neoplasms
[The role of CYP2C19 polymorphism in the development of adverse effects to drugs and the risk for diseases]
Nephritis, Interstitial
Omeprazole-induced acute interstitial nephritis is not related to CYP2C19 genotype or CYP2C19 phenotype.
Nephrosis
Contribution of down-regulation of intestinal and hepatic cytochrome P450 3A to increased absorption of cyclosporine A in a rat nephrosis model.
Nephrosis
The Effects of CYP2C19 genotype on the susceptibility for nephrosis in cardio-cerebral vascular disease treated by anticoagulation.
Nephrotic Syndrome
Diltiazem on tacrolimus exposure and dose sparing in Chinese pediatric primary nephrotic syndrome: impact of CYP3A4, CYP3A5, ABCB1, and SLCO1B3 polymorphisms.
Nephrotic Syndrome
Important role of prodromal viral infections responsible for inhibition of xenobiotic metabolizing enzymes in the pathomechanism of idiopathic Reye's syndrome, Stevens-Johnson syndrome, autoimmune hepatitis, and hepatotoxicity of the therapeutic doses of acetaminophen used in genetically predisposed persons.
Nephrotic Syndrome
Individualized Tacrolimus Therapy for Pediatric Nephrotic Syndrome: Considerations for Ontogeny and Pharmacogenetics of CYP3A.
Neuralgia
A candidate gene study of serotonergic pathway genes and pain relief during treatment with escitalopram in patients with neuropathic pain shows significant association to serotonin receptor2C (HTR2C).
Neuralgia
Impact of fraction unbound, CYP3A, and CYP2D6 in vivo activities, and other potential covariates to the clearance of tramadol enantiomers in patients with neuropathic pain.
Neuroblastoma
Histone deacetylase inhibitors valproate and trichostatin A are toxic to neuroblastoma cells and modulate cytochrome P450 1A1, 1B1 and 3A4 expression in these cells.
Neuroblastoma
Novel naphthyloxy derivatives - Potent histamine H3 receptor ligands. Synthesis and pharmacological evaluation.
Neutropenia
A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan.
Neutropenia
A physiologically based pharmacokinetic - pharmacodynamic modelling approach to predict incidence of neutropenia as a result of drug-drug interactions of paclitaxel in cancer patients.
Neutropenia
Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228).
Neutropenia
Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir.
Neutropenia
Pharmacokinetics of eribulin mesylate in patients with solid tumors receiving repeated oral rifampicin.
Neutropenia
Population pharmacokinetic-pharmacodynamic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis.
Neutropenia
Population Pharmacokinetic-Pharmacodynamic Modeling and Covariate Analyses of Neutropenia and Thrombocytopenia in Patients With Solid Tumors Treated With Lurbinectedin.
Neutropenia
Predictive Value of FMO3 Variants on Plasma Disposition and Adverse Reactions of Oral Voriconazole in Febrile Neutropenia.
Neutropenia
Role of pharmacogenetics on adjuvant chemotherapy-induced neutropenia in Chinese breast cancer patients.
Neutropenia
The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors.
Non-alcoholic Fatty Liver Disease
A Fibroblast Growth Factor 21-Pregnane X Receptor Pathway Downregulates Hepatic CYP3A4 in Nonalcoholic Fatty Liver Disease.
Non-alcoholic Fatty Liver Disease
Acetaminophen-induced liver injury in obesity and nonalcoholic fatty liver disease.
Non-alcoholic Fatty Liver Disease
CYP3A Activity and Expression in Nonalcoholic Fatty Liver Disease.
Non-alcoholic Fatty Liver Disease
CYP3A suppression during diet-induced nonalcoholic fatty liver disease is independent of PXR regulation.
Non-alcoholic Fatty Liver Disease
Environmental toxin-linked nonalcoholic steatohepatitis and hepatic metabolic reprogramming in obese mice.
Non-alcoholic Fatty Liver Disease
Establishment of an ex Vivo Model of Nonalcoholic Fatty Liver Disease Using a Tissue-Engineered Liver.
Non-alcoholic Fatty Liver Disease
Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease.
Non-alcoholic Fatty Liver Disease
Modulation of xenobiotic nuclear receptors in high-fat diet induced non-alcoholic fatty liver disease.
Non-alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters.
Non-alcoholic Fatty Liver Disease
Nonalcoholic Fatty Liver Disease and Diabetes Are Associated with Decreased CYP3A4 Protein Expression and Activity in Human Liver.
Non-alcoholic Fatty Liver Disease
Silybin Restored CYP3A Expression through the Sirtuin 2/Nuclear Factor ?-B Pathway in Mouse Nonalcoholic Fatty Liver Disease.
Non-alcoholic Fatty Liver Disease
Three-dimensional perfused human in vitro model of non-alcoholic fatty liver disease.
Non-alcoholic Fatty Liver Disease
Transcriptional Repression of CYP3A4 by Increased miR-200a-3p and miR-150-5p Promotes Steatosis in vitro.
Obesity
Acetaminophen-induced liver injury in obesity and nonalcoholic fatty liver disease.
Obesity
Association of clozapine-related metabolic disturbances with CYP3A4 expression in patients with schizophrenia.
Obesity
Decreased CYP3a Expression and Activity in Guinea Pig Models of Diet-Induced Metabolic Syndrome: Is Fatty Liver Infiltration Involved?
Obesity
Expression of the CYP3A and CYP2C11 enzymes in a nutritionally obese rodent model: response to phenobarbital treatment.
Obesity
High fat diet induced obesity alters ovarian phosphatidylinositol-3 kinase signaling gene expression.
Obesity
Lean body weight dosing avoids excessive systemic exposure to proton pump inhibitors for children with obesity.
Obesity
Modulation of CYP3a expression and activity in mice models of type 1 and type 2 diabetes.
Obesity
Obese Children Require Lower Doses of Pantoprazole Than Nonobese Peers to Achieve Equal Systemic Drug Exposures.
Obesity
Oral Morphine Pharmacokinetic in Obesity: The Role of P-Glycoprotein, MRP2, MRP3, UGT2B7, and CYP3A4 Jejunal Contents and Obesity-Associated Biomarkers.
Obesity
Population pharmacokinetics of midazolam and its metabolites in overweight and obese adolescents.
Obesity
Tissue Specific Modulation of cyp2c and cyp3a mRNA Levels and Activities by Diet-Induced Obesity in Mice: The Impact of Type 2 Diabetes on Drug Metabolizing Enzymes in Liver and Extra-Hepatic Tissues.
Obesity, Morbid
Short- and medium-term impact of bariatric surgery on the activities of CYP2D6, CYP3A4, CYP2C9, and CYP1A2 in morbid obesity.
Onychomycosis
Longitudinal monitoring of CYP3A activity in patients receiving 3 cycles of itraconazole pulse therapy for onychomycosis.
Osteomalacia
Enhancement of hepatic 4-hydroxylation of 25-hydroxyvitamin D(3) through CYP3A4 induction in vitro and in vivo: Implications for drug-induced osteomalacia.
Osteomalacia
Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha,25-dihydroxyvitamin D(3): implications for drug-induced osteomalacia.
Osteomalacia
Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia.
Osteonecrosis
Correlation Between Steroid-Induced Osteonecrosis of The Femoral Head and Hepatic CYP3A Activity: A Systematic Review and Meta-Analysis.
Osteonecrosis
Genetic polymorphisms of CYP3A4 among Chinese patients with steroid-induced osteonecrosis of the femoral head.
Osteonecrosis
Increased hepatic cytochrome P4503A activity decreases the risk of developing steroid-induced osteonecrosis in a rabbit model.
Osteonecrosis
Low levels of steroid-metabolizing hepatic enzyme (cytochrome P450 3A) activity may elevate responsiveness to steroids and may increase risk of steroid-induced osteonecrosis even with low glucocorticoid dose.
Osteonecrosis
[Hepatic CYP3A activity in association with development of osteonecrosis of the femoral head]
Osteonecrosis
[The role of CYP2C19 polymorphism in the development of adverse effects to drugs and the risk for diseases]
Osteoporosis
A clinical therapeutic protein drug-drug interaction study: coadministration of denosumab and midazolam in postmenopausal women with osteoporosis.
Osteoporosis
Contribution of genetic variations in estradiol biosynthesis and metabolism enzymes to osteoporosis.
Osteoporosis
The CYP3A4*18 genotype in the cytochrome P450 3A4 gene, a rapid metabolizer of sex steroids, is associated with low bone mineral density.
Osteosarcoma
Variants of FasL and ABCC5 are predictive of outcome after chemotherapy-based treatment in osteosarcoma.
Ototoxicity
Sildenafil and furosemide associated ototoxicity: consideration of drug-drug interactions, synergy, and broader clinical relevance.
Ovarian Neoplasms
Influence of CYP3A4 genotypes in the outcome of serous ovarian cancer patients treated with first-line chemotherapy: implication of a CYP3A4 activity profile.
Ovarian Neoplasms
Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer.
Ovarian Neoplasms
Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer.
Ovarian Neoplasms
Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1.
Ovarian Neoplasms
The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer.
Ovarian Neoplasms
Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium.
Overweight
Double-dosed pantoprazole accelerates the sustained symptomatic response in overweight and obese patients with reflux esophagitis in Los Angeles grades A and B.
Overweight
Population pharmacokinetics of midazolam and its metabolites in overweight and obese adolescents.
Overweight
Short- and medium-term impact of bariatric surgery on the activities of CYP2D6, CYP3A4, CYP2C9, and CYP1A2 in morbid obesity.
Pancreatic Neoplasms
Impact of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir in pancreatic cancer patients.
Pancreatic Neoplasms
Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib.
Pancreatic Neoplasms
Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study.
Pancreatic Neoplasms
Ritonavir and Efavirenz Significantly Alter the Metabolism of Erlotinib--an Observation in Primary Cultures of Human Hepatocytes That Is Relevant to HIV Patients with Cancer.
Pancreatitis
Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma.
Pancytopenia
Lurbinectedin: A New Treatment Option for Relapsed/Refractory Small-Cell Lung Cancer.
Parkinson Disease
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4--implications for susceptibility to Parkinson's disease.
Parkinson Disease
A study of the pharmacokinetic interaction of istradefylline, a novel therapeutic for Parkinson's disease, and atorvastatin.
Parkinson Disease
CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes.
Parkinson Disease
Structural and mechanistic insights into the interaction of cytochrome P4503A4 with bromoergocryptine, a type I ligand.
Pemphigoid, Bullous
Refractory bullous pemphigoid improved by discontinuation of phenytoin as an CYP3A4 inducer.
Peptic Ulcer
Antimicrobial susceptibility and clarithromycin resistance patterns of Helicobacter pylori clinical isolates in Vietnam.
Peptic Ulcer
Association of CYP2C19, TNF-?, NOD1, NOD2, and PPAR? polymorphisms with peptic ulcer disease enhanced by Helicobacter pylori infection.
Peptic Ulcer
Blood concentration of pantoprazole sodium is significantly high in hepatogenic peptic ulcer patients, especially those with a poor CYP2C19 metabolism.
Peptic Ulcer
Comparison of the efficacy of rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of peptic ulcer diseases.
Peptic Ulcer
Correlation of CYP2C19 genetic polymorphisms with helicobacter pylori eradication in patients with cirrhosis and peptic ulcer.
Peptic Ulcer
CYP3A and CYP2C19 activity in urine in relation to CYP3A4, CYP3A5, and CYP2C19 polymorphisms in Russian peptic ulcer patients taking omeprazole.
Peptic Ulcer
EFFECT OF CYP2C19 GENETIC POLYMORPHISMS ON THE EFFICACY OF PROTON PUMP INHIBITOR-BASED TRIPLE ERADICATION THERAPY IN SLAVIC PATIENTS WITH PEPTIC ULCERS: A META-ANALYSIS.
Peptic Ulcer
Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer.
Peptic Ulcer
Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole.
Peptic Ulcer
Effects of Genetic Polymorphisms of Cytochrome P450 Enzymes and MDR1 Transporter on Pantoprazole Metabolism and Helicobacter pylori Eradication.
Peptic Ulcer
Effects of the CYP2C19 Genetic Polymorphism on Gastritis, Peptic Ulcer Disease, Peptic Ulcer Bleeding and Gastric Cancer.
Peptic Ulcer
Fluoxetine inhibition of CYP3A4 potentiating adrenal suppression and peptic ulcer disease from intra-articular triamcinolone injections.
Peptic Ulcer
Polymorphisms in the host CYP2C19 gene and antibiotic-resistance attributes of Helicobacter pylori isolates influence the outcome of triple therapy.
Peptic Ulcer
Poor metabolizer genotype status of CYP2C19 is a risk factor for developing gastric cancer in Japanese patients with Helicobacter pylori infection.
Peptic Ulcer
Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping: possible effect of age, liver disease and length of therapy.
Peptic Ulcer
Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers.
Peptic Ulcer
The frequency of CYP2C19 genetic polymorphisms in Russian patients with peptic ulcers treated with proton pump inhibitors.
Peptic Ulcer
Urine metabolic ratio of omeprazole in relation to CYP2C19 polymorphisms in Russian peptic ulcer patients.
Peptic Ulcer
[HIGH FREQUENCY OF CYP2C19 ULTRARAPID METABOLIZERS IN RUSSIAN PATIENTS WITH PEPTIC ULCER].
Peptic Ulcer
[THE EFFECTIVENESS OF ERADICATION IN PATIENTS WITH PEPTIC ULCER DISEASE ASSOCIATED WITH HELICOBACTER PYLORI, DEPENDING ON THE GENOTYPE OF THE DRUGMETABOLISM OF PROTON PUMP INHIBITORS].
Pericardial Effusion
Hemopericardium with tamponade following rivaroxaban administration and its attenuation by CYP3A4 inhibitors.
Peripheral Arterial Disease
CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID Trial.
Peripheral Arterial Disease
Genetic polymorphisms influence on the response to clopidogrel in peripheral artery disease patients following percutaneous transluminal angioplasty.
Peripheral Arterial Disease
Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease.
Peripheral Nervous System Diseases
Drug interaction between itraconazole and bortezomib: exacerbation of peripheral neuropathy and thrombocytopenia induced by bortezomib.
Peripheral Nervous System Diseases
Effect of CYP2C19 and CYP3A4 gene polymorphisms on the efficacy of bortezomib-based regimens in patients with multiple myeloma.
Peripheral Nervous System Diseases
Severe Neuropathic Pain With Concomitant Administration of Vincristine and Posaconazole.
Porphyrias
Effects of heme arginate on cytochrome P450-mediated metabolism of drugs in patients with variegate porphyria and in healthy men.
Porphyrias
Microsomal enzyme induction and clinical aggravation of porphyria: the evaluation of human urinary 6beta-hydroxycortisol/cortisol ratio as the index of hepatic CYP3A4 activity.
Porphyrias, Hepatic
Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial).
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
In interaction with gender a common CYP3A4 polymorphism may influence the survival rate of chemotherapy for childhood acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The effect of race on the CYP3A-mediated metabolism of vincristine in pediatric patients with acute lymphoblastic leukemia.
Premature Birth
The association among cytochrome P450 3A, progesterone receptor polymorphisms, plasma 17-alpha hydroxyprogesterone caproate concentrations, and spontaneous preterm birth.
Primary Myelofibrosis
Ruxolitinib exposure in patients with acute and chronic graft versus host disease in routine clinical practice-a prospective single-center trial.
Prostatic Hyperplasia
Cytochrome P450 3A5 is highly expressed in normal prostate cells but absent in prostate cancer.
Prostatic Hyperplasia
Joint effects of inflammation and androgen metabolism on prostate cancer severity.
Prostatic Neoplasms
Androgen Metabolism Gene Polymorphisms, Associations with Prostate Cancer Risk and Pathological Characteristics: A Comparative Analysis between South African and Senegalese Men.
Prostatic Neoplasms
Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment.
Prostatic Neoplasms
Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients.
Prostatic Neoplasms
Association between cytochrome CYP17A1, CYP3A4, and CYP3A43 polymorphisms and prostate cancer risk and aggressiveness in a Korean study population.
Prostatic Neoplasms
Association between the CYP3A4 and CYP3A5 polymorphisms and cancer risk: a meta-analysis and meta-regression.
Prostatic Neoplasms
Associations between smoking, polymorphisms in polycyclic aromatic hydrocarbon (PAH) metabolism and conjugation genes and PAH-DNA adducts in prostate tumors differ by race.
Prostatic Neoplasms
Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191. Online.
Prostatic Neoplasms
Clinical significance of steroid and xenobiotic receptor and its targeted gene CYP3A4 in human prostate cancer.
Prostatic Neoplasms
Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer.
Prostatic Neoplasms
Comprehensive evaluation of the association between prostate cancer and genotypes/haplotypes in CYP17A1, CYP3A4, and SRD5A2.
Prostatic Neoplasms
CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia.
Prostatic Neoplasms
CYP3A4 genetic variant and disease-free survival among white and black men after radical prostatectomy.
Prostatic Neoplasms
CYP3A4 polymorphisms--potential risk factors for breast and prostate cancer: a HuGE review.
Prostatic Neoplasms
CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia.
Prostatic Neoplasms
CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer.
Prostatic Neoplasms
Cytochrome P450 3A gene variation, steroid hormone serum levels and prostate cancer--The Rotterdam Study.
Prostatic Neoplasms
Cytochrome P450 3A5 is highly expressed in normal prostate cells but absent in prostate cancer.
Prostatic Neoplasms
Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4.
Prostatic Neoplasms
Frequency and prognostic significant of CYP3A4-A-290G polymorphism in acute myeloid leukemia.
Prostatic Neoplasms
Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: the Flint Men's Health Study.
Prostatic Neoplasms
HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo.
Prostatic Neoplasms
Impact of a genetic variant in CYP3A4 on risk and clinical presentation of prostate cancer among white and African-American men.
Prostatic Neoplasms
Innovative C2-symmetric testosterone and androstenedione dimers: Design, synthesis, biological evaluation on prostate cancer cell lines and binding study to recombinant CYP3A4.
Prostatic Neoplasms
Joint effects of inflammation and androgen metabolism on prostate cancer severity.
Prostatic Neoplasms
Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.
Prostatic Neoplasms
P-glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain Disposition and Oral Availability of the Novel Taxane Cabazitaxel (Jevtana) in Mice.
Prostatic Neoplasms
Pharmacokinetic Drug-Drug Interaction of Apalutamide, Part 1: Clinical Studies in Healthy Men and Patients with Castration-Resistant Prostate Cancer.
Prostatic Neoplasms
Polymorphisms in CYP17 and CYP3A4 and prostate cancer in men of African descent.
Prostatic Neoplasms
Polymorphisms in NAT2, CYP2D6, CYP2C19 and GSTP1 and their association with prostate cancer.
Prostatic Neoplasms
Regulation of CYP3A4 and CYP3A5 expression and modulation of "intracrine" metabolism of androgens in prostate cells by liganded vitamin D receptor.
Prostatic Neoplasms
Review of studies on metabolic genes and cancer in populations of African descent.
Prostatic Neoplasms
Single and multigenic analysis of the association between variants in 12 steroid hormone metabolism genes and risk of prostate cancer.
Prostatic Neoplasms
The CYP3A4 *1B polymorphism and prostate cancer susceptibility in a Portuguese population.
Prostatic Neoplasms
The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer.
Prostatic Neoplasms
The PXR rs7643645 polymorphism is associated with the risk of higher prostate-specific antigen levels in prostate cancer patients.
Prostatic Neoplasms
The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide.
Prostatic Neoplasms
TSPYL Family Regulates CYP17A1 and CYP3A4 Expression: Potential Mechanism Contributing to Abiraterone Response in Metastatic Castration-Resistant Prostate Cancer.
Prostatic Neoplasms
Variant in sex hormone-binding globulin gene and the risk of prostate cancer.
Prostatic Neoplasms
[Treatment of metastatic castration-resistant prostate cancer : Drug interaction potentials of abiraterone acetate and enzalutamide].
Proteinuria
CYP3A5 and CYP3A7 genetic polymorphisms affect tacrolimus concentration in pediatric patients with nephrotic range proteinuria.
Pruritus
An update on the physiopathology and therapeutic management of cholestatic pruritus in children.
Psoriasis
Evaluating Potential Disease-Mediated Protein-Drug Interactions in Patients With Moderate-to-Severe Plaque Psoriasis Receiving Subcutaneous Guselkumab.
Psoriasis
Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis.
Psoriasis
Secukinumab Treatment Does Not Alter the Pharmacokinetics of the Cytochrome P450 3A4 Substrate Midazolam in Patients With Moderate to Severe Psoriasis.
Psoriasis
[The role of CYP2C19 polymorphism in the development of adverse effects to drugs and the risk for diseases]
Puberty, Precocious
Association study of four activity SNPs of CYP3A4 with the precocious puberty in Chinese girls.
Pulmonary Disease, Chronic Obstructive
Drug metabolism in severe chronic obstructive pulmonary disease: A phenotyping cocktail study.
Pulmonary Disease, Chronic Obstructive
Expression of cytochrome P450 mRNAs in Type II alveolar cells from subjects with chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Genetic Polymorphisms of CYP2C9/CYP2C19 in Chronic Obstructive Pulmonary Disease.
Pulmonary Disease, Chronic Obstructive
Lack of a pharmacokinetic interaction between steady-state roflumilast and single-dose midazolam in healthy subjects.
Pulmonary Disease, Chronic Obstructive
Prediction of new targets and mechanisms for quercetin in the treatment of pancreatic cancer, colon cancer, and rectal cancer.
Pulmonary Disease, Chronic Obstructive
The effect of CYP3A4 genetic variants on the susceptibility to chronic obstructive pulmonary disease in the Hainan Han population.
Pulmonary Disease, Chronic Obstructive
The Expression Profiles of ADME Genes in Human Cancers and Their Associations with Clinical Outcomes.
Pulmonary Disease, Chronic Obstructive
Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
Pulmonary Edema
Association between CYP2C19 gene polymorphisms and susceptibility to high-altitude pulmonary edema.
quinine 3-monooxygenase deficiency
Brain Accumulation of Ponatinib and Its Active Metabolite, N-Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2).
quinine 3-monooxygenase deficiency
CYP3A deficiency alters bile acid homeostasis and leads to changes in hepatic susceptibility in rats.
quinine 3-monooxygenase deficiency
Cyp3a deficiency enhances androgen receptor activity and cholesterol synthesis in the mouse prostate.
quinine 3-monooxygenase deficiency
Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines.
quinine 3-monooxygenase deficiency
In Vitro Model for a Drug Assessment of Cytochrome P450 Family 3 Subfamily A Member 4 Substrates Using Human Induced Pluripotent Stem Cells and Genome Editing Technology.
quinine 3-monooxygenase deficiency
Modeling of Hepatic Drug Metabolism and Responses in CYP2C19 Poor Metabolizer Using Genetically Manipulated Human iPS cells.
quinine 3-monooxygenase deficiency
P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability.
quinine 3-monooxygenase deficiency
Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease.
Renal Insufficiency
Association of plasma concentration of 4?-hydroxycholesterol with CYP3A5 polymorphism and plasma concentration of indoxyl sulfate in stable kidney transplant recipients.
Renal Insufficiency
Colchicine-induced acute myopathy in a patient with concomitant use of simvastatin.
Renal Insufficiency
Factors involved in phenoconversion of CYP3A using 4?-hydroxycholesterol in stable kidney transplant recipients.
Renal Insufficiency
Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection.
Renal Insufficiency
Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients.
Renal Insufficiency
Renal insufficiency has no effect on the pharmacokinetics of vicriviroc in a ritonavir-containing regimen.
Renal Insufficiency
Significant increase in plasma 4?-hydroxycholesterol concentration in patients after kidney transplantation.
Renal Insufficiency
The hepatic and intestinal metabolic activities of P450 in rats with surgery- and drug-induced renal dysfunction.
Renal Insufficiency, Chronic
Chronic kidney disease status modifies the association of CYP2C19 polymorphism in predicting clinical outcomes following coronary stent implantation.
Renal Insufficiency, Chronic
CYP2C19 genotype has prognostic value in specific populations following coronary stenting.
Renal Insufficiency, Chronic
Differential Impact of Clinical and Genetic Factors on High Platelet Reactivity in Patients with Coronary Artery Disease Treated with Clopidogrel and Prasugrel.
Renal Insufficiency, Chronic
Down-regulation of hepatic CYP3A and CYP2C mediated metabolism in rats with moderate chronic kidney disease.
Renal Insufficiency, Chronic
Down-regulation of hepatic CYP3A in chronic renal insufficiency.
Renal Insufficiency, Chronic
Effect of Chronic Kidney Disease on Nonrenal Elimination Pathways: A Systematic Assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP.
Renal Insufficiency, Chronic
Effect of Serum Parathyroid Hormone on Tacrolimus Therapy in Kidney Transplant Patients: A Possible Biomarker for a Tacrolimus Dosage Schedule.
Renal Insufficiency, Chronic
Gender differences in impact of CYP2C19 polymorphism on development of coronary artery disease.
Renal Insufficiency, Chronic
Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial).
Renal Insufficiency, Chronic
Risk of Colchicine-Associated Myopathy in Gout: Influence of Concomitant Use of Statin.
Reperfusion Injury
Decreased oral absorption of cyclosporine A after liver ischemia-reperfusion injury in rats: the contribution of CYP3A and P-glycoprotein to the first-pass metabolism in intestinal epithelial cells.
Reperfusion Injury
The prominent impairment of liver/intestinal cytochrome P450 and intestinal drug transporters in sepsis-induced acute kidney injury over acute and chronic renal ischemia, a mouse model comparison.
Respiratory Insufficiency
Dexamethasone hepatic induction in rats subsequently treated with high dose buprenorphine does not lead to respiratory depression.
Rhabdomyolysis
Assessment of ADRs associated with lipid-lowering agents recorded in the Department of Internal Medicine, University Hospital, Jena.
Rhabdomyolysis
Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis.
Rhabdomyolysis
Clopidogrel-precipitated rhabdomyolysis in a stable heart transplant patient.
Rhabdomyolysis
Fatal Statin-Induced Rhabdomyolysis by Possible Interaction with Palbociclib.
Rhabdomyolysis
Life-threatening rhabdomyolysis following the interaction of two commonly prescribed medications.
Rhabdomyolysis
Palbociclib in combination with simvastatin induce severe rhabdomyolysis: a case report.
Rhabdomyolysis
Pharmacokinetic model for the inhibition of simvastatin metabolism by itraconazole.
Rhabdomyolysis
Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.
Rhabdomyolysis
Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.
Rhabdomyolysis
Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage.
Rhabdomyolysis
Rhabdomyolysis after concomitant use of cyclosporine, simvastatin, gemfibrozil, and itraconazole.
Rhabdomyolysis
Rhabdomyolysis caused by the moderate CYP3A4 inhibitor fluconazole in a patient on stable atorvastatin therapy: a case report and literature review.
Rhabdomyolysis
Rhabdomyolysis in an HIV-Infected Patient on Anti-Retroviral Therapy Precipitated by High-Dose Pravastatin.
Rhabdomyolysis
Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors.
Rhabdomyolysis
Severe rhabdomyolysis associated with simvastatin and role of ciprofloxacin and amlodipine coadministration.
Rhabdomyolysis
The clinical significance of statins-macrolides interaction: comprehensive review of in vivo studies, case reports, and population studies.
Rhabdomyolysis
Weakness and pain in arms and legs · dark urine · history of vertebral osteomyelitis · Dx?
Rhabdomyolysis
[Brown urine : Myoglobin-induced renal failure after concomitant administration of simvastatin and amiodarone].
Rhabdomyolysis
[The incremental effect and mechanism of cyclosporine on blood concentration of statins and statin package insert information in Japan]
Rheumatic Diseases
Decreased intestinal CYP3A and P-glycoprotein activities in rats with adjuvant arthritis.
Rhinitis, Allergic
Bioactivation of a novel 2-methylindole-containing dual chemoattractant receptor-homologous molecule expressed on T-helper type-2 cells/D-prostanoid receptor antagonist leads to mechanism-based CYP3A inactivation: glutathione adduct characterization and prediction of in vivo drug-drug interaction.
Rhinitis, Allergic
Effect of age and gender on the pharmacokinetics of ebastine after single and repeated dosing in healthy subjects.
Rickets
Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populations.
Sarcoma
Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma.
Sarcoma
Efficacy, Tolerability and Pharmacokinetic Impact of Aprepitant in Sarcoma Patients Receiving Ifosfamide and Doxorubicin Chemotherapy: A Randomized Controlled Trial.
Sarcoma
MDR1 not CYP3A4 gene expression is the predominant mechanism of innate drug resistance in pediatric soft tissue sarcoma patients.
Sarcoma
Stable expression of human cytochrome P450 3A4 in V79 cells and its application for metabolic profiling of ergot derivatives.
Sarcoma
Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer.
Sarcoma, Avian
Evaluation of viral and mammalian promoters for driving transgene expression in mouse liver.
Sarcoma, Ewing
CYP3A isoforms in Ewing's sarcoma tumours: an immunohistochemical study with clinical correlation.
Sarcoma, Experimental
Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer.
Schistosomiasis
Study of the Urinary Ratio of 6 beta-Hydroxycortisol/Cortisol as a Biomarker of CYP3A4 Activity in Egyptian Patients with Chronic Liver Diseases.
Schistosomiasis mansoni
Effect of ketoconazole, a cytochrome P450 inhibitor, on the efficacy of quinine and halofantrine against Schistosoma mansoni in mice.
Seizures
Early post-traumatic seizures are associated with valproic acid plasma concentrations and UGT1A6/CYP2C9 genetic polymorphisms in patients with severe traumatic brain injury.
Seizures
Effects of carbamazepine on the P-gp and CYP3A expression correlated with PXR or NF-?B activity in the bEnd.3 cells.
Seizures
Effects of cytochrome P450 (CYP)2C19 polymorphisms on pharmacokinetics of phenobarbital in neonates and infants with seizures.
Seizures
Effects of UGT2B7, SCN1A and CYP3A4 on the therapeutic response of sodium valproate treatment in children with generalized seizures.
Seizures
Identification of N-acyl-N-indanyl-?-phenylglycinamides as selective TRPM8 antagonists designed to mitigate the risk of adverse effects.
Seizures
Neurovascular Drug Biotransformation Machinery in Focal Human Epilepsies: Brain CYP3A4 Correlates with Seizure Frequency and Antiepileptic Drug Therapy.
Seizures
Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations.
Seizures
Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors.
Sepsis
Repression of PXR-mediated induction of hepatic CYP3A gene expression by protein kinase C.
Severe Combined Immunodeficiency
Murine Cyp3a knockout chimeric mice with humanized liver: prediction of the metabolic profile of nefazodone in humans.
Sleep Initiation and Maintenance Disorders
Effects of genetic polymorphisms of CYP2C19 on the pharmacokinetics of zolpidem.
Small Cell Lung Carcinoma
Gene Polymorphisms and Chemotherapy in Non-small Cell Lung Cancer.
Squamous Cell Carcinoma of Head and Neck
Association of poor metabolizers of cytochrome P450 2C19 with head and neck cancer and poor treatment response.
Squamous Cell Carcinoma of Head and Neck
Study the polymorphism of CYP3A5 and CYP3A4 loci in Iranian population with laryngeal squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Tobacco habituated and non-habituated subjects exhibit different mutational spectrums in head and neck squamous cell carcinoma.
ST Elevation Myocardial Infarction
Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel.
ST Elevation Myocardial Infarction
Correction to: Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel.
ST Elevation Myocardial Infarction
Correlates of pre-hospital morphine use in ST-elevation myocardial infarction patients and its association with in-hospital outcomes and long-term mortality: the FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) programme.
ST Elevation Myocardial Infarction
CYP2C19 and CYP3A4 Activity and ADP-induced Platelet Reactivity in Prasugrel- or Ticagrelor-treated STEMI Patients: Monocentric Study in PRAGUE-18 Trial Participants.
ST Elevation Myocardial Infarction
Efficacy and safety of glycoprotein IIb/IIIa inhibitors in addition to P2Y12 inhibitors in ST-segment elevation myocardial infarction: A subanalysis of the POPular Genetics trial.
ST Elevation Myocardial Infarction
Increase in the risk of clopidogrel resistance and consequent TIMI flow impairment by DNA hypomethylation of CYP2C19 gene in STEMI patients undergoing primary percutaneous coronary intervention (PPCI).
ST Elevation Myocardial Infarction
Routine CYP2C19 Genotyping to Adjust Thienopyridine Treatment After Primary PCI for STEMI: Results of the GIANT Study.
Starvation
Expression and distribution of cytochrome P450 enzymes in male rat kidney: effects of ethanol, acetone and dietary conditions.
Starvation
Primary mouse hepatocytes for systems biology approaches: a standardized in vitro system for modelling of signal transduction pathways.
Starvation
[Effect of starvation and acetone on the enzyme systems of biotransformation and toxicity of xenobiotics--CYP2E1 substrates in rats]
steroid 21-monooxygenase deficiency
Clinical Role of CYP2C19 Polymorphisms in Patients with Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency.
steroid 21-monooxygenase deficiency
Extraadrenal 21-hydroxylation by CYP2C19 and CYP3A4: effect on 21-hydroxylase deficiency.
Stevens-Johnson Syndrome
Association of ABCB1, CYP3A4, EPHX1, FAS, SCN1A, MICA, and BAG6 polymorphisms with the risk of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Chinese Han patients with epilepsy.
Stomach Neoplasms
Effects of the CYP2C19 Genetic Polymorphism on Gastritis, Peptic Ulcer Disease, Peptic Ulcer Bleeding and Gastric Cancer.
Stomach Neoplasms
Frequencies of poor metabolizers of cytochrome P450 2C19 in esophagus cancer, stomach cancer, lung cancer and bladder cancer in Chinese population.
Stomach Neoplasms
Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients.
Stomach Neoplasms
Poor metabolizer genotype status of CYP2C19 is a risk factor for developing gastric cancer in Japanese patients with Helicobacter pylori infection.
Stomach Neoplasms
Prediction of progression of chronic atrophic gastritis with Helicobacter pylori and poor prognosis of gastric cancer by CYP3A4.
Stomach Neoplasms
[Effect of jianpi liqi recipe on mRNA expressions of TP, DPD, and CYP3A4 in mice with human gastric cancer transplanted tumor].
Stomach Ulcer
A comparative study on endoscopic ulcer healing of omeprazole versus rabeprazole with respect to CYP2C19 genotypic differences.
Stomach Ulcer
Endoscopic analysis of gastric ulcer after one week's treatment with omeprazole and rabeprazole in relation to CYP2C19 genotype.
Stomach Ulcer
Pharmacogenetic testing by polymorphic markers 681G>A and 636G>A CYP2C19 gene in patients with acute coronary syndrome and gastric ulcer in the Republic of Sakha (Yakutia).
Stomach Ulcer
Polymorphism of CYP2C19 and gastric emptying in patients with proton pump inhibitor-resistant gastric ulcers.
Stroke
A pharmacoepidemiology study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention.
Stroke
Age-dependent association of CYP2C19 polymorphisms with clinical outcome of clopidogrel therapy in minor stroke patients with large-artery atherosclerosis.
Stroke
Antiplatelet effect of ticagrelor with aspirin in acute minor stroke and transient ischemic attack stratified by CYP2C19 metabolizer status: subgroup analysis of the PRINCE trial.
Stroke
Association Between ABCB1 Polymorphisms and Outcomes of Clopidogrel Treatment in Patients With Minor Stroke or Transient Ischemic Attack: Secondary Analysis of a Randomized Clinical Trial.
Stroke
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Stroke
Association of clopidogrel high on-treatment reactivity with clinical outcomes and gene polymorphism in acute ischemic stroke patients: An observational study.
Stroke
Association of CYP2C19 Loss-of-Function Alleles with Major Adverse Cardiovascular Events of Clopidogrel in Stable Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention: Meta-analysis.
Stroke
Association with CYP2C19 polymorphisms and Clopidogrel in treatment of elderly stroke patients.
Stroke
Clinical Utility of CYP2C19 Genotype-Guided Antiplatelet Therapy in Patients at Risk of Adverse Cardiovascular and Cerebrovascular Events: A Review of Emerging Evidence.
Stroke
Clopidogrel preventive effect based on cytochrome P450 2C19 genotype in ischaemic stroke: protocol for multicentre observational study.
Stroke
Clopidogrel with aspirin in High-risk patients with Acute Non-disabling Cerebrovascular Events II (CHANCE-2): rationale and design of a multicentre randomised trial.
Stroke
Cost-effectiveness of CYP2C19 genotyping to guide antiplatelet therapy for acute minor stroke and high-risk transient ischemic attack.
Stroke
Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary intervention.
Stroke
CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease.
Stroke
CYP2C19 genotype and early ischemic lesion recurrence in stroke patients treated with clopidogrel.
Stroke
CYP2C19 Loss-of-Function Associated with First-Time Ischemic Stroke in Non-surgical Asymptomatic Carotid Artery Stenosis During Clopidogrel Therapy.
Stroke
CYP2C19 metabolizer status and clopidogrel efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) study.
Stroke
CYP2C19 polymorphism and antiplatelet effects of clopidogrel in Chinese stroke patients.
Stroke
CYP3A Excipient-Based Microemulsion Prolongs the Effect of Magnolol on Ischemia Stroke Rats.
Stroke
Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial.
Stroke
Effect of ticagrelor versus clopidogrel on platelet reactivity measured by thrombelastography in patients with minor stroke or TIA.
Stroke
Effectiveness and safety of high dose clopidogrel plus aspirin in ischemic stroke patients with the single CYP2C19 loss-of-function allele: a randomized trial.
Stroke
Effects of CYP2C19 and P2Y12 Gene Polymorphisms on Clinical Results of Patients Using Clopidogrel after Acute Ischemic Cerebrovascular Disease.
Stroke
Effects of Triflusal and Clopidogrel on the Secondary Prevention of Stroke Based on Cytochrome P450 2C19 Genotyping.
Stroke
Efficacy and safety of CYP2C19 genotype in stroke or transient ischemic attack patients treated with clopidogrel monotherapy or clopidogrel plus aspirin: Protocol for a systemic review and meta-analysis.
Stroke
Efficacy of Clopidogrel for Prevention of Stroke Based on CYP2C19 Allele Status in the POINT Trial.
Stroke
Efficacy of Clopidogrel-Aspirin Therapy for Stroke Does Not Exist in CYP2C19 Loss-of-Function Allele Noncarriers With Overweight/Obesity.
Stroke
Financial Analysis of CYP2C19 Genotyping in Patients Receiving Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention.
Stroke
Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis.
Stroke
Genetic testing for CYP450 polymorphisms to predict response to clopidogrel: current evidence and test availability. Application: pharmacogenomics.
Stroke
Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel.
Stroke
Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy.
Stroke
Influence of
CYP2C19
genotype on antiplatelet treatment outcomes after percutaneous coronary intervention in patients with coronary heart disease.
Stroke
Influence of smoking on CYP2C19 genetic variants and clopidogrel efficacy in patients with minor stroke or transient ischaemic attack.
Stroke
Investigating CYP2C19 loss-of-function allele statuses and their association with stroke of different etiologies in a Taiwanese population.
Stroke
Ischemic stroke and myocardial ischemia in clopidogrel users and the association with CYP2C19 loss-of-function homozygocity: a real-world study.
Stroke
Letter by L. Schlemm and E. Schlemm Regarding Article, "Efficacy of Clopidogrel-Aspirin Therapy for Stroke Does Not Exist in CYP2C19 Loss-of-Function Allele Noncarriers With Overweight/Obesity".
Stroke
Pharmacogenetics of CYP2C19 genetic polymorphism on clopidogrel response in patients with ischemic stroke from Saudi Arabia.
Stroke
Polymorphisms of cytochrome P450 are potential candidates that could potentially help clinicians on the treatment of cardiovascular diseases among Asian populations.
Stroke
Protocol for the comparison of triflusal and clopidogrel in secondary prevention of stroke based on cytochrome P450 2C19 genotyping (MASETRO study): A multicenter, randomized, open-label, parallel-group trial.
Stroke
Reduced number of cardiovascular events and increased cost-effectiveness by genotype-guided antiplatelet therapy in patients undergoing percutaneous coronary interventions in the Netherlands.
Stroke
Response by Chen et al to Letter Regarding Article, "Efficacy of Clopidogrel-Aspirin Therapy for Stroke Does Not Exist in CYP2C19 Loss-of-Function Allele Noncarriers With Overweight/Obesity".
Stroke
Risk of major adverse cardiovascular events for concomitant use of clopidogrel and proton pump inhibitors in patients inheriting CYP2C19 loss-of-function alleles: meta-analysis.
Stroke
Risk of stroke in CYP2C19 LoF polymorphism carrier coronary artery disease patients undergoing clopidogrel therapy: An ethnicity-based updated meta-analysis.
Stroke
The correlation between recurrent risk and CYP2C19 gene polymorphisms in patients with ischemic stroke treated with clopidogrel for prevention.
Stroke
The secondary prevention of stroke according to cytochrome P450 2C19 genotype in patients with acute large-artery atherosclerosis stroke.
Stroke
The Triangulation WIthin a STudy (TWIST) framework for causal inference within pharmacogenetic research.
Stroke
Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial.
Stroke
Variant recurrent risk among stroke patients with different CYP2C19 phenotypes and treated with clopidogrel.
Stroke
[Association of CYP2C19 gene polymorphisms with long-term recurrent risk of ischemic stroke among ethnic Han Chinese from Fujian].
Subarachnoid Hemorrhage
Genetic factors for ischemic and hemorrhagic stroke in Japanese individuals.
Tachycardia, Ventricular
A rapid and sensitive liquid chromatography/tandem mass spectrometry assay for simultaneous quantitation of disopyramide and its major metabolite, mono-isopropyl-disopyramide, in rat plasma and its application to a pharmacokinetic study.
Tachycardia, Ventricular
CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system.
Tardive Dyskinesia
Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms.
Thalassemia
Modification of CYP2E1 and CYP3A4 activities in haemoglobin E-beta thalassemia patients.
Thrombocytopenia
Drug interaction between itraconazole and bortezomib: exacerbation of peripheral neuropathy and thrombocytopenia induced by bortezomib.
Thrombocytopenia
Population Pharmacokinetic-Pharmacodynamic Modeling and Covariate Analyses of Neutropenia and Thrombocytopenia in Patients With Solid Tumors Treated With Lurbinectedin.
Thrombosis
A systematic review and critical assessment of 11 discordant meta-analyses on reduced-function CYP2C19 genotype and risk of adverse clinical outcomes in clopidogrel users.
Thrombosis
Acute stent thrombosis after stent-assisted coiling in an intracranial aneurysm patient carrying two reduced-function CYP2C19 alleles: A case report.
Thrombosis
Association of CYP2C19 Loss-of-Function Alleles with Major Adverse Cardiovascular Events of Clopidogrel in Stable Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention: Meta-analysis.
Thrombosis
Clopidogrel resistance: Case reports of CYP2C19 gene variants in suspected coronary stent thrombosis.
Thrombosis
CYP2C19 genotype and adverse cardiovascular outcomes after stent implantation in clopidogrel-treated Asian populations: A systematic review and meta-analysis.
Thrombosis
CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis.
Thrombosis
CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis.
Thrombosis
CYP2C19 phenotype, stent thrombosis, myocardial infarction, and mortality in patients with coronary stent placement in a Chinese population.
Thrombosis
CYP3A Activity and Rivaroxaban Serum Concentrations in Russian Patients with Deep Vein Thrombosis.
Thrombosis
Cytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome.
Thrombosis
Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial.
Thrombosis
Effects of genetic factors to stent thrombosis due to clopidogrel resistance after coronary stent placement.
Thrombosis
Epidemiology of CYP3A4-mediated Clopidogrel Drug-Drug Interactions and Their Clinical Consequences.
Thrombosis
Evaluation of the effect of SNPs in CYP3A4 and CYP4F2 on the stable phenprocoumon and acenocoumarol maintenance dose.
Thrombosis
Expanding role of pharmacogenomics in the management of cardiovascular disorders.
Thrombosis
Financial Analysis of CYP2C19 Genotyping in Patients Receiving Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention.
Thrombosis
Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel.
Thrombosis
Meta-Analysis of Cytochrome P450 2C19 Polymorphism and Risk of Adverse Clinical Outcomes Among Coronary Artery Disease Patients of Different Ethnic Groups Treated With Clopidogrel.
Thrombosis
Next-Generation Sequencing of CYP2C19 in Stent Thrombosis: Implications for Clopidogrel Pharmacogenomics.
Thrombosis
Potential Usefulness of Clopidogrel Pharmacogenetics in Cerebral Endovascular Procedures and Carotid Artery Stenting.
Thrombosis
Recurrent in-stent thrombosis following V4 segment of vertebral artery stenting: A case report.
Thrombosis
Reduced number of cardiovascular events and increased cost-effectiveness by genotype-guided antiplatelet therapy in patients undergoing percutaneous coronary interventions in the Netherlands.
Thrombosis
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Thrombosis
Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis.
Thrombosis
Simultaneous subacute coronary artery stent thrombosis in a carrier of two CYP2C19 loss-of function polymorphisms (*2/*3).
Thrombosis
Simultaneous Two-Vessel Subacute Stent Thrombosis Caused by Clopidogrel Resistance from CYP2C19 Polymorphism.
Thrombosis
The need of a multicomponent guiding approach to personalize clopidogrel treatment.
Thrombosis
[Efficacy and safety of concomitant use of rabeprazole during dual-antiplatelet therapy with clopidogrel and aspirin after drug-eluting stent implantation: a retrospective cohort study].
Thyroid Cancer, Papillary
Interaction Between Cyclosporine and Palbociclib in a Renal Transplant Patient: Case Report and Pharmacokinetic Perspective.
Thyroid Diseases
Genetic Polymorphisms of Pesticide-Metabolizing Enzymes and Transporters in Agricultural Workers and Thyroid Hormone Levels.
Torsades de Pointes
CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system.
Torsades de Pointes
High dose methadone and ventricular arrhythmias: a report of three cases.
Torsades de Pointes
Inhibition of cytochrome P450 3A: relevant drug interactions in gastroenterology.
Torsades de Pointes
Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.
Torsades de Pointes
Prolongation of the QT interval related to cisapride-diltiazem interaction.
Toxoplasmosis, Cerebral
Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations.
Triple Negative Breast Neoplasms
Recurrent CYP2C19 deletion allele is associated with triple-negative breast cancer.
Tuberculosis
A double transgenic mouse model expressing human pregnane X receptor and cytochrome P450 3A4.
Tuberculosis
Biofragments: An Approach towards Predicting Protein Function Using Biologically Related Fragments and its Application to Mycobacterium tuberculosis CYP126.
Tuberculosis
Comparative study of the effects of anti-tuberculosis drugs and antiretroviral drugs on CYP3A4 and P-glycoprotein.
Tuberculosis
Development of a paediatric physiologically based pharmacokinetic model to assess the impact of drug-drug interactions in tuberculosis co-infected malaria subjects: A case study with artemether-lumefantrine and the CYP3A4-inducer rifampicin.
Tuberculosis
Functional polymorphisms in CYP2C19 & CYP3A5 genes associated with decreased susceptibility for paediatric tuberculosis.
Tuberculosis
Inhibitory Potential of Twenty Five Anti-tuberculosis Drugs on CYP Activities in Human Liver Microsomes.
Tuberculosis
Multiple Doses of Rifabutin Reduce Exposure of Doravirine in Healthy Subjects.
Tuberculosis
Mycobactericidal activity of bedaquiline plus rifabutin or rifampin in ex vivo whole blood cultures of healthy volunteers: A randomized controlled trial.
Tuberculosis
Prediction of potential drug interactions between repurposed COVID-19 and antitubercular drugs: an integrational approach of drug information software and computational techniques data.
Tuberculosis
Serum Rifampicin Levels in Patients with Tuberculosis : Effect of P-Glycoprotein and CYP3A4 Blockers on its Absorption.
Tuberculosis
Unique CYP3A4 genetic variant in Brazilian tuberculosis patients with/without HIV.
Tuberculosis, Multidrug-Resistant
Mycobactericidal activity of bedaquiline plus rifabutin or rifampin in ex vivo whole blood cultures of healthy volunteers: A randomized controlled trial.
Urinary Bladder Neoplasms
Association of low CYP3A activity with p53 mutation and CYP2D6 activity with Rb mutation in human bladder cancer.
Urinary Bladder Neoplasms
Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk.
Urinary Bladder Neoplasms
Expression of xenobiotic metabolizing enzymes in tumours of the urinary bladder.
Urinary Bladder Neoplasms
Frequencies of poor metabolizers of cytochrome P450 2C19 in esophagus cancer, stomach cancer, lung cancer and bladder cancer in Chinese population.
Urinary Bladder Neoplasms
Variation in enzymes of arylamine procarcinogen biotransformation among bladder cancer patients and control subjects.
Urinary Incontinence
Effect of propiverine on cytochrome P450 enzymes: a cocktail interaction study in healthy volunteers.
Vaccinia
Metabolic activation of 4-ipomeanol by complementary DNA-expressed human cytochromes P-450: evidence for species-specific metabolism.
Vascular Diseases
The Effects of CYP2C19 genotype on the susceptibility for nephrosis in cardio-cerebral vascular disease treated by anticoagulation.
Vasculitis
Cyclophosphamide treatment-induced leukopenia rates in ANCA-associated vasculitis are influenced by variant CYP450 2C9 genotypes.
Venous Thrombosis
CYP3A Activity and Rivaroxaban Serum Concentrations in Russian Patients with Deep Vein Thrombosis.
Venous Thrombosis
Genetic variation in the first-pass metabolism of ethinylestradiol, sex hormone binding globulin levels and venous thrombosis risk.
Virus Diseases
Efficacy of local budesonide therapy in the management of persistent hyposmia in COVID-19 patients without signs of severity: A structured summary of a study protocol for a randomised controlled trial.
Virus Diseases
Evaluation of the HC-04 cell line as an in vitro model for mechanistic assessment of changes in hepatic cytochrome P450 3A during adenovirus infection.
Virus Diseases
Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial).
Virus Diseases
Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: hypothesis with implications for personalized medicine.
Virus Diseases
Integrin Receptors Play a Key Role in the Regulation of Hepatic Cytochrome P450 3A.
Vision Disorders
Visual disorders associated with omeprazole and their relation to CYP2C19 polymorphism.
Vitamin D Deficiency
Prevalence and risk factors for efavirenz-based antiretroviral treatment-associated severe vitamin D deficiency: A prospective cohort study.
Vitamin D Deficiency
Vitamin D pathway gene polymorphisms influenced vitamin D level among pregnant women.
Vitamin D Deficiency
Vitamin D Status in Russian Children and Adolescents: Contribution of Genetic and Exogenous Factors.
Wilms Tumor
New frontiers on the molecular underpinnings of hypospadias according to severity.
Xanthomatosis, Cerebrotendinous
Identification of bile acid precursors as endogenous ligands for the nuclear xenobiotic pregnane X receptor.
Xanthomatosis, Cerebrotendinous
Side chain hydroxylations in bile acid biosynthesis catalyzed by CYP3A are markedly up-regulated in Cyp27-/- mice but not in cerebrotendinous xanthomatosis.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ORGANISM
COMMENTARY
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
SOURCE
-
-
brenda
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY
GeneOntology No.
LITERATURE
SOURCE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
physiological function
differences in the activity of both CYP3A4 and CYP3A5 in Koreans, Swedes and Tanzanians. Both 4beta-hydroxycholesterol and quinine/3-hydroxyquinine metabolic ratio show a higher CYP3A activity in women than in men
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
UNIPROT
ENTRY NAME
ORGANISM
NO. OF AA
NO. OF TRANSM. HELICES
MOLECULAR WEIGHT[Da]
SOURCE
SEQUENCE
LOCALIZATION PREDICTION
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable).
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). CP3A4_HUMAN
503
2
57343
Swiss-Prot
Secretory Pathway (Reliability: 1)
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PDB
SCOP
CATH
UNIPROT
ORGANISM
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PROTEIN VARIANTS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
A6986AG
-
single nucleotide polymorphism responsible for different CYP3A genotypes, CYP3A5 allele and genotype frequency in the populations, overview
additional information
-
the CYP3A5 genotype has significant effect on quinine 3-hydroxylation in black Tanzanians, who have lower total CYP3A activity compared to a population of Swedish caucasians, overview
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PURIFICATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CLONED (Commentary)
ORGANISM
UNIPROT
LITERATURE
genes CYP3A5 and CYP3A4, DNA sequence determination, genotyping of two different human populations revealing the CYP3A5 and the CYP3A4 genotypes
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
APPLICATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
medicine
medicine
green tea extract use may cause significant interactions with drugs metabolized by CYP3A4. Effect on CYP3A4 varies among different brands of green tea extract, possibly due to variations in their content of the herbal product's active ingredients
medicine
plasma concentration of 4beta-hydroxycholesterol may be used as an endogenous marker of CYP3A activity
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Zhao, X.J.; Yokoyama, H.; Chiba, K.; Wanwimolruk, S.; Ishizaki, T.
Identification of human cytochrome P450 isoforms involved in the hydroxylation of quinine by human liver microsomes and nine recombinant human cytochromes P450
J. Pharmacol. Exp. Ther.
279
1327-1334
1996
Homo sapiens
brenda
Zhao, X.J.; Kawashiro, T.; Ishizaki, T.
Mutual inhibition between quinine and etoposide by human liver microsomes. Evidence for cytochrome P4503A4 involvement in their major metabolic pathways
Drug Metab. Dispos.
26
188-191
1997
Homo sapiens
brenda
Zhao, X.J.; Ishizaki, T.
The in vitro hepatic metabolism of quinine in mice, rats and dogs: comparison with human liver microsomes
J. Pharmacol. Exp. Ther.
283
1168-1176
1997
Canis lupus familiaris, Homo sapiens, Mus musculus, Rattus norvegicus
brenda
Relling, M.V.; Evans, R.; Dass, C.; Desiderio, D.M.; Nemec, J.
Human cytochrome P450 metabolism of teniposide and etoposide
J. Pharmacol. Exp. Ther.
261
491-496
1992
Homo sapiens
brenda
Mirghani, R.A.; Sayi, J.; Aklillu, E.; Allqvist, A.; Jande, M.; Wennerholm, A.; Eriksen, J.; Herben, V.M.; Jones, B.C.; Gustafsson, L.L.; Bertilsson, L.
CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population
Pharmacogenet. Genomics
16
637-645
2006
Homo sapiens
brenda
Allqvist, A.; Miura, J.; Bertilsson, L.; Mirghani, R.A.
Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers
Eur. J. Clin. Pharmacol.
63
173-179
2007
Homo sapiens
brenda
Wanwimolruk, S.; Wong, K.; Wanwimolruk, P.
Variable inhibitory effect of different brands of commercial herbal supplements on human cytochrome P-450 CYP3A4
Drug Metabol. Drug Interact.
24
17-35
2009
Homo sapiens (P08684), Homo sapiens
brenda
Diczfalusy, U.; Miura, J.; Roh, H.K.; Mirghani, R.A.; Sayi, J.; Larsson, H.; Bodin, K.G.; Allqvist, A.; Jande, M.; Kim, J.W.; Aklillu, E.; Gustafsson, L.L.; Bertilsson, L.
4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians
Pharmacogenet. Genomics
18
201-208
2008
Homo sapiens (P08684), Homo sapiens
brenda
Zhang, H.; Coville, P.F.; Walker, R.J.; Miners, J.O.; Birkett, D.J.; Wanwimolruk, S.
Evidence for involvement of human CYP3A in the 3-hydroxylation of quinine
Br. J. Clin. Pharmacol.
43
245-252
1997
Homo sapiens
brenda
Zhao, X.J.; Ishizaki, T.
Metabolic interactions of selected antimalarial and non-antimalarial drugs with the major pathway (3-hydroxylation) of quinine in human liver microsomes
Br. J. Clin. Pharmacol.
44
505-511
1997
Homo sapiens
brenda
Wanwimolruk, S.; Paine, M.F.; Pusek, S.N.; Watkins, P.B.
Is quinine a suitable probe to assess the hepatic drug-metabolizing enzyme CYP3A4?
Br. J. Clin. Pharmacol.
54
643-651
2002
Homo sapiens
brenda
Mirghani, R.A.; Hellgren, U.; Westerberg, P.A.; Ericsson, O.; Bertilsson, L.; Gustafsson, L.L.
The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo
Clin. Pharmacol. Ther.
66
454-460
1999
Homo sapiens
brenda
Mirghani, R.A.; Yasar, U.; Zheng, T.; Cook, J.M.; Gustafsson, L.L.; Tybring, G.; Ericsson, O.
Enzyme kinetics for the formation of 3-hydroxyquinine and three new metabolites of quinine in vitro; 3-hydroxylation by CYP3A4 is indeed the major metabolic pathway
Drug Metab. Dispos.
30
1368-1371
2002
Homo sapiens
brenda
Mirghani, R.A.; Ericsson, O.; Tybring, G.; Gustafsson, L.L.; Bertilsson, L.
Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man
Eur. J. Clin. Pharmacol.
59
23-28
2003
Homo sapiens
brenda
Igbinoba, S.I.; Akanmu, M.A.; Onyeji, C.O.; Soyinka, J.O.; Owolabi, A.R.; Nathaniel, T.I.; Pullela, S.V.; Cook, J.M.
Influence of a Nigerian honey on CYP3A4 biotransformation of quinine in healthy volunteers
J. Clin. Pharm. Ther.
40
545-549
2015
Homo sapiens
brenda
EXTERNAL LINKS (specific for EC-Number 1.14.14.55)
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
About BRENDA
Social media
Help
Survey
Download
Contribution
Legal
Curated at
Member of
